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PREFACE
The objectives of this thesis are to develop and assess 
critically methods of using the radiopharmaceutical 
technetium“99m labelled diphosphonate in the reliable 
detection of metabolic bone disease.
The work described commenced in 1976 at a time when 
bone scanning with the 'new' phosphate and phosphonate compounds 
had only recently become established in clinical practice.
Most early studies were carried out in patients with 
metastatic disease. This is understandable, and indeed 
the evaluation of a patient with known or suspected malignancy 
remains the most important indication for a bone scan today.
By 1976 the clear superiority of bone scanning over radiology 
in the detection of skeletal métastasés was well documented 
and attention was turning towards the application of 
scintigraphy in benign disease. In my own field of interest, 
metabolic bone disease, several individual articles on bone 
scanning were available but no one had specifically investigated 
this group of disorders.
From initial studies in osteomalacia I observed that 
the bone scan appearances were often similar to those obtained 
in other conditions such as renal osteodystrophy and primary 
hyperparathyroidism. Thus the concept of "metabolic 
features" being present on a bone scan was suggested by
11.
myself and it was observed that such features are non­
specific and may be found in any condition where there 
is generalised increased bone turnover.
An awareness of abnormality on the bone scan in 
metabolic bone disease does however depend upon a subjective 
impression of increased tracer uptake throughout the whole 
skeleton, and this is not always readily apparent. I 
suggested that a more sensitive index of abnormality in 
metabolic bone disease would be obtained if skeletal uptake 
of tracer were quantitated. Initially a semi-quantitative 
index for metabolic bone disease was derived from the bone 
scan image. This metabolic index was evaluated and while 
some favourable results were obtained, the technique did 
not provide a sensitive means of identifying altered skeletal 
metabolism in individual patients.
It had been suggested by several authors that measurement 
of bone to soft-tissue ratios from the bone scan image, 
using a computer programme to select appropriate regions of 
interest, might provide a satisfactory means of quantitating 
bone uptake of tracer. It was my belief, however, that 
use of bone to soft-tissue ratios was likely to be of limited 
value in the identification of metabolic bone disease. 
Nevertheless, critical studies of this technique had not been 
performed; such studies were undertaken and are reported 
in the thesis.
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In the continuing search for a more accurate means 
of quantitating skeletal uptake of diphosphonate, I 
developed a new technique whereby the 24-hour whole-body 
retention of Tc-99m diphosphonate was measured using a 
shadow-shield whole-body monitor. It is generally 
held that Tc-99m diphosphonate is either taken up by the 
skeleton or else excreted via the urinary tract and by 
24 hours after injection most of the tracer initially 
present in soft-tissue has been excreted, with the 
great majority of the remaining activity in the body 
being in bone. Various studies detailing the development, 
evaluation and clinical application of this technique are 
described in the thesis and I believe represent the most 
original and important aspect of my work.
For the past six years, during which time these studies 
were carried out, I have maintained a keen interest in 
developments relating to the bone scanning agents. It is 
clear that differences in skeletal affinity exist between 
various diphosphonates and this may have important 
implications for bone scanning both in malignant and benign 
disease. Currently there is a trend for bone seeking 
radiopharmaceuticals to have increased skeletal affinity, 
leading to higher absolute uptake of tracer by bone. While 
this may lead to more satisfactory views of the skeleton 
being obtained in normal subjects, higher bone uptake of
13.
tracer may not necessarily be desirable for the 
identification of disease. Several studies comparing 
different diphosphonates in clinical practice are therefore 
reported in this thesis.
The application of quantitative techniques utilising 
TC“99m diphosphonate in metabolic bone disease is still 
relatively in its infancy. This task has stimulated me 
and maintained my enthusiasm to this day, and is likely 
to occupy my further attention in years to come.
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CHAPTER- 1 
THE BONE SCAN IN CLINICAL PRACTICE
15.
THE BONE SCAN - Historical aspects
At the present time the bone scan is generally 
accepted as an extremely powerful investigational tool 
in the evaluation of patients with both benign and malignant 
skeletal disease. However it is worth reflecting that it 
is only a matter of some ten years since the introduction of 
the "new" bone seeking agents which made clear visualisation 
of the skeleton possible. The bone scan as we recognise it 
today results from the development of technetium-99m (Tc-99m) 
labelled polyphosphate by Subramanian in 1971 (Subramanian 
and McAfee, 1971). That report is the foundation on which 
subsequent development of Tc-99m labelled bone seeking 
agents is based. The excellent physical characteristics of 
Tc-99m are well documented (Harper et al, 1965; McAfee 
and Subramanian, 1975). The short physical half life of 
6.02 hours is ideal for many studies. The monoenergetic 
gamma emission of 140 keV is easily collimated and the 
absence of biologically hazardous beta decay reduces the 
absorbed dose of radiation. Thus the introduction of a 
bone scanning agent which could be labelled with Tc~99m 
was clearly a major advance, and indeed ideal physical 
properties combined with relatively low cost and easy 
availability make Tc-99m the radionuclide of choice in
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radioisotope imaging procedures for nearly every major 
organ system in man (Harper et al, 1965). In addition 
to the introduction of Tc-99m labelled bone scanning agents 
there was continuing development of nuclear medicine 
imaging devices with improvement in their resolution (Anger 
1964; Cooke and Kaplan, 1972). These factors combined 
to allow clear visualisation of the skeleton and to produce 
the bone scan that we are familiar with today.
The history of bone scanning, however, commences some 
ten years earlier than Subramanian's important publication 
and the first report of skeletal imaging with a radionuclide 
was from Fleming et al (1961) using strontium-85 (Sr-85). 
They found that Sr-85 localised at areas of increased 
osteoblastic activity, and the scan could be used as an 
index of bone repair; they concluded that scanning of 
bone lesions was practical and informative. The increasing 
use of bone scanning in clinical practice throughout the 
1960's was, however, largely due to D M Sklaroff and 
N D Charkes. In many articles (Sklaroff and Charkes,
1964; Charkes and Sklaroff, 1964; Charkes et al, 1964; 
Charkes et al, 1966; Sklaroff and Charkes, 1968; Charkes 
et al, 1968) and innumerable talks they demonstrated to 
perhaps at that time unbelieving audiences, that bone scan 
imaging had a primary role in the detection of skeletal
17.
métastasés. Their extensive experience was supported 
by a series of reports from De Nardo and colleagues 
(De Nardo 1966; De Nardo et al, 1966; De Nardo 1968;
De Nardo et al, 1972) confirming the practicality and 
usefulness of bone imaging. The cumulative experience 
with Sr-85 showed clearly that bone scanning consistently 
detected lesions months before radiographs of the skeleton 
became abnormal. Thus by 1970 the bone scan had.already 
become a clinically acceptable procedure but radiostrontium, 
initially Sr-85 and later Sr-87m (Charkes, 1969), the most 
practical bone agent available was far from ideal (figure 1) 
The low gamma yield, gut excretion of tracer which could 
interfere with lesion visualisation, limitation of use to 
patients with malignant disease because of high radiation 
dose,and prolonged delay from injection to imaging, led 
to increasing dissatisfaction with Sr-85. It is of 
interest today that a bone scan with Sr-85 could only be 
obtained after a delay of some 24-48 hours following 
injection to allow excretion of non-skeletal tracer via 
bowel and urinary tract (Sklaroff and Charkes, 1964) and 
a single view of pelvis could take 30-45 minutes to obtain 
(De Nardo 1966). Sr-87m, on the other hand, had a short
physical half-life (2.8 hours) and larger activities 
could be injected obtaining scans of high information 
density with relatively short patient scanning times
18
Figure 1
a) Sr-85 scan of anterior 
pelvis with métastasés 
present in pelvis, spine 
and femora.
(April, 1963)
♦
b) As above, with overlay to 
define outline of pelvis.
m
♦
c) Tc-99m diphosphonate scan of 
anterior pelvis with 
métastasés present in 
pelvis, spine and femora.
(April, 1982)
&
(Figures la and b provided by Dr N D Charkes.
Figure lb from the Journal of the American Medical Association 1964, 
volume 188, pp 1-4, with permission.
Copyright 1964, American Medical Association.)
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(Volpe 1971). However the main disadvantage of Sr-87m 
was the slow blood clearance of tracer. High background 
activities in blood and soft-tissues resulted in low target 
to background ratios and thus relatively poor visualisation 
of normal and pathological bone until many hours after 
injection (Weber et al, 1969). The short physical half- 
life of Sr-87m however precluded waiting until background 
levels were low, when optimum target to background ratios 
would be obtained. It was reported that the high blood 
and extra-cellular fluid activities of Sr-87m could lead 
to erroneous false-positive diagnoses (Charkes 1969) .
Some of the disadvantages of imaging with the 
strontium isotopes had already been overcome with the 
introduction of fluorine-18 (F-18) by Blau and associates 
(Blau et al, 1962). With more favourable radiation 
dosimetry and faster blood clearance, it was possible to 
administer larger activities resulting in greater 
information density and faster scanning speeds. Visualisâtior
of the entire skeleton thus became practical with F-18.
F-18 quickly replaced the strontium isotopes as the 
scanning agent of choice and extensive experience was 
accumulated with its use (Blau et al, 1962; French and 
McCready, 1967; Sharma and Quinn, 1972; Blau et al., 1972; 
Shirazi et al, 1974; Fordham and Ramachandran, 1974).
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However F-18 required cyclotron production, was 
expensive, and with its short physical half-life 
(1.83 hours) insoluble problems arose regarding widespread 
distribution of this radionuclide. Thus only relatively 
few centres could use F-18, which precluded general 
acceptance of this reliable and effective radionuclide.
The search for a satisfactory bone scan compound 
continued. Many alternative nuclides and radiopharma­
ceuticals were considered. These included gallium-68 
(Hayes et al, 1965; Edwards et al, 1966),and Tc-99m 
pertechnetate (Tow and Wagner, 1967). Because of the 
chemical similarity to calcium, several nuclides of the 
alkaline earth element barium (Ba) were evaluated.
Both Ba-131 and Ba-135m were found to have excellent 
physical characteristics and rapid blood clearance 
(Spencer et al, 1970; Lange et al, 1970; Subramanian 
1970). Another promising group of agents were chelates 
of the rare earth elements (the lanthanides) (O'Mara 
et al, 1969). Of these compounds the HEDTA (N-hydroxy 
ethylenediamine triacetic acid) chelate of dysprosium-157 
appeared to have the most suitable properties (Subramanian 
et al, 1971; Yano et al, 1971).
While some initial excitement was generated by the 
agents described above, their roles as bone scanning 
agents in clinical practice were completely supplanted by the
21 .
introduction of Tc-99m polyphosphate by Subramanian and 
McAfee (1971).
Introduction of Tc-99m phosphate
Animal studies using polyphosphate labelled with 
phosphorus-32 (P-32) were first carried out by Pels and 
co-workers in 1959 (Pels et al, 1959). They demonstrated 
that the accumulation of tracer in bone relative to soft 
tissue was greater for polyphosphate than orthophosphate. 
There were major therapeutic implications from this work 
regarding the possibility of delivering higher amounts of 
P-32 selectively to sites of bone métastasés, and indeed 
subsequent studies (Kaplan et al, 1960) on human subjects 
with carcinoma of the prostate verified increased 
localisation of polyphosphate P-32 in bone in proportion to 
the severity of malignant disease. If polyphosphate with 
increased skeletal affinity had applications in the realm 
of therapy, could it not also be of use in the diagnosis 
of disease?
Many years earlier Neuman and Neuman (1953) had 
described localisation of anionic metal complexes in bone.
As Tc-99m readily forms anionic complexes, it was considered 
feasible to obtain selective osseous localisation of this 
radionuclide (Subramanian and McAfee, 1971). The 
polyphosphates, also known as condensed phosphates, are 
compounds which possess chains of -P-O-P-units (figure 2) 
joined together. Their ability to prevent deposition of
22
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Figure 2
Chemical structure of polyphosphate^ pyrophosphate 
and diphosphonate.
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calcium carbonate from solution is well known (Fleisch 
and Russell, 1970) and it was predicted that polyphosphates 
would have strong affinity for hydroxyapatite crystals in 
the mineral phase of bone, and in particular for sites of 
new bone formation. Such affinity had been previously 
demonstrated in autoradiographic studies using P-32 labelled 
polyphosphate (Pels et al, 1959).
Techniques were already available for reducing Tc-99m 
pertechnetate with stannous chloride (Eckelman and Richards,
1970) which made it possible to label phosphate compounds 
with Tc-99m.
This was the background to that initial publication 
from Subramanian and McAfee (1971). Thus a compound with 
high skeletal affinity was combined with a radionuclide 
with near perfect physical properties; introducing Tc-99m 
labelled phosphate bone scanning agents to clinical practice 
(Subramanian et al, 1972a). While the first bone scans may have 
had some irritating body background activity, the skeleton 
was nevertheless clearly discernible.
Pollowing the initial development and introduction of 
Tc-99m polyphosphate, attention turned to other phosphates 
which could be suitable bone scanning agents. Technetium-99m
pyrophosphate appeared promising. Pyrophosphate is believed 
to be important in regulating the calcification process in 
bone, although its precise role in calcium metabolism and
24.
in disorders of bones and teeth is not well defined 
(Fleisch and Russell, 1970; 1972). When labelled with
Tc-99m, pyrophosphate provided improved bone to background 
activity ratios, and satisfactory scans were obtained in 
experimental animal and early patient studies (Perez et al, 
1972; Cohen et al, 1972; Hosain 1973; Fletcher et al,
1973; Huberty et al, 1974). Bone scanning had come of 
age, the scans looked like bone surveys - an advantage 
Sklaroff and Charkes did not have with Sr-85 and Sr-87m.
Shortly after the introduction of Tc-99m polyphosphate 
and Tc-99m pyrophosphate, still another group of bone 
scanning agents, the diphosphonates, became available.
The development of the diphosphonates stemmed from the 
search for a therapeutic agent in bone disease which combined 
the biological properties of pyrophosphate and polyphosphate, 
together with resistance to enzymatic destruction in vivo 
(Fleisch et al, 1969; Francis et al, 1969). While the 
possibility of using both polyphosphate and pyrophosphate 
as therapeutic agents had been considered (Russell and 
Smith, 1973), their rapid destruction by tissue phosphatases 
made this impossible. During the late 1960's, however, 
a diphosphonate (hydroxyethylidene diphosphonate) was shown 
to be of value in the treatment of myositis ossificans 
(Bassett et al, 1969) and was soon after evaluated in
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Paget's disease (Smith et al, 1971). Today, diphosphonates 
are a standard therapy for Paget's disease (Russell et al, 
1974; Khairi et al, 1977) and many other potential clinical 
applications have been suggested (Russell and Smith, 1973). 
Tc-99ra labelled diphosphonate (hydroxyethylidene diphos­
phonate) as a bone scanning agent was independently proposed 
and evaluated by several groups of workers (Tofe and Francis, 
1972; Castronovo and Callahan, 1972; Subramanian et al, 
1972b; Yano et al, 1973) and evidence was obtained that 
diphosphonate provided improved scans when compared with 
either Tc-99m pyrophosphate (Citrin et al, 1975; Fogelman 
et al, 1977) or F-18 (Silberstein et al, 1973). Within a 
year a major clinical study from Pendegrass et al (1973) 
using Tc-99m diphosphonate summarised their experience with 
500 bone scans. It had taken Sklaroff and Charkes almost 
eight years to obtain similar numbers of patient studies 
using Sr-85 (Charkes et al, 1968).
Thus within a short period of time, three new, good 
bone scanning agents had become available (Tc-99m poly­
phosphate, pyrophosphate and diphosphonate) and a brief 
report from Subramanian in 1971 had led to as many as 50 
publications reporting on their use by 1973. Since that 
time cumulative experience has suggested that the 
diphosphonates are the bone scanning agents of choice
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(Dunson et al, 1973; Serafini et al, 1974; Krishnamurthy 
et al, 1974; Lundell et al, 1975) with superior detection 
of lesions in metastatic disease (Citrin et al, 1975; 
Fogelman et al, 1977; Silberstein et al, 1978). While 
other agents such as Tc-99m monofluorophosphate (Citrin 
et al, 1974), Tc~99m sodium trimetaphosphate (Nelson 
et al, 1975), and Tc-99m imidodiphosphate (Subramanian 
et al, 1975a) have since been evaluated, none presented 
a serious challenge to Tc-99m hydroxyethylidene diphos­
phonate. Subramanian and colleagues in 1975 however 
introduced a new diphosphonate, methylene diphosphonate 
(Subramanian et al, 1975b). This compound had more 
rapid blood clearance than hydroxyethylidene diphosphonate 
and also appeared to have higher skeletal affinity. 
Certainly it became a great commercial success and is 
currently the most widely used bone scanning agent.
However, the search for a better scanning agent has by 
no means stopped and at present two further diphosphonate 
compounds (hydroxymethylene diphosphonate and dicarboxy- 
propane diphosphonate) are available. Each appears to have 
higher absolute bone uptake than methylene diphosphonate 
but any advantage to their use in clinical practice has 
still to be shown. However, there seems little point in 
quibbling over which is the very best agent when we are 
truly fortunate to have bone scanning agents which perform 
their job so superbly well.
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Paper 1 . Skeletal uptake of diphosphonate: A review (1980)
European Journal of Nuclear Medicine 5 : 473-476
I Fogelman
Purpose of Investigation
This paper reviews the current literature relating to 
mechanisms of diphosphonate uptake by bone . Several 
important concepts are discussed. Firstly, whether 
alterations in local vascularity or skeletal metabolism 
are primarily responsible for variations in bone uptake 
of tracer. While accepting the importance of vascularity 
in the regulation of tracer delivery to the skeleton it is 
seen that markedly increased uptake of tracer cannot be 
adequately explained by alterations in vascularity alone.
The evidence supporting the importance of increased bone 
turnover for tracer uptake is presented. Secondly, it 
is recognised that considerable controversy exists as to 
the exact site of localisation of tracer in bone, and the 
available evidence regarding this is summarised.
Eur. J, Nucl. Med. 5, 473-476 (1980) sz,N uclearMedicine
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Abstract. The diphosphonates are currently the skele­
tal imaging agents of choice and while extremely 
sensitive for bony abnormality their mechanism of 
action remains poorly understood. The current con­
cepts in bone uptake mechanisms are reviewed and 
it is concluded that diphosphonate uptake is most 
likely related to sites of newly forming bone with 
diphosphonate adsorbed onto the surface of hydroxya­
patite crystals. In situations where there is markedly 
increased skeletal uptake of tracer, increased vascular­
ity alone cannot account for changes in tracer uptake 
and changes in skeletal extraction, related to newly 
forming bone are more important.
Introduction
Bone scanning has revolutionised the investigation 
of patients with skeletal disease and it is now well 
recognised that in the search for metastatic involve­
ment of bone, the scan may become positive 6 
months, 1 year or even 18 months before changes 
are seen on X-ray (Tofe et al. 1975 ; Citrin et al. 1977). 
Also the use o f bone scanning is established in Paget’s 
disease (Serafini 1976) and various other benign bone 
disorders (Handm aker and Leonards 1976), with re­
cent interest in the evaluation of patients with m eta­
bolic bone disease (Sy and M ittal 1975; Fogelman 
et al. 1978b). While there is universal agreement that 
the currently available bone seeking radiopharm aceu­
ticals (the diphosphonates) are extremely sensitive for 
skeletal abnormality, their mechanism of action re­
mains poorly understood. The purpose of this review 
is to summarise the evidence that is presently available 
as to their mode of action and site of localisation 
and to discuss some of the remaining problems which 
exist in clarifying the processes that occur at the bone 
surface.
Several of the earlier studies which will be quoted 
have been carried out with phospate compounds, 
while in clinical practice today, the diphosphonates 
are virtually exclusively used. However, it is likely 
that both groups of agents behave at least in a qualita­
tively similar manner in relation to bone (Charkes
1979).
Stability of Bone Seeking Radiopharmaceuticals
Several studies have now shown that the diphospho­
nate compounds have excellent physical and chemical 
properties as bone scanning agents (Dunson et al. 
1973; Citrin et al. 1975 b), They provide highly repro­
ducible bone scans despite variations in technetium 
presentation, labelling and injection procedures (Ci­
trin 1977). In addition prolonged shelf life and varia­
tions in temperature and pH apparently have mini­
mal effect on stability (G arnett et al. 1975). It is gener­
ally assumed that the technetium diphosphonate com­
plex travels to bone and stays there as a unit (Jones 
et al. 1976). It is likely that this is indeed the case 
and Tofe and Francis (1974) have shown that the 
ratio of technetium to diphosphonate which is depos­
ited in bone is the same at 3 and 24 h following 
injeetion.
Tissue Distribution of Diphosphonate
The diphosphonates are either taken up by bone or 
else rapidly cleared through the kidneys (McDougall 
and Citrin 1975) and in a normal subject approxi­
mately 70% of the injected activity will be excreted 
via the urinary tract within 6 h of injection (Citrin 
et al. 1975 a). However renal clearance is not the pri­
mary determinant of skeletal uptake of tracer. This 
depends upon the intrinsic affinity of the tracer for
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bone modified by other factors which wil be discussed 
later. It has been shown that the uptake of diphos­
phonate in bone compared to other soft tissue varies 
between a factor o f x 20 and x 1,000 (Rohlin and 
Nosslin 1977).
Factors Involved in Skeletal Uptake 
of Diphosphonate
a) Vascularity. Before a radiopharmaceutical can be 
taken up by a bone, it must be delivered there by 
its vascular supply. Skeletal vascularity is therefore 
of fundamental importance but the question arises 
as to whether increased uptake of tracer can be fully 
explained by an eqivalent increase in the blood supply 
to bone. It is known that following a sympathectomy 
to a limb there is increased tracer uptake (thought 
to be related to vessel dilatation) (Charkes 1979) and 
that in Paget’s disease where there is high blood flow 
to the involved sites, there is also intense uptake of 
tracer (Serafini 1976). Genant et al. (1974) found cor­
respondingly increased tracer uptake and vascularity 
with thermal-induced alterations in blood flow to 
bone in rats. They also found increased skeletal tracer 
uptake in rachitic rats and argued that this was due 
to increased vascularity as mineralisation is generally 
.reduced in rickets. However, Kaye et al. (1975) found 
that skeletal vascularity was normal in rachitic rats 
and although the mineralisation rate is reduced in 
rickets, there is so much excess osteoid present 
throughout the whole skeleton which is mineralising, 
albeit at a slower rate, that the total mineralisation 
in the whole animal is increased (Nordin 1978). Siegel 
et al. (1976) studied various groups of rats in whom 
femoral artery ligation and fractures o f bone were 
carried out and found that skeletal uptake of tracer 
correlated with change in vascularity. However, if 
one reduces blood flow to a bone then tracer uptake 
will obviously be reduced and their findings in the 
fracture situation where tracer uptake is increased 
were less convincing.
Recent studies from the Mayo Clinic have corre­
lated capillary extraction of bone tracers with their 
diffusion coefficients (Hughes et al. 1977; Kelly and 
Bassingthwaighte 1977). It was suggested that the 
principal mechanism for the movement of tracer from 
blood to bone is passive diffusion through the clefts 
in the capillary walls into the extravascular, extracel­
lular fluid. This type of diffusion is proportional to 
molecular size and smaller ions such as strontium 
and fluorine spread more rapidly than the technetium 
phosphonate agents. Nevertheless it seems likely that 
the initial dilution process does not determine the 
ultimate degree of tracer uptake on bone. W ootton
(1974) has shown that fluorine-18 is 100% extracted 
by normal bone in a single passage and Garnett et al,
(1975) subsequently showed that technetium-pyro- 
phosphate has 64% extraction in bone compared to 
fluorine-18. They suggested that the capillary mem­
brane reduced the efficiency with which pyrophos­
phate was extracted by normal bone and that in abnor­
mal bone increased tracer uptake was due to a combi­
nation of increased blood flow and more efficient 
extraction.
Hughes et al. (1978) have shown that the skeletal
1 uptake of diphosphonate when injected as a bolus 
compared to constant infusion over a thirty minute 
interval was equivalent and this is of real Interest 
as it appears the contact time of tracer with bone 
may not be of importance. This has relevance eg, 
in chronic renal failure where increased blood levels 
of tracer occur due to soft tissue retention (Fogelman 
et al. 1978 a) and suggests that high skeletal tracer 
uptake in such patients (Sy and M ittal 1975) reflects 
skeletal avidity rather than prolonged exposure of 
bone to tracer.
Lavender et al. (1979) in a series of elegant experi­
ments using a canine tibia in which an osteotomy 
had been carried out with an isolated tibial artery 
showed that a moderate increase in blood flow (by 
100%) was associated with a much greater increase 
in the diphosphonate residue (by 800%). They con­
cluded that vascularity may increase tracer uptake 
(potentially by 100%) but that for higher uptake some 
other factor related to newly forming bone was re­
sponsible for increased extraction. Similar results and 
conclusions were obtained by Sagar et al. (1978) who
2 showed that increased vascularity (by 400%) led to
* an increase in diphosphonate uptake of only 70%.
Charkes et al. (1978) devised a 5 compartmental m od­
el for radiopharmaceutical uptake by bone and it 
was deduced that for a significant increase of blood 
flow (by 500%) there was only relatively little increase 
in skeletal uptake of tracer.
The conclusion from these findings is that while 
increased vascularity is certainly a factor in increased 
skeletal uptake o f tracer, markedly increased uptake 
(by more than a factor o f 100%) cannot simply be 
explained by alterations in vascularity alone.
b) Skeletal Metabolism. It is well recognised that condi­
tions with accelerated bone turnover e.g., Paget’s dise­
ase, primary hyperparathyroidism, and renal osteo­
dystrophy show increased skeletal uptake of tracer 
(Fogelman et al. 1978 a) and if vascularity alone can­
not fully explain this uptake then it must be related 
in some way to the increased modelling and remodel­
ling of bone (Jones et al. 1976). Gareia et al. (1976) 
have shown in an animal model that only a bone
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forming system can lead to increased tracer uptake 
and they concluded that where an osteolytic lesion 
existed in bone it led to inereased tracer uptake by 
a compensatory osteogenic response.
We have shown that total skeletal uptake of tracer 
(as measured by 24 h whole-body retention of di­
phosphonate) correlated well with plasma imnumo- 
reactive parathyroid hormone in patients with primary 
hyperparathyroidism and that skeletal uptake fell with 
time following parathyroidectomy, i.e., skeletal up­
take of tracer fell as skeletal metabolic activity grad­
ually returned towards normal (Fogelman et al., in 
press).
The importance of skeletal metabolism is accepted 
(Jones et al. 1976; Bell 1972) but some controversy 
exists as to the mechanisms and site of localisation 
of tracer. It is generally believed that uptake is related 
to the mineral phase of bone (Jones et al. 1976) but 
recently it has been suggested that uptake by enzyme 
systems (Zimmer et al. 1975) and immature collagen 
may also be important (Rosenthall and Kaye 1975).
Bone Mineral
It has been shown in vitro that diphosphonate uptake 
is related to bone mineral and it has been suggested 
that diphosphonate chemi-adsorbs on to hydroxyapa- 
tile crystals (Francis 1969). It is likely that the reac­
tivity of tracer is different for the various phases and 
hydration states of forming hydroxyapatite (Khan 
et al. 1979). It would seem that uptake of tracer is 
mainly associated with “ newly forming bone” and 
that there is little uptake in mature bone (Jones et al. 
1976; Tilden et al. 1973). It is also attractive to pos­
tulate that in high bone turnover states increased tracer 
uptake is due to increased bone resorption which ef­
fectively causes an increase in exposure of potentially 
available binding sites.
Several groups have performed autoradiography 
on bone or cartilage using diphosphonate (Jones et al. 
1976 ; Khan et al. 1979 ; Tilden et al. 1973 ; van Lange- 
velde et al. 1977 ; Guillemart et al. 1978) and have 
shown that uptake is related to the interphase between 
osteoid and mineralised bone i.e., at the site of active 
mineralisation. While Jones et al. (1976) found no 
activity in osteoid, Guillemart et al. (1978) and Tilden 
et al. (1973) did note some scattered activity through­
out osteoid.
Enzymes Systems
Zimmer et al. (1975) have suggested that enzymes 
such as alkaline phosphatase complexing with di­
phosphonate may explain uptake of tracer on bone 
surfaces. However, this seems unlikely for in Paget’s 
disease, for example, there are extremely high blood 
levels of alkaline phosphatase and if diphosphonate 
complexed with this enzyme there would be consider­
able delay in blood clearance of diphosphonate, and 
this does not occur (Jones et al. 1976).
Immature Collagen (Osteoid)
Kaye et al. (1975) in a series of in vitro studies showed 
a striking increase in tracer uptake on to demineral­
ised bone and they coneluded that there was preferen­
tial binding of tracer by immature collagen. However, 
bone was exposed to various chemical and physical 
traumas and these findings cannot necessarily be re­
lated to the physiological state. Also the same group 
(Rosenthall and Kaye, 1975) found no correlation 
of 5 h bone to soft tissue ratios (reflecting skeletal 
uptake of tracer) with the percentage of bone surface 
covered by osteoid. We have reported a case of Pa­
get’s osteosarcoma where the tum our (with malignant 
osteoid present) did not appear to take up any tracer 
with the lesion cold on bone scanning (McKillop et al. 
1977). We have also studied a case of adult hypo- 
phosphatasia (the essential problem here is very low 
alkaline phosphatase levels with a basic mineralisa­
tion defect leading to excess osteoid (Birtwell et al. 
1967)) and this patient’s bone scan appeared normal 
in terms of tracer uptake. However, hot spots were 
seen in the femora where pseudofractures were pres­
ent. We also measured the total skeletal uptake of 
tracer using our whole-body retention technique (Fo­
gelman et al. 1978a) and found this to be in the nor­
mal range. We, therefore, have a situation where there 
is excess osteoid present but skeletal uptake of tracer 
is normal and this seems to suggest that mineralisa­
tion may be the more im portant factor. Also the au­
toradiographic findings reported above are further 
strong evidence in support of this. Where technetium 
deposition has been seen in osteoid on autoradiogra­
phy (Tilden et al. 1973; Guillemart et al. 1978), it 
was probably due to nuclei of calcium phosphate pres­
ent rather than strong specific adsorption with the 
organic matrix itself.
The evidence to date strongly supports the view 
that diphosphonate uptake is related to sites of newly 
forming bone with the diphosphonate being adsorbed 
on to the surface of hydroxyapatite crystals. Never­
theless high turnover states eg, Paget’s disease, prim a­
ry hyperparathyroidism and renal osteodystrophy do 
have excess osteoid present and it will be necessary 
to perform autoradiography in these conditions and, 
in particular, in osteomalacia (where osteoid is greatly
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increased) to localise the specific site of uptake. Even 
then it may not be possible to differentiate uptake 
by immature collagen and calcium phosphate crystals 
present in the osteoid, and the final answer may have 
to await electron microscopy studies of bone.
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Comment
The two main contenders as regards site of localisation 
of diphosphonate in bone are immature collagen (osteoid) 
and bone mineral, particularly at sites of new bone 
formation. I believe that the available evidence strongly 
favours diphosphonate uptake in association with bone 
mineral.
Since the present review further work has become 
available supporting this view. Francis et al (1981) 
reacted technetium-99m (Tc-99m) diphosphonate with a 
mixture of pure inorganic hydroxyapatite and pure organic 
bone matrix to provide a competitive adsorption environment 
for the diphosphonate. It was found that while some 
adsorption of diphosphonate to matrix alone does occur, 
when hydroxyapatite and matrix compete in the same system, 
as happens in vivo, then diphosphonate is adsorbed 
preferentially to hydroxyapatite (the ratio of Tc-99m 
hydroxyapatite to Tc-99m matrix being 40:1).
Christensen and Krogsgaard (1981) using epiphyseal 
growth plates of rats have again confirmed by autoradio­
graphy that Tc-99m labelled diphosphonate localises 
primarily at sites of active mineralisation. In addition, 
labelling of diphosphonate corresponded with the fluorescence 
of tetracycline, a known marker of bone mineralisation' 
(Teitelbaum and Nichols, 1977), but did not coincide with 
new production of collagen, as judged by localisation of 
tritium labelled proline. When sections labelled in vivo
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with Tc-99m diphosphonate were decalcified using ethylene 
diamine tetraacetic acid (EDTA), loss of radioactivity 
was shown. This is in contrast to those sections 
incubated in water where no loss was seen, thus providing 
further evidence of the affinity of diphosphonate for the 
mineral phase of bone.
While there is strong evidence supporting the view that 
diphosphonate adsorbs on to the surface of hydroxyapatite 
crystals, it is important to realise that the exact 
mechanism by which diphosphonate binds to bone is not 
yet fully understood. In addition, as will be shown in 
the thesis, differences in skeletal affinity exist 
amongst the various diphosphonates. This has been 
attributed to differences in binding characteristics, 
perhaps related to those molecules present on the central 
carbon atom of the diphosphonate (Deutsch and Barnett,
1980). However, such explanations are neither proven 
nor wholly satisfactory and it is clear that much basic 
research is still required to answer the 'simple' question 
of what happens to diphosphonate on bone.
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Paper 2. Bone scanning in clinical practice: A review
Diphosphonates, Fourth Symposium CEMO (in press) 
I Fogelman, J H McKillop
Purpose of Investigation
The bone scan is still most commonly used in the 
search for metastatic disease but increasingly there 
is recognition of the value of bone scanning in benign 
bone disorders. This paper identifies and summarises 
some of the more important applications of the bone 
scan in clinical practice.
BONE SCANNING IN CLINICAL PRACTICE: A REVIEW
Ignac Fogelman, James H M c K i l l o p
The isotope bone scan is a relatively new method of imaging the 
skeleton which has rapidly assumed major clinical importance. It 
provides a simple, sensitive test for the l o c a l i s a t i o n  and 
e v a l u a t i o n  of skeletal disease, and will often present diag n o s t i c  
info r m a t i o n  w h i c h  cannot be obtained from other non-i n v a s i v e 
procedures. In this review the pathophysiology of bone uptake of 
r a d i o p h a rmaceutical, the relative sensitivity of bone scan and 
radiograph, and the more important indications for bone scanning 
in clinical practice are described.
P A T H O P H Y S I O L O G Y  OF BONE UPTA K E  OF R A D I O P H A R M A C E U T I C A L
A skeletal radiograph indicates the net result of bone resorption  
and repair and a d e s t r u c t i v e  lesion in trabecular bone must be 
greater than 1 to 1.5 cm in diameter with loss of ap p r o x i m a t e l y  
50% of bone m i n eral before it becomes apparent on x-ray (1). The 
bone scan, however, reflects skeletal m e t abolic activity and w h i l e  
the exact m e c h a n i s m  of uptake of tracer (technetium - 99m labelled 
d i p h o s phonate) by bone remains incompletely understood, it is 
thought mo St  likely that di p h o s p h o n a t e  adsorbs onto the c a l cium of 
h y d r o x y a p a t i t e  (2). The major factors which affect this 
a d s o r p t i o n  on to bone are believed to be osteoblastic activity and 
skeletal vasc u l a r i t y  (3). Rather than bone dest r u c t i o n  the bone 
scan, therefore, reflects the reaction of normal bone to a variety 
of disease processes, be they neoplastic, metabolic, traumatic, or 
inflammatory (4). Early in bone resorption reactive bone may not 
be present in sufficient q uantities to be detected
radiographically, although the bone scan may be strongly positive. 
This ability to detect functional change, which occurs earlier 
than structural change is the reason why bone scanning is so much 
more sensitive than c o n v e n t i o n a l  radiology. However, bone scans 
are relatively n o n - s p e c i f i c  because almost any disease process in 
bone results in a change in o s t e o blastic activity and blood flow. 
Nevertheless, the pattern of a bnormality in the bone scan may be 
sufficiently ch a r a c t e r i s t i c  in many conditions to allow a specific  
diagnosis, but often the scan findings do require to be cor r e l a t e d  
with c o r r e s p o n d i n g  radiographs.
THE BONE SCAN IN M A L I G N A N T  DISEASE
The most common use of the radionuclide bone scan in clinical 
practice has been in the e v a l u a t i o n  of patients with suspected or 
established malignant d i s e a s e ( F i g u r e  1). The bone scan is 
superior to skeletal x-rays for screening for bony involvement in 
most tumours for two reasons. Firstly, in most tumours the bone 
scan is more sensitive than skeletal x-rays for the d e t e c t i o n  of
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early bone involvement, because of the ability of the isotope 
method to d emonstrate the change in skeletal m e t a b o l i s m  occurring 
in response to tumour invasion. The radiological studies are 
dependent upon structural changes which occur later. Citrin et 
al (5) reported a series of 16 patients with normal x-rays at the 
time of a bone scan d e m o n s t r a t i n g  m e t a static disease in w h o m  the 
x-rays subsequently confirmed malignant involvement of the 
skeleton. The mean time between an abnormal scan and d evelopment 
of radiological a b n o r mality was 6 m o n t hs. One notable exception 
to increased s ensitivity for bone scanning is multiple myeloma 
(6). In this group of patients the bqene scan is usually 
abnormal, but at fewer sites than skeletal x-rays from the same 
patients. The lack of sensitivity of the bone scan in myeloma is 
presumed to be due to failure of the tumour process to elicit an 
o s teoblastic response in the bone. The second main advantage of 
the bone scan over skeletal radiology for screening for malignant  
disease in bone is the greater ease with which the whole skeleton 
can be evaluated by the former method. This is important in view 
of the w i d e s p r e a d  d i s s e m i n a t i o n  found in many tumours (7). The 
principal disadvantage of the bone scan in detecting bone 
métastasés is the lack of specificity (Figure 2), making it 
essential to correlate bone scan findings with x-rays and, if 
necessary, with bone biopsy (8). This c o r r e lation is especially 
important in patients with extra osseous primaries in w h o m  the 
bone scan shows a single a b n o r m a l i t y  (9, 10).
Bone involve m ent in extra osseous m a l i gnancy
Breast cancer patients have been extensively studied by bone scans 
in many centres. Though it is generally agreed that there is a 
high incidence of bone m é t a stasés in clinically advanced disease, 
widely d i f f ering figures have been reported for the frequency of 
bone involvement in patients wit h  clinically early disease (11). 
Many workers would now accept that the frequency of bone scan 
abnormality is less than 2% in clinical stage I and around 2-5% in 
stage XI. Some authors have advocated that bone scans be 
performed only in stage I and XX patients who have symptoms of 
bone m é t a stasés (12). In view of the non traumatic nature of the 
procedure we believe bone scans are still indicated in all breast 
cancer patients for the following reasons:
a. e x t ensive surgery is not indicated when bone m é t a s t a s é s  are 
de m o n s t r a t e d  as it cannot be curative
b. bone pain is a poor guide as to the presence of m é t a stasés  
(13).
c. patients with bone méta s t a s é s  at presentation have a poor 
prognosis (14, 15)
d. the initial bone scan is useful for comparing w i t h  scans 
during follow-up.
3.
Bone scans have also been used extensively in the follow-up after 
mastectomy. Many wo r k e r s  believe routine bone scanning is 
indicated during follow-up; others disagree, and suggest that 
routine studies be reserved for patients with adverse prognostic 
factors such as positive axillary nodes or evidence of vas c u l a r  
invasion. The bone scan should be the first i n v e s t i g a t i o n  in the 
patient w i t h  a clinical s u s p icion of métastasés (11).
The use of bone scans is well established in prostatic cancer and 
the study is valuable in the initial and follow-up a s s e ssment of 
all patients (16). It is u n clear w h e t h e r  the intensity of tracer 
uptake w i t h i n  m e t a s t a t i c  lesions can be used to m o n itor the 
response to hormonal therapy. In renal tumours bone scans appear 
to be of value in the s c r e ening for metastatic disease (17). It 
should also be re memb ered that renal tract pathology may be 
detected as an incidental finding on a bone scan (Figure 3). In 
patients with carcinoma of the cervix bone scans produce a useful 
yield of occult m é t a s t a s é s  only in patients with locally advanced 
disease (18).
The role of bone scans in e v a l u a t i o n  of patients with lung cancer 
remains c o ntroversial, though the consensus of opinion is that a 
bone scan should be obtained prior to thoracotomy (19). The bone 
scan is a useful method of detecting h y p e r trophic pulmonary 
o s t e o a r t h r o p a t h y  (8).
Primary bone tumours
Bone scans are v a l uable in the detection of osteoid osteoma, and 
should be performed in all patients in whom the diagnosis is 
suspected but x-rays are negative (20). Figure 4 shows a patient 
with an x-ray negative osteoid osteoma detected by bone scanning.
The bone scan is markedly abnormal at the site of primary 
osteosarcoma, but it has no advantage over x-rays in d e m o n s t r a t i n g  
the extent of the primary tumour (21). The frequency of distant 
métastasés at p r e s e n t a t i o n  is less than 5% (22, 23), but a bone
scan should be obtained at this time in view of the radical change 
in therapy n e c e ssitated by this finding. Since the intro d u c t i o n  
of adjuvant chemotherapy, a significant proportion of oste o s a r c o m a 
patients (15-20%) have bone métastasés as their first tumour 
recurrence (22, 23) and serial bone scans should be performed
during follow-up. Bone scanning agents may accumulate in soft 
tissue métastasés from o s t e o sarcoma, but they are an u n r e liable 
means of screening for such recurrences (2 3).
BONE SCANNING IN O S T E O M Y E L I T I S
Acute o s t e o m y e l i t i s  remains a difficult diagnosis. Acute 
osteo m y e l i t i s  produces an intensely increased uptake of bone
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scanning agents w i t h i n  24 hours of the onset of symptoms (24). 
Oc c a s i o n a l l y  the first i n d i c a t i o n  of osteomyelitis on the scan is 
an area of decreased tracer uptake w h i c h  is thought to represent 
an area of septic i n f a r c t i o n  (25). A. bone scan should be
obtained in all patients with a suspicion of acute os t e o m y e l i t i s  
and negative x-rays. The bone scan appears to be unreliable, 
however, in the diagnosis of acute osteomyelitis in infants (26).
D i f f iculty may be e x p e r i e n c e d  in d i f f e r e n t i a t i n g  acute 
o s t e o m y e l i t i s  and overlying cellulitis on standard bone scan 
images. This problem can sometimes be overcome by taking blood 
pool images, immediately after ad m i n i s t e r i n g  the tracer, in 
a d d ition to delayed images. In cellulitis there will be an 
initial high activity on the blood pool image but less intense 
focal activity on the delayed image whereas the initial high 
activity will be sustained in the case of acute o s teomyelitis 
(27) .
The bone scan is less useful in separating acute o s t e o myelitis 
from chronic o s t e o m y e l i t i s  in remission, as both will be 
a s s o ciated w ith a focal hot spot. Gallium-67 citrate imaging may 
be helpful as an a b n ormal Ga-67 image usually indicates an acute 
e x a c e r b a t i o n  (28). Recent work suggests that imaging w i t h  
Indium-111 labelled p o l y m o r p h o n u c l e a r  leucocytes may also be 
valuable in this context (29).
A s pecialised problem in the diagnosis of osteomyelitis is the 
e v a l uation of the patient w ith a painful prosthetic joint, 
particularly a hip replacement. The symptom may be due either to 
loosening of the prosthesis or to infection around it. It has 
been suggested that the pattern of bone scan uptake around the 
prosthesis can allow d i f f e r e n t i a t i o n  of these two diagnoses from 
standard bone scans (30), though there is debate about this.
From recent work it appears that Gallium-67 citrate images may 
yield false positive results in joint loosening. It has been 
suggested that the likelihood of infection is increased if the 
bone scan agent and G a l l i u m - 6 7  show incongruent distribution, 
while congruent d i stribution, unless very intense is more likely 
to indicate prosthetic loosening (28).
BONE SCAN A P P E A R A N C E S  IN THE M E T A B O L I C  BONE D I SORDE R S
As skeletal uptake of tracer is related to o steoblastic activity 
and blood flow, the bone scan essentially displays a functional 
image of skeletal m e t a b o l i c  activity and one would predict that 
the bone scan w o u l d  be of c o n s iderable value in metabolic bone 
disease.
However, in contrast to m e t a s t a t i c  disease where the 
c h a r a c t e r i s t i c  feature of the bone scan is the i r regularity of
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image (Figure 1) in m e t abolic bone disease the w h ole skeleton is 
often involved by the m e t a b o l i c  process and typically there is 
diffusely increased skeletal uptake of tracer. N e vertheless, 
while focal lesions may not be present, certain r e c o g nisable 
patterns of bone scan abno rmality and m e t a bolic features are 
particularly common in the m e t a b o l i c  bone disorders (31-33).
0 s t eomala c i a
The bone scan a p p e a rances in vi t a m i n  D deficient o s t e o m a l a c i a  are 
often strongly suggestive of a metabolic bone d i s order (32). 
However, the scan features are non-s p e c i f i c  and can be seen in 
other metabolic bone conditions (eg renal osteodystrophy). 
R e c o g n i s a b l e  scan features include generalised increased tracer 
uptake by the axial skeleton, long bones, p e riarticular areas, 
with the c a l varium and mandible appearing prominent. The renal 
images may appear faint and o c c a s i o n a l l y  are not seen due to 
c o m p e t i t i o n  between the skeleton and the k i d n e y s  for the tracer, 
reflecting increased bone uptake. The c o s t o - c h o n d r a l  junctions 
often appear prominent ('beading') and a c h a r a c t e r i s t i c  appearance 
of the sternum may also be seen where there is increased activity 
particularly round the lateral borders - the so-called 'tie' 
s te rnum ( 32 , 33) .
P s e u d o f r a c t u r e s  are common in severe o s t e o malacia and lesions may 
be s ymmetrical and c h a r a c t e r i s t i c a l l y  involve the ribs, femora, 
pelvic rami and scapula. P s e u d o f r a c t u r e s  on the bone scan are 
seen as focal areas of increased tracer uptake and in particular 
in the ribs where c o n v e n t i o n a l  x-rays may be normal, the bone scan 
is the more sensitive i n v e s t i g a t i o n  (34). However, 
pseudo-fractures in the pelvis may occasionally be missed on the 
bone scan due either to their s y m m e trical nature or because they 
are obscured by bladder activity (32).
Renal Os t e o d y s t r o p h y
Patients with renal o s t e o d y s t r o p h y  frequently have bone scan 
images which show the most striking a p p e arances seen in the 
various metabolic bone disorders. It is thought that most of the 
abnormal bone scan findings are due to the effect of secondary 
h y p e r p a r a t h y r o i d i s m  but c o - e x i s t i n g  osteo m a l a c i a  probably 
contributes. T y p ically there is markedly increased tracer uptake 
throughout the whole skeleton (31,35). In k e e p i n g  with the high 
bone uptake the renal images are often not visualised on the bone 
scan (31). The other m e t a b o l i c  features previously described for 
o steo m a l a c i a  are also commonly seen. Focal abnorm a l i t i e s  are 
generally not seen although on occasion the o steomalacia component 
of renal o s teodystrophy may be so severe that p s e u d o fractures 
occur.
Primary H y p e r p a r a t h y r o i d i s m
Patients with primary h y p e r p a r a t h y r o i d s m  can have bone scans 
ranging from normal to appe a r a n c e s  similar to those found in renal 
o s t e o d y s t r o p h y  depending on the severity of the bone disease (36,
37). While increased skeletal uptake of tracer can be det e c t e d  
by sensitive q u a n t i t a t i v e  techniques in virtually all patients 
with primary h y p e r p a r a t h y r o i d i s m ,  at least 50% of patients wil l  
have bone scan images w h i c h  appear subjectively normal (38).
Os t e o p o r o s i s
In oste o p o r o s i s  there is usually only a gradual reduction in bone 
mass w h i c h  occurs over many years. In k e e ping w i t h  this the bone 
scan a p p e a rances are usually normal. Osteo p o r o t i c  bones are 
abnormally brittle and p a t h o l o g i c a l  fractures may occur. These 
appear on the bone scan as focal abnormalities and w h e n  ver t e b r a l 
collapse has occurred, the scan appearances are c h a r a c t e r i s t i c  I
with linearly increased tracer uptake c o r r e sponding to the w h o l e  (
of the collapsed v e r t e b r a l  body (Figure 2), Generally this 
increased tracer activity fades over the following 12-18 m o n t h s  
and by comparing the scan and x-ray some est i m a t i o n  of the 
interval since collapse may be obtained (38, 39). O c c a s i o n a l l y ,
very poor scan images with low bone to background ratios are noted 
in severe or "end-stage" o s t e o p o r o s i s  and it has been suggested 
that these occur because of markedly reduced or absent 
oste o b l a s t i c  activity (40).
THE BONE SCAN IN PAGET'S DISEASE
Paget's disease is a c o mmon c o n dition with an incidence of 
ap p r o x i m a t e l y  4% in hospital patients over the age of 40 years.
The bone scan appe a r a n c e s  are often c h a r a c teristic (41) and it is 
important to recognise this con d i t i o n  as Paget's disease will 
often be an incidental finding on a scan performed for another 
reason, for example in the search for tumour or infection. The 
main feature on the bone scan in Paget's disease is intense uptake 
of tracer which is usually distributed uniformly throughout the 
involved bones (Figure 5). E x p a n s i o n  and dis t o r t i o n  of the 
affected bone is also commonly seen. When polyostotic Paget's 
disease is present there is seldom any doubt as to the correct 
diagnosis, so much so that it may be possible to detect 
co-e x i s t i n g  Paget's and m e t a s t a t i c  disease (8). When m o n o s t o t i c  
disease is present it may be difficult to d i f f e r e n t i a t e  this from 
other pathology and in par t i c u l a r  from a sclerotic lesion in the 
spine eg from carcinoma of the prostate, but often even the
a ppearance of a single lesion is so c h a r a cteristic as to be highly
suggestive of Paget's disease. While c o r r elation of x-rays and
bone scans in Paget's disease have shown that neither method alone
detects all lesions, it is clear that the bone scan is the more
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sensitive technique (41-43). In addition, those sites that are 
o ccasionally missed on the bone scan are m e t a b o 1 i c a 1 ly inactive 
(42, 43). Indi c a t i o n s  for performing a bone scan in Paget's 
disease include the i n v e s t i g a t i o n  of a patient wit h  elevated s e rum 
alkaline phosphatase levels and in any case where Paget's disease 
is clinically suspected. Where the diagnosis has been
esta b l i s h e d  a bone scan is of value to demonstrate the extent of
skeletal involvement and as a base line for future reference as 
patients with Paget's disease often have co-existent disorders 
such as o s t e o - a r t h r i t i s , rheumatoid arthritis or on occasion 
meta s t a t i c  disease. Patients undergoing therapy for Paget's 
disease, eg with either calcitonin or dipho s p h o n a t e  may show an 
i mprovement in the bone scan that parallels biochemical changes, 
while x-rays will usually remain unchanged. N e vertheless at the 
present time, while of some academic interest, there does not 
appear to be any clear i n d i cation for sequential bone scans as a 
means of mon i t o r i n g  therapy in Paget's disease as this can be more 
simply gauged by routine biochemistry.
THE BONE SCAN IN ARTHRITIS
Joint Ima ging
In the normal skeleton there is some increase of tracer uptake 
seen on the bone scan in the bone immediately adjacent to joints, 
and in general this appears symmetrical. For a joint to appear 
positive on scanning there requires to be increased tracer uptake 
relative to an unin v o l v e d  joint or markedly higher uptake whe n  
compared w i t h  adjacent n o n - a r t i c u l a r  bone.
R h e u m a t o i d  Arthritis
Inflammatory synovitis is associated with increased blood flow to 
the synovium and p e r i - a r t i c u l a r  bones, and as hyperaemia is 
recognised as a cause of increased tracer uptake it is likely that 
this is an important factor leading to a positive bone scan in 
rheumatoid arthritis. However, the intensity of uptake of a bone 
seeking r a d i o p h a r m a c e u t i c a l  has been shown to be higher than a 
blood pool imaging agent in acute inflammation suggesting that 
there is increased uptake of tracer by p e ri-articular bone, 
perhaps due to local remodelling following bone resorption 
(44,45).. W h a t e v e r  the precise m e c h anism there is no doubt that 
in rheumatoid arthritis intense areas of increased tracer uptake 
are seen at sites of activity on the bone scan, but the 
a ppearances in themselves are non-specific and may be seen in a 
wide variety of conditions including psoriatic and gouty 
arthritis, ankylosing spondylitis, seronegative polyarthritis, 
h y p e r t r o p h i c  osteoar t h r o p a t h y ,  reflex sympathetic dystrophy 
syndrome and regional mig r a t o r y  osteoporosis (28). However, it 
has been suggested that certain features on the scan such as 
s ymmetrical disease with peripheral joint activity greater than 
axial activity, u n i f o r m  i n v o lvement of the wrists and proximal
8.
joints of the limbs and feet, and typical skeletal defo r m i t i e s 
would favour a d i a g nosis of rheumatoid arthritis (46).
In rheumatoid a r t h ritis the bone scan has been shown to be able to 
antedate clinical and radiographic m a n i f e s t a t i o n  of i n f l a m m a t o r y  
synovitis (45-47), N e vertheless, once a diagnosis of 
i n f l ammatory synovitis has been established the bone scan will not 
provide any a d d i tional i n f o r m a t i o n  and therefore its role in the 
routine management of patients with rheumatoid arthritis is 
limited (28), While it has been suggested that the bone scan may 
provide an accurate means of monitoring a patient's response to 
therapy (28), its advantage in clinical practice over simpler 
techniques remains to be established.
In c h i ldren the bone scan has proven to be d i s a p p o i n t i n g  in the 
det e c t i o n  of rheumatoid arthritis. This is thought due to the 
fact that tracer uptake in the growth plate obscures any increased 
uptake in p e r i - a r t i c u l a r  bone, induced by i n f l a mmatory synovitis 
(45).
Ank y losing Spondylitis
Acute sa c r o - i l i i t i s  will produce a positive bone scan image and it 
is now well recognised that the bone scan may detect 
rad 1 o 1ogicla 1 ly negative s a c r o - iliitis ( 28, 48, 49 ). The 
d i f f iculty w h ich arises when a s s e ssing the s a c r o-iliac joints on 
the bone scan is that they usually appear hotter than the 
surr o u n d i n g  pelvis and sacrum in normal subjects, and even more so 
in young subjects in who m  sacro - i l i i t i s  is most frequently seen. 
Also while s a c r o - i l i i t i s  may be unilateral it is commonly 
bilateral and in this situation it may not be possible to detect 
any abno r m a l i t y  on subjective evaluation. To overcome such 
d i fficulties a q u a n t itative technique,, using a computer, has been 
developed w h e r e b y  a ratio relating the uptake of tracer by each 
s a c r o-iliac joint to that of the body of the sacrum is obtained 
(49, 50). This ratio is a b n o r m a l l y  high early in the disease
process whe n  x-ray findings are often minimal or absent, but tends 
to approach normal as end-stage fusion of the joints develops.
In patients w ith a n k y l o s i n g  spondylitis it may be possible to 
identify on the bone scan a diffuse increase in spinal uptake of 
tracer, most often seen in the low dorsal spine and in ad d i t i o n  
more focal a b n o r m a l i t i e s  at the apophyseal joints are frequently 
seen. As there is a tendency to bony ankylosis the scan image 
will often fail to clearly illustrate the normal segmental anatomy 
of the spine. A n k y l o s i n g  spondylitis may also be a s s o ciated with  
a peripheral a r t h r o p a t h y  which will be seen on the bone scan (48),
O s t e o a r t h r i t i s
In o s t e o a r t h r i t i s  the i n c r eased mechanical stresses o c c u rring a t 
altered joint surfaces lead to an osteoblastic reaction and
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reactive new bone formation w h i c h  is readily d e m o n s t r a t e d  by bone 
scanning. Typically the scan appearances show a s y m m e t r i c  tracer 
uptake at sites of involvement, w h i c h  correspond to the w e ight 
bearing joints and the distal joints of the hands and feet.
Patchy tracer uptake with more focal areas in the lower lumbar 
spine is also a common scan finding w h e n  degen e r a t i v e  disease is 
present. As d e g e n e r a t i v e  disease of the spine is common such 
scan appe a r a n c e s  may o ccasionally lead to some c o n f u s i o n  when 
m e t a static disease is suspected. For this reason it is always 
essential to x-ray any such area of abnormality to c o n firm the 
presence of degen e r a t i v e  change.
In the a s s e s s m e n t  of o s t e o a r t h r i t i s  of the knee the bone scan has 
been shown to be more sensitive than physical examination, 
radiography and d o u b l e - c o n t r a s t  arthrography (51) and it was shown 
that the scan provided important supplementary i n f o r m a t i o n  in 
those patients in w h o m  surgery was contemplated.
ASEPTIC NECROSIS AND I NFARCTION
Bone scans can be helpful in the diagnosis of aseptic necrosis and 
infarction, in disorders such as L e g g - P e r t h e 's disease, sickle 
cell anaemia and caisson disease (28). The initial p a t h ological 
process in each is bone ischaemia, and bone images obtained at 
this stage wil l  show a zone of decreased tracer uptake. As the 
pathological process continues a peripheral zone of increased 
uptake develops and slowly replaces the photon deficient area.
The bone scan should be performed as an early i n v e s t i g a t i o n  in 
patients with suspected a v a s c u l a r  necrosis, as it will often 
c o n firm the diagnosis at a time when x-rays are negative or 
equivocal. It should be noted that special views may be required 
on occasion eg pinhole images of the hips in the "frog leg" 
position in children with suspected Le g g - P e r t h e ' s  disease. The 
value of a bone scan in p redicting aseptic necrosis of the femoral 
head after femoral neck fracture is currently being assessed.
T H E _ B ONE SCAN IN T R A U M A
Bone scanning is not a primary diagnostic modality in patients 
with bony trauma. However, it can be useful in some particular 
situations, such as a s s e s s m e n t  of radiologically difficult sites 
such as the wrists, hips, ribs and sternum, where a persistently  
negative bone scan virtually excludes a fracture. A positive 
scan is not completely d i a g n o s t i c  of fracture as it may be seen 
due to other trauma induced pathologies such as su b - p e r i o s t e a l  
haematoma. Bone scans may remain abnormal for some time after a 
fracture (39) but p e r s istently positive scans beyond about 18 
months are usually asso c i a t e d  e i ther with secondary degen e r a t i v e 
disease or healing in poor alignment. The use of the bone scan 
in s t u dying adequacy of fracture healing has been evaluated in a 
number of animal models but has not yet found wide a c c e ptance in 
clinical practice.
Two spec i a l i s e d  areas of trauma w h e r e  bone scanning is very 
valuable are diagnosis of stress fractures and a s s e s s m e n t  of 
ba t t e r e d  babies. In stress fractures, c h a r a c t e r i s t i c a l l y  found 
in athletes, recurring episodes of minor stress lead to some 
d i s o r g a n i s a t i o n  of the bone trabeculae. This causes sufficient 
o s t e o b l a s t i c  response to give an abnormal bone scan, some two or 
three weeks prior to the onset of radiological signs of 
s u b p e r i o s t e a l  new bone or sclerosis along a line of healing (52). 
Thus the bone scan enables earlier restriction of activity, 
allowing he a l i n g  to o c cur and preventing p r o g ression to a more 
gross fracture. The bone scan is helpful in the diagnosis of the 
"battered baby syndrome" w h e r e  multiple scan a b n o r m a l i t i e s  may be 
found throughout the skeleton, resulting both from frank fracture 
and from s u b p e r i o s t e a l  h a e m a t o m a  (53).
FIGURE la
Normal, posterior view 
thoracic spine.
FIGURE Ib
Multiple bony métastasés 
in patient with carcinoma 
of breast.
K
>
FIGURE 2
Posterior view thoracic spine 
in osteoporotic subject 
showing multiple collapsed 
vertebrae with multiple 
focal abnormalities in ribs 
due to trauma and fracture.
FIGURE 3
Anterior view pelvis 
showing retention of 
tracer in left urinary 
tract due to hydronephrosis 
and hydroureter.
%
FIGURE 4
Anterior view pelvis showing 
osteoid osteoma left femoral 
neck. X-ray negative.
FIGURE 5
Posterior view thoraco­
lumbar spine showing 
Pagetoid involvement of 
lumbar vertebra 1 and 
left hemi-pelvis.
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Comment
This paper having been recently written, post-dates 
the studies described in the thesis but is included 
because I believe it clearly indicates the extent to 
which the bone scan is now accepted as a diagnostic 
procedure in many clinical settings.
As regards the use of bone scanning in metabolic 
bone disease De Nardo et al (1972) after ten years' of 
experience stated that "while the scan provides a 
sensitive method for detecting diseases that elicit a 
localised reparative reaction of the skeleton, the scan 
is not helpful in the evaluation of diseases that diffusely 
affect the skeleton". Part of the work in this thesis 
shows this to have been an over pessimistic assessment 
and indeed current books and review articles on bone 
scanning will inevitably include sections on metabolic 
bone disease (Citrin and McKillop, 1978; McDougall 1979;
Sy 1981).
& ;
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CHAPTER 2
■RECOGNITION OF METABOLIC FEATURES AND QUANTITATION 
OF SKELETAL UPTAKE OF TRACER FROM THE BONE SCAN IMAGE
33
In this chapter, four papers (3-6) are presented 
which deal with bone scan appearances, and methods of 
quantitating skeletal uptake of tracer from the scan 
image in metabolic bone disease.
34 .
Paper 3. The role of bone scanning in osteomalacia (1978) 
Journal of Nuclear Medicine 19 : 245-248
I Fogelman, J H McKillop, R G Bessent , I T Boyle,
J G Turner, W R Greig
Purpose of Investigation
At the time this investigation was conceived there 
were relatively few reports of bone scanning in metabolic 
bone disease. It was, however, apparent to me from previous 
studies that the pattern of abnormality seen on the scan in 
both primary hyperparathyroidism and renal osteodystrophy 
were very similar. While there had been no formal study 
describing the bone scan appearances in osteomalacia, I 
wondered whether here too the appearances would conform to 
the same overall pattern which perhaps was typical of 
metabolic bone disease in general. In addition, I wondered 
•whether such scan appearances could be utilised to 
differentiate patients with metabolic bone disease from 
control subjects. Accordingly, bone scans were obtained 
in patients with osteomalacia, and these together with 
normal scans and scans from patients with metastatic disease, 
were evaluated without any knowledge of the clinical 
information.
The Role of Bone Scanning in Osteomalacia
Ign ac  F o g e lm a n ,  J a m e s  H. M cKillop, R o d ney  G. Bessent,  lain T. B oyle ,
John  G . Turner, a n d  W ill iam  R, G re ig
The Royal Infirmary, Glasgow, Scotland
The presence of eight '^‘metabolic features^^ was assessed on the bone  
scintigrams of ten patients with osteomalacia. In all of these bone images, 
suffi,cient features were present to strongly suggest a metabolic disorder. 
These scintiphotos were included in a controlled blind study using 30  nor­
mal hone scans and 20  scans of metastatic disease, ISine of the ten metabolic  
bone images were correctly identified by two independent observers. Skeletal  
uptake of radiotracer, expressed as bone-to-soft-tissue ratio, was signifi­
cantly higher in the osteomalacic patients than in a group of 80  controls,
J Nucl Med 19: 245-248, 1978
Bone scanning is now established as a highly sen­
sitive means of detecting bone métastasés, and its 
superiority over radiographic detection is well recog­
nized (1 ,2 ). Nevertheless, its use in metabolic bone 
disease has been limited, although several workers 
have suggested that it may have a useful role to play 
in these disorders (3 -7 ) .  Using Tc-99m HEDP, we 
have obtained bone images in ten patients with os­
teomalacia, and this communication describes our 
findings.
METHODS
The study group consists of ten patients complain­
ing of bone and muscle pain and with histologically 
proven osteomalacia from various causes (Table 1). 
In each patient multiple views of the skeleton were 
recorded on Polaroid film from a gamma camera 
fitted with a high-resolution medium-sensitivity col­
limator. Spinal views were obtained with 300,000 
counts, and all other views with a minimum of 
100,000 counts. Bone images were obtained 4 hr 
after the i.v. injection of 15 mCi of Tc-99m HEDP. 
The scintiphotos were evaluated for the presence of 
the following features, which although not neces­
sarily specific have been reported in various meta­
bolic bone diseases: (a) a subjective impression of 
increased tracer uptake by the axial skeleton (4 ,8 ), 
by the long bones (3 -5 ) ,  and by the wrists (5 ) ; (b) 
prominent calvarium and mandible (5 ,7 ); (c) bead­
ing of the costochondral junctions (4 ,5);  and (d) 
faint kidney images (4).  In addition, two other
features— focal abnormalities representing pseudo­
fractures (Fig. 1) (9,10) and a “tie” sternum (Fig. 
2 ), which we have observed in osteomalacic patients 
— were also included. All of these “metabolic fea­
tures” were scored either as absent, probably present, 
or definitely present. The ten sets of images were also 
included in a controlled blind study using 50 addi­
tional, randomly selected sets of bone scans; 30 nor­
mal studies and 20 showing metastatic disease. Two 
observers evaluated the 60 sets of bone images inde­
pendently without knowledge of patient identifica­
tion. Each image was recorded as normal, metastatic, 
or metabolic (Table 3).
In addition to the Polaroid prints, all images were 
recorded and stored on a minicomputer by means of 
an analog-to-digital interface. The pictures were 
stored on computer magnetic tape for later retrieval 
and processing, and were displayed on a color TV 
screen. Bone-to-soft-tissue ratios were measured by 
using the computer to define regions of interest 
around the L2 vertebra and an area just below the 
kidney on the TV image. In each area the ratio of 
the counts per unit area from the former region to 
the latter was calculated from the teletype printout 
of the total counts. Similarly, these ratios were cal­
culated for a control group of 80 females with breast
Received July 26, 1977; revision accepted Oct. 18, 1977. 
For reprints contact: I. Fogelman, Royal Infirmary, Dept, 
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TABLE 1. CLINICAL A N D  BIOCHEM ICAL D A T A  FROM  O STEO M A LA C IC  PATIENTS
Patien t  No., 
a g e ,  a n d  sex Diagnosis
Serum colcium 
(normol 
2 .2 -2 .6  mmol/ l )
Serum p h o s p h o te  
(normol 
0 .8—1.4 mmol/ l )
Serum o ikoline  
p h o s p h o to s e  (normol 
8 0 - 2 8 0  u / l )
A lbumin (normol 
3 5 - 5 5  g / l )
1. 34 M Vitomin-D defic iency 
o s teo m ala c ia
1.8 1.5 1,501 38
2. 74 F Vitomin-D defic iency 
os teom oloc io
2.15 1.0 57 6 36
3. 68 F Postgas trec tom y
os teom olocio
2.05 0.85 679 34
4. 23 F Vitomin-D defic iency 
os teom olocio
2.0 1.3 99 0 33
5 . 20 M Crohn 's  d i s e a s e  
os teom olocio
1.9 0.7 933 25
6. 30 F Vitomin-D defic iency 
os teom oloc io
2.1 0.75 1,195 40
7. 67 F Pos tgastrec tom y
os te o m a la c ia
1.8 1.2 1,004 41
B. 15 M Vitomin-D defic iency 
os teom oloc io
1.6 1.35 2,218 45
9. 33 M Coelioc d iseose  
os teom olocio
1.9 0.8 1,391 45
10. 79 F Anticonvulsont-
in duced
os teom oloc io
1.7 1.1 9 2 7 34
carcinoma (age range 32-84 yr) without either 
clinical or scintigraphic suspicion of bone métastasés.
RESULTS
The relevant clinical and biochemical details of 
the osteomalacic patients are shown in Table 1.
Table 2 summarizes the qualitative and quantita­
tive results of the scintigraphic studies in the osteo­
malacic patients. The mean bone-to-soft-tissue up­
take ratio for the osteomalacic group was 6.57 ±  
1.43 (s.d .), whereas that in the 80 control patients 
was 4.05 +  0.69. Using the Wilcoxon rank sum test, 
the uptake in the osteomalacic group was signifi­
cantly higher (p <  0.001 ).
The results of the controlled blind study of the 
60 bone images are shown in Table 3. Both observers
correctly identified all 30 normal studies and all 20 
metastatic studies. Each observer also correctly iden­
tified nine of the ten images from the osteomalacic 
patients.
DISCUSSION
The bone-to-soft-tissue ratio is usually found to 
be normal in patients with primary hyperparathy­
roidism (6,11).  Seven of our osteomalacic patients 
had elevated ratios compared to our control group; 
this suggests increased tracer uptake by the axial 
skeleton, but it was not always apparent from the 
Polaroid images (Table 2 ). An elevated bone-to- 
soft-tissue ratio, when present, however, will support 
a presumptive diagnosis of osteomalacia.
The most consistent subjective “abnormalities”
FIG. 1. D orso lum bar  sp ine .  Mult ip le  hot spots  in ribs.  R ad io ­
g ra p h s  confi rm ed p s eu d o f rac tu res  a t  these  sites.
FIG. 2. A nte r io r  view of chest  with  m a rk e d  in c re a se d  u p ta k e  
of t ra c e r  by  s te rnum ,  e sp e c ia l ly  a t  its m a rg in s — so-cal led  " t i e  
s te rnum " .
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TABLE 2 . BONE-TO-SOFT-TISSUE (B/ST) RATIOS AND SUBJECTIVE ASSESSMENT* OF SCAN IMAGES
Inc re a sed  u p ta k e  of Promi-
ra d io p h a rm a c eu t i c a l  by Hot n en t
Bead ing spots m a n d ib le
Axial costo ­ "Tie (pseudo- a n d Faint
Patient sk e le ­ Long chondra l s ter­ f rac ­ ca l­ k idney ra t io
No. ton bones W ris ts junction n um " tures) varium im ages B/ST
1 4- + 4-4- 4-4- +4- 4-4- 4- 4.7
2 + +4- 4--F + -F4- 4-4- 4-4- 4-4- 7.8
3 4-4- 4— h — — -F+ 4- 4-4- 5.0
4 -F4- 4-4- nof re c o rd e d 4-4- 4-4- 4-4- 4--H -44- 7,6
5 4-+ 4-+ 4-4- -4 — 4-4- 4— h -4 6.9
6 4-4- 4-4- -f+ 4- — 4-4- 4-4- 4—t- 9.0
7 4-4- 4- 4-+ 4- 4-4- 4-4- — 4- 4.9
8 4—h 4-4- 4-4- 4-f 4- — -44- 4—h 7.2
9 4- 4-4- 4-4- 4-4- 4- 4-+ -44- 4- 6.8
10 4- 4-4- 4- — 4- 4-4- 4- -4 5.8
* A b se n t  — P robab ly  p re sen t  -f-; Defini tely p re s e n t  -]—
TABLE 3. CONTROLLED BLIND ASSESSMENT 
OF BONE SCINTIGRAMS
M etabolic M eta s ta t ic Normal
N u m b e r  
O b se rv e r  J.G.T. 
O b se rv e r  J.H.McK.
10
9
9
20
21
21
30
30
30
noted on the bone images were increased uptake of 
radiopharmaceutical by the long bones and wrists, 
with apparent prominence of the calvarium and man­
dible (Table 2 ). However, these appearances are 
nonspecific and are found in other metabolic con­
ditions such as hyperparathyroidism (4).  Other use­
ful indications of a metabolic disorder— although 
seen less often in our cases— were the presence of 
beading of the costochondral junctions, and the “tie 
sternum.” Again, these features may be nonspecific 
in that they can be seen in patients with renal osteo­
dystrophy, although there is often a significant degree 
of osteomalacia in such patients.
Although the kidneys were visualized in all pa­
tients, in five the kidneys were faint, perhaps reflect­
ing reduced excretion of tracer by the kidneys due 
to increased skeletal uptake. Pseudofractures were 
detected in nine patients. In one patient, the pre­
vious radiological skeletal survey had been normal, 
whereas on the scintigram multiple hot spots were 
seen over the ribs. Subsequent coned radiographs of 
the areas of abnormality confirmed the presence of 
several pseudofractures, although these were still not 
seen in some of the areas indicated by the bone 
study. In the other patients, routine radiographs 
identified pseudofractures at the sites of abnormality
seen on the bone image. In two patients, however, 
pelvic pseudofractures shown unequivocally by con­
ventional radiology were not detected on initial scan 
interpretation. On review of the bone images it was 
apparent that in one patient there were scintigraphic 
abnormalities attributable to the pseudofractures, but 
these had been missed because of their symmetrical 
nature. In the second patient, no pelvic abnormality 
was detectable, even on review.
Although the bone images in osteomalacia appear 
to be nonspecific, we considered that in all our pa­
tients, the scintigrams strongly suggested a metabolic 
disorder. These images were therefore included in a 
controlled blind study with 50 sets of normal and 
metastatic bone scintigrams. Table 3 shows that nine 
of the ten sets of metabolic scans were diagnosed as 
such by two independent observers. There was com­
plete agreement on all the normal and metastatic 
images, and on eight of the metabolic ones. No nor­
mal or metastatic scan was recorded as metabolic. 
Each observer considered one osteomalacic scan to 
be metastatic, and these scans had multiple focal 
abnormalities representing pseudofractures. Thus an 
awareness of “metabolic features” on a bone image 
may alert one to the presence of a metabolic dis­
order, often with high probability. However, the 
bone-scan appearances are nonspecific and it is im­
portant that adequate clinical information be avail­
able during the reading of such scans, since the 
presence of focal abnormalities, for example, can be 
mistaken for other conditions, such as metastatic 
disease.
The bone scintigram, therefore, has a role to play 
in the detection of osteomalacia, since a combination 
of several “metabolic features,” together with a 
raised bone-to-soft-tissue ratio, support this diag-
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iiosis. Multiple focal defects in such an image sug­
gest the presence of pseudofractures, although other 
conditions cannot be excluded. Roentgenographs of 
such lesions are mandatory.
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PURPOSE OF THE SYMPOSIUM
The purpose of this symposium is to provide 
a forum for the exchange of information 
related to the biological transport, mech­
anisms of localization and metaboiic path­
ways of radiotracers used in medicine. The 
need for the discussion of basic radiotracer 
chemistry and pharmacoiogy has been 
widely recognized and we hope that this 
symposium will serve to satisfy this need.
Sessions w ill include both invited and 
contributed papers. The submission of 
abstracts will be called for later.
This meething has been approved for 24 hr 
of Category 1 credit.
If you are interested in attending or actively 
participating in the symposium, please fill 
out the form on this page, and mail it to:
Dr. Lelio G. Colombetti, Chairman 
First International Symposium on Radio­
pharmacology 
Pharmacology Department 
Loyola University Stritch School of 
Medicine 
2160 South First Avenue 
Maywood, Illinois 60153
Innsbruck, Austria
MAIN TOPICS
GENERAL CONSIDERATIONS
Radiotracers receptors
Molecular properties of radiotracer re­
ceptors
Binding forces in radiotracer-receptor 
systems
Characterization of radiotracer-receptor 
interactions
BIOLOGICAL TRANSPORT OF RADIO­
TRACERS
Membranes: composition, structure and 
function
Thermodynam ics and kinetics in the 
transport of radiotracers
Mechanisms and energy involved in the 
transport of radiotracers
STRATEGY OF RADIOTRACERS DESIGN
Linear-free, energy related models 
“novo” model
Classical design concepts
MECHANISMS OF LOCALIZATION
Compartmental localizations
Cell function as a mechanisms of locali­
zations: muscle, kidneys, hepatocytes, 
etc.
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Comment
This paper introduces for the first time the term 
"metabolic features" and also the important concept of 
such features being recognisable on bone scans from 
patients with metabolic bone disease. While all the 
individual features, with the exception of the "tie" 
sternum had been previously described in various 
publications, their general application to metabolic bone 
disease had not been recognised. This theme is further 
developed and the wider application of metabolic features 
illustrated in papers 4 and 5. It should be noted, 
however, that the presence of focal lesions on the scan 
cannot be considered a metabolic feature and in retrospect 
should not have been included as such. Nevertheless when 
the scan appearances do suggest the presence of a metabolic 
disorder and focal lesions are present , particularly in the 
ribs, the possibility of osteomalacia with pseudofractures 
should be considered in the differential diagnosis.
It has been shown in the present study that by 
recognition of metabolic features on the bone scan, 
patients with osteomalacia can be identified in the great 
majority of cases, and differentiated from both normal 
subjects and those with metastatic disease. It must, 
however, be emphasised that the metabolic features described 
are not specific to osteomalacia and may be seen in a wide 
variety of metabolic bone disorders or in any situation 
where there is generalised increased bone turnover.
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Paper 4. Semi-quantitative interpretation of the bone scan 
in metabolic bone disease. Definition and 
validation of the metabolic index (1979)
European Journal of Nuclear Medicine 4: 287-289
I Fogelman, D L Citrin, J G Turner, I D Hay,
R G Bessent, I T Boyle
Purpose of Investigation
Following on from the work described in paper 3, I 
suggested that metabolic features on the bone scan may be 
seen in a wide variety of clinical settings. Indeed these 
features simply demonstrate increased uptake of tracer at 
various sites in the skeleton and many are normally seen on 
the adolescent bone scan, reflecting the high avidity of the 
growing skeleton for bone seeking radiopharmaceuticals. 
However, I believed that recognition of those features on 
the adult bone scan might be of value in the identification 
of patients with increased skeletal metabolism. I considered 
that simple visual evaluation of the bone scan was too 
subjective for this purpose and suggested that a semi- 
quantitative scoring system be derived from the scan image.
Quantitation of skeletal uptake of tracer is 
theoretically attractive for if generalised increased bone 
turnover exists, there will also be increased skeletal avidity 
for bone seeking radiopharmaceuticals (Neuman and Neuman,
1953).
37 .
However, in the absence of focal lesions on the bone scan 
image an awareness of abnormality depends upon a 
subjective impression of increased tracer uptake by the 
skeleton, and this is not always apparent. Accurate 
quantitation of tracer uptake by the skeleton may 
provide a sensitive means of evaluating altered skeletal 
metabolism.
In the present study three independent observers 
numerically graded seven metabolic features on the bone 
scan images from 50 control subjects and 100 patients with 
various metabolic bone disorders, the total score for an 
individual subject being defined as the metabolic index. 
The purpose of the study was to evaluate whether this 
metabolic index allowed differentiation between control 
subjects and those with metabolic bone disease.
Eur. J. Nucl, Med. 4, 287-289 (1979) sz,N uclearMedicine
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Semi-Quantitative Interpretation of the Bone Scan 
in Metabolic Bone Disease
Definition and Validation of the Metabolic Index
Ignac Fogelman Q Dennis L. Citrin^, John G. Turner \  Ian D. Hay \  Rodney G. Bessent^, 
and Iain T. Boyle ‘
' University Departments o f Medicine and Nuclear Medicine, G lasgow Royal Infirmary, Glasgow, 0 4  OSF, Scotland 
 ^ Department o f  Human Oncology and Medicine, University o f W isconsin Hospitals, Madison, W isconsin 53706, USA  
 ^ Department o f  Clinical Physics and Bio-Engineering, Glasgow, Scotland
Abstract. Certain easily recognisable features are com­
monly seen in the bone scans of patients with meta­
bolic bone disorders. Seven such features have been 
numerically graded by three independent observers 
in the scans of 100 patients with metabolic bone dis­
ease and of 50 control subjects. The total score for 
each patient is defined as the metabolic index. The 
mean metabolic index for each group of patients with 
metabolic bone disease is significantly greater than 
that for the control group ( f  <0.001).
Introduction
The bone scan is of value in the diagnosis and assess­
ment of patients with benign skeletal disease (M arty 
et al., 1976). In metabolic bone disease certain pat­
terns of bone scan abnormality are common and we 
have previously described several scan features which 
are characteristic of these disorders (Fogelman et al., 
1978 a). Other workers have suggested techniques for 
numerical assessment of scan features in parathyroid 
disease, (Olgaard et al., 1976; Sy and M ittal, 1975; 
Krishnamurthy et ah, 1977) but inter-group correla­
tion and comparison with a control group have not 
been reported. In this study we describe a semi-quan­
titative diagnostic index for metabolic bone disease 
derived from the bone scan.
Materials and Methods
One hundred patients with metabolic bone disease (29 patients 
with renal osteodystrophy, 14 with osteomalacia, 15 with osteopo-
Send offprint requests to: Dr. I. Fogelman
rosis, 13 with primary hyperparathyroidism, 9 with thyrotoxicosis, 
20 with acromegaly) and 50 control subjects were studied. In each 
patient the diagnosis was confirmed by relevant biochemical and 
radiological studies. In addition bone biopsies were obtained in 
all patients with osteoporosis, osteomalacia and primary hyperpa­
rathyroidism. The control group was com posed o f 50 female pa­
tients with primary breast cancer who had been referred to our 
Department o f Nuclear Medicine for bone scanning as part o f  
their initial evaluation or routine post mastectomy follow-up. There 
was no clinical suspicion o f skeletal métastasés in these patients 
and in all cases the bone scans were reported as showing no focal 
abnormality by three independent observers. By these criteria, the 
patients were considered to be suitable "normal" controls and 
their scans were re-analysed for the presence o f  metabolic features 
as described below.
In all patients the bone scan was obtained 4 hours after the 
intravenous injection o f 15 mCi o f ‘' ‘^ '"Tc-hydroxyethylidene di- 
phosphonate (H .E.D.P.). Multiple views of the skeleton were 
recorded on Polaroid film using an Ohio Nuclear Series 100 gamma 
camera fitted with a high resolution medium sensitivity collimator. 
Views of the spine were obtained with 300,000 counts, o f pelvis, 
shoulder and sternum with 150,000 counts, o f skull with 100,000 
counts, and o f  limbs with 30,000 counts.
The scan images of patients and controls were independently 
evaluated in a random order by three observers who were unaware 
o f the clinical diagnosis. Each bone scan was inspected for seven 
metabolic features (listed in Table 1) which we have previously 
shown to be common in metabolic bone disease, (Fogelman et ah, 
1978a). These features were independently scored by each observer: 
0 -  Normal; I -  Abnormal; or 2 - Markedly abnormal (e.g. 
Figs. 1-3). The sum o f the scores for each metabolic feature 
was defined as the M etabolic Index for that patient.
Table I .  Metabolic features
1. Increased activity in axial skeleton
2. Increased activity in long bones
3. Increased activity in periarticular area (wrist)
4. Prominent calvarium and mandible
5. Beading o f the costo-chrondral junctions
6. “ Tie" sternum
7. Faint or absent kidney images
0340-6997/79/0004/0287/$0I.00
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Kig. I. Bone scans o f anterior thorax. Normal, with 2 examples o f  beading of the costo-chondral junctions. (These and images shown 
in Figs. 2 and 3 are graded 0. 1 and 2 respectively)
Fig. 2. Posterior views o f lumbosacral spine demonstrating normal, faint and absent kidney images
Results
The mean scores obtained for the metabolic index 
by each of the 3 observers for the different study 
groups are shown in Table 2. There was good concor­
dance between individual observers. The last 2 col­
umns of Table 2 show the mean of the 3 observers’ 
results and the absolute range for each group.
The metabolic index of each patient group was 
significantly higher than that of the control group 
(P <0.001, using the Wilcoxon Rank Sum Test). 
There was. however, overlap between individual pa­
tient results and normal controls. This was not seen 
in patients with renal osteodystrophy and osteomala­
cia. where each individual patient’s result lay outside 
the normal range. The mean metabolic index of the 
renal osteodystrophy and osteomalacia groups was 
significantly higher than the other patient groups 
(R<0.02). In addition, the mean metabolic index of 
the thyrotoxic group was significantly higher than 
that of the osteoporotic group ( P < 0.005).
The distribution of individual results of the meta­
bolic index (mean of 3 observers) is shown in Fig. 4.
Discussion
In contrast to metastatic disease where focal abnor­
malities are characteristically seen, the bone scan
Table 2. Results o f metabolic index": mean and range o f 3 observers
No. Observers Mean Absolute
range
1 2 3
Controls 50 0.6 0.8 0.7 0.7 0 -  2.3
Osteoporosis 15 2.1 1.7 2.2 2.0 0.3 5.0
.Acromegaly 20 4.0 4.0 5.1 4.4 0 -10.7
Primary 13 5.3 5.0 5.0 5.1 0.3 12.3
Hyperparathyroidism
Thyrotoxicosis 9 5.1 6.0 5.2 5.4 0 -  9.0
Renal Osteodystrophy 29 9.5 8.5 8.5 8.8 3.3-14.0
Osteomalacia 14 9.3 7.9 10.2 9.1 4.3-12.3
" Metabolic Index in an individual patient is a whole number 
without decimals
diagnosis of metabolic bone disease depends upon 
recognition of generalised increased bone uptake of 
radiopharmaceutical. This may be difficult to assess 
on visual interpretation and simple quantitation of 
the bone scan image as measured by bone to soft 
tissue ratios may also be unreliable, (Fogelman et al., 
1978 b). We have previously described scan features 
which are commonly seen in metabolic bone disease 
and found that these features differentiated between
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Fig. 4. Distribution o f individual results for metabolic index. (Mean o f three observers)
lap with the control range rendering a normal result 
in an individual patient of limited value.
The metabolic index provides a reproducible semi- 
quantitative diagnostic index for metabolic bone dis­
ease. It focuses attention on specific metabolic fea­
tures of the bone scan, and an elevated value may 
alert an observer to the presence of a metabolic bone 
disorder which requires further investigation.
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Comment
This study illustrates that a numerical score reflecting 
skeletal avidity for tracer can be obtained from a bone 
scan image by visually evaluating several metabolic features, 
This metabolic index has been shown to allow differentiation 
of groups of patients with various metabolic bone disorders 
from control subjects. Nevertheless, the overlap in 
most groups, between patients and controls, limits its 
value in individual patients.
However, the metabolic index score is extremely simple 
and quick to obtain, and can thus provide a convenient 
semi-quantitative means of evaluating a bone scan image. 
Indeed it has been used in this way in a recent study by 
Alberts et al (1981) where bone scans from patients with 
symptomatic renal osteodystrophy were evaluated for severity 
of disease. The metabolic index may also be of some value 
where sequential studies are being performed on an 
individual patient to document change, either improvement or 
deterioration, over a period of time. At its simplest 
the metabolic index will focus an observer's attention as 
to the presence or otherwise of metabolic features on the 
bone scan.
Nevertheless, even the above statements as to the 
limited usefulness of the metabolic index in metabolic
39.
bone disease may need review in the light of current 
bone scanning practice. When this study and indeed 
all the bone scan imaging described in this thesis were 
carried out, Tc-99m hydroxyethylidene diphosphonate 
(HEDP) was the radiopharmaceutical used. Currently 
TC“99m methylene diphosphonate (MDP) is the most widely 
used bone scanning agent and this has significantly 
higher skeletal uptake than HEDP (see paper 14). From 
personal experience I believe that the presence of 
metabolic features on the bone scan is less obvious when 
higher bone uptake is routinely obtained in normal subjects, 
and the metabolic index is thus likely to prove less 
discriminating with MDP scans. A comparison of the 
available diphosphonate bone scanning agents and the 
clinical implications of their use is discussed in 
chapter 5.
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Paper 5. Semi-quantitative analysis of the bone scan in 
acromegaly: Correlation with human growth
hormone values (1980)
British Journal of Radiology 53: 874-877
I Fogelman, I D Hay, D L Citrin, G H Beastall, 
J G Turner, R G Bessent.
Purpose of Investigation
The purpose of this investigation was to evaluate 
bone scan images in patients with acromegaly, and 
correlate the metabolic index, reflecting skeletal 
avidity for a bone-seeking radiopharmaceutical, with 
serum growth hormone values, a biochemical measure of 
disease activity.
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Semi-quantitative analysis of the bone scan in acromegaly: 
correlation with human growth hormone values
By I. Fogelman, B.Sc., M.B., M.R.C.P., I. D. Hay, Ph.D., M.B., M.R.C.P., D. L. Citrin, Ph.D., M.B., 
M.R.C.P.,* G. H. Beastall, B.Sc., Ph.D.,f J. G. Turner, M.D., F.R.A.C.P. and R. G. Bessent, M.A. 
D.Phil., M.Inst.P.
University Departments of Medicine and Nuclear Medicine, Royal Infirmary, Glasgow  
^Division of Clinical Oncology, University of Wisconsin, Madison, Wisconsin 53706, U S A  
fD epartm ent of Clinical Biochemistry, Royal Infirmary, Glasgow
{Received September 1979 and in revised form  February 1980)
A bstract
99'Pc"'-H EDP  bone scans were obtained in 20 acromegalic 
patients. T w elve patients had active disease w ith elevated  
basal serum human growth horm one (H G H ) levels. E ight 
patients were in clinical and biochem ical remission.
T h e  bone scans,assessed independently by three observers, 
showed features characteristic o f m etabolic bone disease in  
patients w ith active acromegaly. T he m etabolic index  
derived from the scan correlated well w ith serum IIG H  
levels (i? —0.71, p  <  0.002).
T he bone scan may accurately reflect oversecretion o f  
H G H  and is o f potential value in the assessm ent of patients 
w ith acromegaly.
Radioisotope bone scans are widely used in the 
diagnosis of metastatic and metabolic bone disease. 
In  active acromegaly bone formation is significantly 
increased (Riggs et ah, 1972) but no clinical study of 
bone scanning in this disorder has been described. 
We have obtained 9f>Tc™ diphosphonate bone scans 
in a group of 20 acromegalic patients and correlated 
the results with clinical status and biochemical 
evidence of anterior pituitary overactivity.
P a t ie n t s  a n d  M e t h o d s
Clinical data
Twenty acromegalic patients were studied (13 
female, seven male). Their mean age was 48 years 
(range 16-68 years). Eighteen of the patients were 
treated for acromegaly between 15 months and 16 
years prior to the study. Two of the patients had 
received no treatm ent at the time of study but sub­
sequently transsphenoidal microsurgery was per­
formed. Details of previous treatm ent are shown in 
Table I.
T A B L E  I 
M o d e of previous t r e a t m e n t
Transsphenoidal microsurgery 6
Transsphenoidal cryosurgery 6
Transfrontal craniotomy 5
External irradiation 1
U ntreated 2
20
The diagnosis of acromegaly was based on clinical 
criteria and confirmed in all cases by non-suppres- 
sibility of human growth hormone (HGH ) by an 
oral 50 g glucose load. Histological evidence of an 
anterior pituitary adenoma was obtained in 19 
patients at the time of hypophysectomy. The remain­
ing patient was treated with external irradiation and 
tissue confirmation was not obtained.
Bone scans
In each patient a bone scan was obtained four 
hours after the intravenous injection of 555 MBq 
(15 mCi) of ^^Tc^^-hydroxyethylidene diphospho­
nate (HEDP). Multiple views of the skeleton were 
recorded on polaroid film from an Ohio Nuclear 
Series 100 gamma camera fitted with a high resolu­
tion medium sensitivity collimator. Views of the 
spine were obtained with 300000 counts, of pelvis, 
shoulder and sternum with 150000 counts, of skull 
with 100000 counts and of limbs with 30000 counts. 
The scan images were independently evaluated by 
three observers (I.E., D .L .C., J.G .T .) for the follow­
ing features which are characteristic of metabolic 
bone disease: a subjective impression of increased 
radiopharmaceutical uptake by the axial skeleton, by 
the long bones and by the wrists, prominent cal­
varium and mandible, beading of the costochondral 
junctions, “ tie” sternum and faint kidney images 
(Figs. 1-3), (Fogelman et al., 1978). These scan 
features were numerically graded: 0—normal; 1 — 
abnormal; 2—markedly abnormal. The total score 
for each patient was defined as the “ metabolic 
index” , which has been previously shown to differ­
entiate between control subjects and patients with 
metabolic bone disease (Fogelman et al., 1979).
Biochemical investigations
The H G H  status of each patient was assessed by 
measurement of a diurnal H G H  profile because of 
the known marked fluctuation in H G H  levels and 
the unreliability of a single fasting HGFI sample
874
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F ig . 1.
Anterior view  of thorax on bone scan from acromegalic 
patient show ing increased tracer uptake by costochondral 
junction (“ beading” ) and a “tie” sternum.
F ig . 3 .
Views o f wrists and hands show ing increased tracer uptake 
by periarticular areas— in the wrists and small joints of the 
hand.
F ig . 2 .
Lateral view  o f skull show ing increased uptake by calvarium  
and mandible. Prognathism is apparent.
(Cryer and Daughaday, 1969). Blood samples were 
taken through an indwelling venous catheter at two- 
hourly intervals between 08.00 and 20.00 hours dur­
ing one day. Serum HGH levels were measured 
using a radioimmunoassay modified from the 
method of Hunter and Greenwood (1964), and the 
mean HGH level calculated for each patient from the 
seven samples of the diurnal profile and the fasting 
basal sample of the glucose tolerance test.
A patient was considered biochemically “active” 
if his mean HGH level was above 10 mU/I. By this 
criterion 12 patients were active while the other 
eight were inactive (Table II).
Serum calcium, inorganic phosphate and alkaline 
phosphatase were estimated in all patients using 
standard techniques as employed by the Department 
of Clinical Biochemistry in the Royal Infirmary, 
Glasgow.
l l i e  values for the mean metabolic index and 
HGH levels were correlated using the Spearman 
rank correlation coefficient. Comparison of the 
results for the metabolic index from the three 
observers was performed using a paired Wilcoxon 
rank sum test.
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T A B L E  II inactive patients 2.3 (^<0.001). In  individual
A. A c r o m e g a l i c patients s h o w i n g  b i o c h e m i c a l activity patients there was good correlation between the
mean metabolic index and mean serum H G H  level 
(R = 0 .7 1 ,/)< 0.002) (Table III).
Serum calcium was normal in all patients. Serum 
inorganic phosphate was elevated ( >  1.4 mmol/1) in 
five patients (25%) and alkaline phosphatase 
(> 2 8 0  U/1) in three patients (15%). These abnor­
malities were only found in patients with active 
disease.
H G H  level N um ber o f patients
M ild <  50 mU/1 6
M oderate 5 0 -1 5 0 m U /l 3
Severe > 1 5 0  mU/1 3
12
B. A c r o m e g a l i c patients w i t h  b i o c h e m i c a l inactivity
H G H  level N um ber o f patients
0 -5  mU/1 5
5 -1 0 m U /l 3
8
T A B L E  III  
R esults of m e t a b o l i c index a n d  h g h  levels
Pt
M etabolic index
Obs. 1 Obs. 2 Obs. 3 M ean
H G H
m U /i
1 10 10 12 10.7 4955
2 11 9 11 10 491
3 7 9 10 8.7 420
4 4 7 9 6.7 141
5 6 7 8 7 111
6 5 6 8 6.3 50
7 8 9 9 8.7 27
8 5 2 3 3.3 24
9 2 2 2 2 17
10 0 2 2 1.3 13
11 0 0 1 0.3 12
12 5 3 4 4 11
13 0 0 0 0 10
14 5 6 6 5.7 7
15 5 3 6 4.7 6
16 0 0 2 0.7 4
17 0 0 1 0.3 1.5
18 2 2 3 2.3 1.4
19 2 1 2 1.7 1
20 2 2 3 2.3 1
R e s u l t s
There was no significant difference between the 
three observers’ results for the metabolic index. The 
Spearman rank correlation coefficient between ob­
servers 1 and 2, 1 and 3, and 2 and 3 was 0.88, 0.91 
and 0.95 respectively (y x  0.001, in all cases). The 
mean metabolic index for the acromegalic group as a 
whole was 4.4, significantly higher than previously 
described for a control group (0.7, y x  0.001) 
(Fogelman et al., 1979). T he mean metabolic index 
for patients with active disease was 5.8 and for
D i s c u s s i o n
Routine skeletal radiology plays an im portant role 
in the diagnosis of acromegaly but is an insensitive 
means of assessing the current metabolic activity of 
the condition (Steinbach et ah, 1959; Puckette and 
Seymour, 1967). T he present study has shown that, 
in patients with active acromegaly, the bone scan 
will often display features characteristic of a meta­
bolic bone disorder. Other features noted on the 
bone scan were prognathism with enlarged frontal 
sinuses and focal abnormalities representing de­
generative changes.
T he metabolic index derived from the bone scan 
has previously been shown to provide a sensitive 
means of identifying the presence of metabolic bone 
disease (Fogelman et al., 1979) and in the present 
study was found to correlate well with biochemical 
activity as measured by H G H . We have decided 
empirically to interpret a metabolic index of over 
four {i.e., five or above) as abnormal {i.e., strongly 
suggestive of a metabolic bone disorder) and by this 
criterion there were five false negative and two false 
positive results. However, these patients all had 
H G H  levels of between 6 and 24 mU/1 and although 
we have found a correlation between the metabolic 
index and H G H  levels it seems that this test is not 
sensitive enough to predict accurately whether an 
individual patient is active or inactive, particularly 
when H G H  levels are only moderately elevated or 
else high normal. As expected, serum  alkaline 
phosphatase and inorganic phosphate levels were of 
little diagnostic value (Hall et al., 1975).
T he bone scan and derived metabolic index pro­
vides a numerical score for assessing current meta­
bolic activity in acromegalic patients. I t  is thus 
possible to obtain a semi-quantitative measure of the 
peripheral effect of H G H  and this may be of value in 
assessing patients where there is a discrepancy be­
tween the apparent clinical severity of the disease 
and the absolute H G H  level (Nabarro, 1977). This 
technique may also be of value in monitoring the 
duration of abnormal skeletal metabolism in patients 
following neurosurgical treatment.
876
September 1980
Semi-quantitative analysis o f the hone scan in acromegaly : correlation with human growth hormone values
Radionuclide imaging draws attention to the high 
incidence of skeletal disease in acromegaly and it is 
concluded that the bone scan and derived metabolic 
index may provide useful clinical information in 
patients with known or suspected hypersecretion of 
H G H .
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Comment
While acromegaly is not generally considered to be a 
metabolic bone disorder, it is recognised that growth 
hormone is a potent stimulator of osteoblastic activity 
(Riggs et al, 1972) and that periosteal bone formation  ^
and cortical hypertrophy occur in this condition (Frohman 
1981). Routine radiology may play a supportive role in 
the diagnosis of acromegaly but is extremely insensitive 
in assessing the current metabolic activity of disease.
The present study attracted me for two reasons.
Firstly there was no previous report on the use of bone 
scanning in acromegaly and this study provided an 
opportunity to determine whether metabolic features would 
be recognisable on the scan images in a condition where 
new bone formation was known to occur. Secondly in this 
prospective study which included patients with disease 
activity ranging from inactive to severe, metabolic 
indices could be derived from the bone scans and correlated 
with serum growth hormone levels, an independent biochemical 
marker reflecting disease activity. While calcium kinetic 
studies in acromegaly had previously shown increased bone 
uptake of tracer (Eisenberg and Gordon, 1961; Nadarajah 
et al, 1968), this was not correlated with disease activity
42.
In the present study it was found that the metabolic 
index correlated well with growth hormone levels 
suggesting that the degree of altered skeletal metabolism 
is directly dependent on the activity of acromegaly.
As can be seen the metabolic features described 
previously in other metabolic bone disorders were observed 
in patients with active acromegaly, thus confirming that 
such features may be seen outwith the narrow confines of 
a few specific conditions. However, in acromegaly 
prognathism can often be recognised on the scan image 
and this may allow differentiation. Although not the 
purpose of the study, degenerative changes were frequently 
noted, and the bone scan provides a convenient means of 
evaluating the extent of osteoarthritis in acromegaly, 
should this be required.
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Paper 6. A critical assessment of bone scan quantitation 
(bone to soft tissue ratios) in the diagnosis 
of metabolic bone disease (1981)
European Journal of Nuclear Medicine 6: 93-97
I Fogelman, R G Bessent, D Gordon
Purpose of Investigation
As stated previously, it would be highly desirable 
to be able to quantitate accurately skeletal uptalee of 
radiopharmaceutical to provide a more sensitive means 
of detecting increased bone turnover. Several groups 
had suggested that measurement of bone to soft-tissue 
(B/ST) ratios from the bone scan image may provide a 
satisfactory method for quantitating bone uptake of tracer 
(Wiegmann et al, 1976; 1977; Holmes 1978; Lien et al,
1976). Utilising a computer programme , bone to soft- 
tissue ratios are measured by selecting regions of interest 
over both bone and adjacent soft-tissue on the television 
display. The bone and soft-tissue count densities in 
these areas are then obtained. The B/ST ratio is thus 
easily measured, and theoretically should reflect skeletal 
avidity for tracer.
It was my belief, however, that B/ST ratios were 
likely to be of limited value in the identification of
44.
patients with metabolic bone disease because of the small 
area of bone that was selected to reflect total skeletal 
metabolism. Nevertheless, critical studies of the 
technique had not been performed. The present study 
reports B/ST ratio measurements in a large series of 
patients with metabolic bone disease and control subjects. 
The reproducibility of B/ST measurements and the inter- 
and intra-observer variation of the contributing procedures 
were also evaluated.
Eur J Nucl Med (1981) 6 :93-97 SaTs. Nuclear
Medicine
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A Critical Assessment of Bone Scan Quantitation 
(Bone to Soft Tissue Ratios) in the Diagnosis of Metabolic Bone Disease
Ignac Fogelm an\ Rodney G. Bessent^, and Derek Gordon^
' University Departments o f  Medicine and Nuclear Medicine, Royal Infirmary, Glasgow, Scotland 
’ West o f Scotland Health Boards, Department o f Clinical Physics and Bio-engineering, Glasgow, Scotland
Abstract. Accurate quantitation from the bone scan 
image of skeletal uptake of radiopharmaceutical 
would be of value in the assessment of patients with 
metabolic bone disease. Repeat measurements of 
bone to soft tissue (B/ST) ratios on the one set of 
images were made for 103 subjects, a) by the same 
observer using lumbar vertebra 2 for the area of bone ; 
b) by the same observer using lumbar vertebra 2 
then lumbar vertebra 4; c) by two observers both 
using lumbar vertebra 2. The median difference be­
tween repeat measurements by the same observer was 
well under 1% but the 5-95 percentile range was — 13 
to +  14%. Between the two observers there was a 
median difference of 10.6% with a 5-95 percentile 
range of —11 to -1-44%.
We also measured B/ST ratios in 150 control sub­
jects and 139 patients with various metabolic bone 
disorders. While statistically significant differences for 
B/ST ratios were found between the osteomalacia, 
renal osteodystrophy, Paget’s groups, and the control 
population ( P < 0.001 in all cases), there was appreci­
able overlap between individual patient results and 
the control range.
It is concluded, therefore, that measurement of 
B/ST ratios for the individual is of limited value in 
clinical practice.
Introduction
In contrast to metastatic disease where the character­
istic feature of the bone scan is the irregularity of 
the image with focal abnormalities present, in meta­
bolic bone disease typically there is diffusely increased 
skeletal activity. Recognition of abnormalities in such 
cases depends upon a subjective impression of gener­
ally increased skeletal uptake of tracer and errors 
in interpretation are likely, particularly in milder ex­
amples of disease. Accurate quantitation of skeletal 
uptake of tracer may thus be helpful in the diagnosis 
of metabolic bone disease. Measurement of bone to 
soft tissue (B/ST) ratios from the bone scan image 
has been proposed as a useful index (Weigmann et al. 
1976; Weigmann et al. 1977; Holmes 1978; Lien et al. 
1976), but there is doubt as to the value of this tech­
nique (Fogelman et al. 1978a; Fogelman et al. 
1978 b). In view of the number of variables contribut­
ing to a B/ST measurement we considered it impor­
tant to investigate in detail the reproducibility of the 
technique and the inter- and intra-observer variability 
of the contributing procedures. To these ends we have 
measured B/ST ratios in a large series of both patients 
with metabolic bone disease and control subjects and 
have asked the following questions on the technique;
1. Is the B/ST measurement by a single observer 
reproducible for an individual subject?
2. Does the exact area of soft tissue selected affect 
the result?
3. Does the exact area of bone selected affect the 
result?
4. W hat is the inter-observer variability?
We also wished to assess the usefulness of an opti­
mum B/ST measurement in diagnosing metabolic 
bone disease when carried out under carefully con­
trolled conditions by one observer. We therefore went 
on to ask these further questions:
5. Does the bone to soft tissue ratio alter with 
advancing age?
6. W hat is the diagnostic value of the B/ST ratio 
in metabolic bone disease?
Patients and Methods
The control group consisted o f 150 females with breast carcinoma, 
but without either clinical or radiological suspicion o f bone métas­
tases, who had been referred to our department for routine bone
0340-6997/81 /0006/0093/S01.00
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Table 1. Percentage differences between 2 measurements o f  bone 
to soft tissue ratio on each lumbar image
Method Number
of
subjects
Median % 
difference 
between 
repeat
measurements
5 95 percentile 
range o f  
difference (%)
One observer using 
lumbar vertebra 2 
on 2 separate 
occasions
103 0.73 -  13.1 to -y 14.4
One observer using 
lumbar vertebra 2 
and lumbar vertebra 
4 but same soft 
tissue area
93 0.34 -  12.4 to -t-14.0
Two observers using 
lumbar vertebra 2
93 10.60 -  10.6 to 4-43.8
Fig. I. Monochrome representation of colour television image o f  
lumbosacral spine showing areas defined for bone and soft tissue 
measurements
scanning and had been found to have a negative scan. The study 
group consisted o f 139 patients with various metabolic bone dis­
orders (Table 4|. Bone scans were performed on all subjects 4 h 
after intravenous injection o f  15 mCi o f  technetium-99m hydroxy- 
ethylidine diphosphonate (H FD P) using a 25 cm gamma camera 
with a high resolution, low energy, parallel collimator. .Ml images 
were recorded by computer on magnetic tape for later retrieval 
and processing, and displayed on a colour television set. Bone 
to soft tissue ratios were measured by drawing a region o f  interest 
(ROD around the second lumbar vertebra (or. in the case o f  Paget's 
disease, an involved vertebra) and an area just below the kidney 
and clear o f the spine and pelvis on the television image (Fig. 1). 
1 he bone and soft tissue count densities in these areas and their 
ratio, which we define as the bone to soft tissue ratio, were calculat­
ed from the teletype print out o f the total count and areas. One 
hundred and three subjects (47 controls and 56 o f the study group) 
had B ST ratios calculated on 2 separate occasions from the one 
image by the sa me observer using lumbar vertebra 2. In 93 of  
these cases (47 controls. 46 o f study group) B/ST ratios were also 
calculated on the same occasion by the same observer using 2 
dilTerent areas o f bone (lumbar vertebrae 2 and 4) but the same 
soft tissue area, to assess any variation in ratios from altering 
the area of bone selected. In addition B/ST ratios were calculated 
for these 93 subjects from the same images by another observer, 
using lumbar vertebra 2 only, to assess inter-observer variation.
Finally, in 26 control subjects multiple regions o f interest (17 
on average) were selected across the area o f soft tissue (avoiding 
kidney) to assess any variation attributable to altering the precise 
area selected for soft tissue measurement.
.Ml repeat measurements o f B/ST ratios and count densities 
were compared by calculating the median percentage difference 
between the pairs o f  results, with the 5 95 percentile range of  
percentage difl'erence giving a measure o f the variability o f individ­
ual results.
The variability due to moving the soft tissue area was quanti­
fied for each subject by calculating the percentage difference be­
tween each measurement and the mean count density for that 
patient.
The effects o f  age and metabolic bone disease on the measured 
B/ST ratio were examined using the results from the one observer 
who made measurements on all 150 controls and 139 patients. 
Using the W ilcoxon rank sum test, statistical comparisons were 
made between the various age decades within the control group, 
and also between the total control group and the various metabolic 
disease groups.
Results and Discussion
A. Technique of BjST Measurement
Results for the variation between repeat measure­
ments of B/ST ratio on the same images under differ­
ent condition are given in Table 1.
1. One Observer on 2 Occasions. Using lumbar verte­
bra 2 on both occasions the median difference be­
tween repeat measurements for the whole group of 
103 subjects was very small at only 0.7%. However, 
this conceals the wide range of variation between indi­
vidual repeated results, the 5-95 percentile range be­
ing — 13.1 to -F 14.4% difference.
To localise more clearly the major source of varia­
tion, the bone and soft tissue count densities from 
this study were examined separately (Table 2). Both 
components of the B/ST ratio gave a low median 
percentage difference between the pairs of measure­
ments. However, the 5-95 percentile range of differ­
ence of the soft tissue count density was over twice 
that of the bone count density. This is probably to 
be expected since the vertebra is a well defined part
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Tabic 2. Percentage differences between 2 measurements o f bone 
count density and soft tissue count density on each image
Measurement Median % difference 
between repeat 
measurements
5-95 percentile 
range o f 
difference (%)
Bone count density 0.0 -  4.2 to +  8.7
(lumbar vertebra 2)
Soft tissue count -  1.63 — 12.7 to 4-13.8
density
Table 3. Bone to 
by one observer
soft tissue ratios in control group, measured
Age range Number Median B/ST ratio Full range
Whole group 150 4.03 2.44-6.00
30-40 15 3.90 2.08-5.40
41-50 51 4.10 2.70-5.80
51-60 43 4.30 3.20-6.00
61-70 34 3.90 2.40-5.90
71-80 7 3.70 3.10-4.00
of the image, easy to outline on the television screen, 
in contrast to the possible range of selection of a 
suitable soft tissue area which does not include pelvic 
or renal activity.
2. Variation o f  Soft Tissue Count Density with Posi­
tion o f Selected Area. For 26 of the control subjects 
a total of 439 measurements of soft tissue count den­
sity were made from the 26 lumbar/sacral images. 
The median difference between separate measure­
ments and the mean for each subject was 0.8% indi­
cating a symmetrical distribution. The 5-95 percentile 
range of difference was from —13.7% to 4-14.9%, 
demonstrating a distribution very similar to that ob­
tained from the duplicate measurements of soft sissue 
count density on the much larger total group of con­
trols and patients (Table 2).
3. One Ob.server Using Lumbar Vertebrae 2 and 4. 
When measurements were made using the 2 vertebrae 
on the same image the median difference between 
pairs of results was also very low at 0.34% (Table 1) 
with a 5-95 percentile range of —12.4 to +14.0%  
difference. Since the same soft tissue area was used 
for each ratio this range indicates the variability of 
bone count density alone between lumbar vertebrae 
2 and 4. The range of differences is about twice that 
for repeat measurements of bone density on a single 
vertebra (Table 2) and indicates that the precise area 
of bone selected can have a significant effect on the 
measured B/ST ratio, similar in importance to that 
of choosing a slightly different soft tissue area.
4. Two Observers Using the Same Vertebra. Returning 
to lumbar vertebra 2 only, but with two observers 
using the same image, gave a median difference this 
time of 10.6% (Table 1) showing a systematic differ­
ence in their technique. Furthermore the 5-95 percen­
tile range of difference for individual subjects was 
large at — 10.6 to +43.8% , being nearly double the 
range for repeated measurements by one observer, 
and 3 of the individual percentage differences were 
greater than 60%.
Table 4. Bone to soft tissue ratios in various patient groups measu­
red by one observer
Group Number Median B/ST 
ratio
Full range
Control 150 4.03 2 .4 + 6 .0 0
Osteoporosis 24 4.06 2.90-5.50
Thyrotoxicosis 8 4.35 2.80-8.50
Osteomalacia 16 6.75 2.60-9,50
Primary 21 4.17 3.00 9.90
hy per pa ra thy roi d ism
Renal osteodystrophy 26 5.99 3.30-9.60
Paget’s 23 9.10 5,70-29.0
Acromegaly 21 4.41 2.50-5.90
B. Effect o f  Age and Disease on B f S T  Ratio
The results on technique suggest that while individual 
results are subject to wide variation it may be that 
average group results for B/ST ratio are clinically 
meaningful. Measurements should be made by the 
same observer, being careful in selection of soft tissue, 
bone area, and following a constant study protocol. 
Adhering to these conditions we found as follows;
5. Age Variationof Normal Bj ST  Ratio. Table 3 shows 
the results for B/ST ratios measured by one observer 
in the control group as a whole and also for each 
decade between 30 and 80 years. When the various 
decades were compared, the only statistically signifi­
cant differences were between the 51-60 years group 
and the 61-70 and 71-80 years group (F<0.01 in 
each case). It is perhaps not surprising that the B/ST 
ratio is somewhat lower in patients over 60 years 
old as they have reduced bone mass and there is 
also histological evidence that osteoblastic activity is 
reduced as one grows older (Merz and Schenk 1970; 
Avioli 1976).
6. Bone to Soft Tissue Ratio in Metabolic Bone Dis­
ease. Table 4 shows the values for median B/ST ratios 
measured by one observer in the various patient 
groups studied and the distribution of individual re­
sults is shown in Fig. 2. The osteomalacia, renal os-
96 I. Fogelman et al.: Bone to Soft Tissue Ratios in M etabolic Bone Disease
Bone/ 
soft tissue 
ratio
*
24 I e
* *1*
26
»0|
zoe l :
“4
••
••
M eant 2 SO
Control
23
gp ’50 I
•— 8“‘
21/ / / + / / / /
leodyslrophy and Paget's group were all significantly 
dilTerent from the control group ( P < 0.001 in all 
cases). The Paget's group was also significantly dif­
ferent from all other groups (P < 0.005 for the osteo­
malacia group, P <  0.001 for the rest) and the renal 
osteodystrophy group was significantly different from 
all except the thyrotoxicosis, and osteomalacia groups 
(P< 0.001).
All individual patient results for B/ST ratio mea­
surements in the Paget's group lay outside the control 
range (Fig. 2) but this finding is somewhat artificial 
in that the area of bone selected in these cases was 
an involved vertebra. Also this finding is of limited 
clinical value as patients with Paget's disease usually 
have characteristic bone scan appearances (Serafini 
1976).
In the osteomalacia and renal osteodystrophy 
groups there was appreciable overlap of individual 
patient results and the control range (Fig. 2). In the 
osteoporosis, primary hyperparathyroidism and acro­
megaly groups, virtually all individual results lay 
within the control range (Fig. 2) and these groups 
were indistinguishable from the control population. 
For primary hyperparathyroidism these results are 
in keeping with other workers (Weigmann et al. 1977) 
and our own previous experience (Fogelman et al. 
1978a; Fogelman et al. 1977). However, while radio­
logic examination is generally negative in this condi­
tion. it has been shown histologically that there is 
skeletal involvement in approximately 90% of cases 
of patients with primary hyperparathyroidism 
(Holmes 1977), and in this situation measurement 
of B/ST ratios seems particularly disappointing.
Fig. 2. Distribution o f individual bone to soft tissue ratios in 
various groups o f  metabolic bone disorders
While acromegaly is generally not considered to be 
a metabolic bone disorder, it has been shown histolog­
ically that bone formation is significantly increased 
in this condition (Riggs et al. 1972) and one might 
have expected to find increased values for B/ST ratios. 
The median value for B/ST ratios in the osteoporotic 
group, was not significantly different from the control 
population (Table 4).
In the thyrotoxicosis group there was a wide range 
of individual results overlapping the control range 
(Fig. 2). This group was not distinguishable from any 
other group (except the Paget’s group) but since it 
contained only 8 subjects no firm conclusions can 
be drawn.
Conclusions
The overall conclusions from the studies on the tech­
nique of B/ST measurement are that the fiarly large 
groups of subjects used produce low average differ­
ences between repeat results when studied by one 
observer using the same or different vertebrae. How­
ever, there is a significant systematic difference be­
tween our two observers but more important is the 
wide range of individual differences found in all cases. 
It should be remembered that these were repeat mea­
surements on the same image from a single study. 
When the differences due to variation of patient posi­
tioning, obesity, water loading and radiopharmaceuti­
cal quality in interpatient comparisons are considered 
the lack of clear differentiation between disease 
groups is not unexpected (Table 4).
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The comparisons of B/ST ratio measurements in 
control and disease groups illustrated in Fig. 2 and 
Table 4 were based upon measurements by one ob­
server, It is likely, therefore that measurements on 
individual patients by different observers would lead 
to wider spreads in the various groups and poorer 
discrimination between groups. Furthermore at 4 h 
the soft tissue activity is still changing to some extent 
(Citrin et al. 1975) so the precise time of measurement 
will affect the B/ST ratio obtained. Because of the 
considerable overlap of individual patient results with 
the control range, (except for the rather artificially 
measured group with Paget’s disease) a positively ele­
vated value for B/ST ratio may be of some help in 
confirming increased skeletal uptake of radiopharm a­
ceutical, but a normal value does not exclude this.
It is concluded, therefore, that on the grounds 
of variability of individual results together with failure 
to distinguish clearly between disease patients and 
controls, attempts to quantitate skeletal uptake of 
radiopharmaceutical by measurement of a bone to 
soft tissue ratio are of limited value in clinical prac­
tice.
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Comment
It is seen that if repeat bone to soft-tissue (B/ST) 
ratio measurements are obtained, by a single observer, in 
large groups of patients then average differences between 
results are low. An increased error was, however, 
introduced when the area of soft-tissue selected was varied, 
and a wide range of individual patient results obtained 
when two observers independently measured B/ST ratios.
However for comparison of B/ST ratio values in 
patients with metabolic bone disease and control subjects, 
all measurements were performed by myself. Thus even 
when B/ST ratios were obtained by a single observer, a huge 
overlap of individual results was found in all patient 
groups and with the control group. Although an elevated 
B/ST result may support the presence of increased bone 
turnover, a normal result certainly does not exclude it.
It is probable that if different observers were to measure 
B/ST ratios this would lead to even greater uncertainty as 
to the significance of any differences shown between results.
It is, therefore, concluded from these studies that 
B/ST ratio measurements are of very limited value in the 
diagnosis of metabolic bone disease. This is not surprising 
as the measurement is obtained by selecting a very small 
area of bone in the hope of being able to detect relatively 
small but significant alterations in total skeletal 
metabolism. In addition there is the demonstrated
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uncertainty introduced by the variability of counts 
obtained in selecting the soft-tissue region. Perhaps 
the ratio of total skeletal counts to total soft-t issue 
counts would provide a more sensitive measure of skeletal 
metabolism, but there is no convenient means of obtaining 
this, and in practice any measurements would be extremely 
laborious with great uncertainties and errors introduced 
by attempting to separate bone and soft-tissue in areas 
such as the ribs.
It is, however, possible that B/ST ratio measurements 
performed on sequential bone scan studies may be of some 
value.in an individual patient to document improvement or 
deterioration in their condition. There is indirect 
evidence to support this as Espinasse et al (1981) have 
suggested that quantitative scintigraphic parameters are 
suitable for the assessment of therapy in Paget's disease. 
■However, in Paget's disease focal lesions with extremely 
high tracer uptake are seen and easily identified on the 
bone scan and Espinasse was able to analyse ratios of 
activity of involved Pagetic sites to activity of 
symmetrical non-involved bone areas. It has still to be 
established whether B/ST ratio measurements are of value 
in monitoring the effect of therapy in sequential bone 
scan studies where a generalised alteration in skeletal 
metabolism exists.
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SUMMARY 
CHAPTER 2
RECOGNITION OF METABOLIC FEATURES AND QUANTITATION 
OF SKELETAL UPTAKE OF TRACER FROM THE BONE SCAN IMAGE
48.
In this chapter several studies are described 
evaluating bone scan images, both visually and with 
quantitative techniques, as a means of identifying the 
presence of metabolic bone disease. In paper 3 the 
original concept of recognisable metabolic features 
being present on the bone scan is introduced and it is 
suggested that such features may be characteristic of 
the metabolic bone disorders in general. In this first 
report of bone scanning in osteomalacia, it is shown that 
patients with osteomalacia can easily be differentiated 
from both normal subjects and patients with metastatic 
disease on the basis of recognisable metabolic features 
on the bone scan.
It is, however, argued that often when increased 
skeletal uptake of tracer is present, simple visual 
evaluation of the bone scan may prove too subjective to 
detect this and hence quantitation of tracer uptal^e is 
desirable to provide a more sensitive measure of increased 
bone turnover.
Paper 4 develops the theme that metabolic features 
may be seen in various metabolic bone disorders and other 
conditions where there is generalised increased bone 
turnover. Seven characteristic bone scan features are 
selected and a semi-quantitative scoring system is described 
whereby a numerical scoring system is applied to each
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feature, the total score being defined as the metabolic 
index. It is shown that the metabolic index allows clear 
differentiation of various groups of metabolic patients 
from control subjects but an appreciable overlap with 
individual patient results is seen. Paper 5 provides 
the first report of bone scanning in acromegaly. In this 
study it was of interest that metabolic features were 
frequently noted on the bone scans of acromegalic subjects 
and it was found that metabolic indices correlated well 
with serum growth hormone levels. However, while this 
study validates the metabolic index as a measure of 
skeletal involvement in this systemic disorder, it was 
nevertheless found that the test was not sensitive enough 
to differentiate individual subjects with active disease 
from those with inactive disease.
Several groups had previously suggested that measurement 
of bone to soft-tissue (B/ST) ratios from the bone scan image 
may provide a valuable means of quantitating skeletal uptake 
of tracer. Paper 6 describes a critical evaluation of 
this technique and its application to a large group of 
patients with various metabolic bone disorders. It was 
concluded that B/ST ratio measurements would be of very 
limited value in clinical practice, once again because of 
the large overlap of individual patient results with the 
control group.
50 .
It is thus seen that in individual patients, 
neither visual evaluation of the bone scan nor quantitative 
techniques derived from the scan image provide a sensitive 
measure of altered skeletal metabolism.
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CHAPTER 3
A COMPARISON OE SKELETAL SCINTIGRAPHY AND RADIOLOGY 
IN METABOLIC BONE DISEASE
52
In this chapter, following an initial review of 
the different principles and mechanisms by which 
radiology and scintigraphy each image the skeleton, 
two papers (7 and 8) are presented comparing these 
techniques in metabolic bone disease.
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PRINCIPLES OF SKELETAL SCINTIGRAPHY COMPARED TO RADIOLOGY
While it is now recognised that the bone scan is 
more sensitive than radiology in detecting skeletal 
abnormality, it is important to be aware that each of these 
investigations assesses different parameters in relation to 
bone. X-ray absorption indicates bone mineral content and 
shows the net result of bone destruction and repair. The 
bone scan, however, depends upon osteoblastic activity and 
to a lesser extent skeletal vascularity for uptake of 
tracer (Davis and Jones, 1976) (see chapter 1). In the 
context of disease the scan indicates the dynamic response 
of bone to whatever insult is present, be it traumatic, 
inflammatory or neoplastic.
If involvement of the skeleton by malignancy is 
chosen as a specific example of disease, then when tumour 
cells invade bone they produce two basic effects: bone
destruction, and an osteoblastic reaction which represents 
attempts by the surrounding bone to repair the destructive 
effects (Milch and Changus, 1956). Radiographs demonstrate 
both processes - bone destruction is seen as radiolucencies 
(osteolytic areas) and bone repair as radiodensities 
(osteosclerotic areas). Bone destruction, however, must 
be advanced before an abnormality is seen on the radiograph,
54.
and it has been suggested that a lesion in trabecular bone 
must be greater than 1-1,5 cm in diameter, with loss of 
approximately 50% of bone mineral before radiolucencies 
will be apparent on a conventional radiograph (Edelstyn 
et al, 1967), Early in bone repair, insufficient mineral 
has been laid down to be visualised radiographically as 
radiodensities. For these reasons the radiograph is 
normal during the early phase of tumour involvement, and 
several studies have confirmed that histologically proven 
métastasés may not be detected by radiology (Borak 1942; 
Shackman and Harrison, 1948). The bone scan is based on 
an entirely different principle. Tracer uptake is not 
directly dependent on bone destruction, but reflects the 
functional reaction of the bone to tumour invasion. There 
is an increase in new bone formation with increased 
skeletal blood flow following tumour invasion and this is 
demonstrated by high uptake of a bone seeking radiopharma­
ceutical. It is important to note that the increased 
concentration of tracer is not due to or directly dependent 
on the metabolism of the tumour cells themselves, but is 
directly related to the local changes in bone metabolism 
consequent upon tumour invasion.
Thus, early in bone invasion by tumour, a positive 
bone scan may be associated with normal radiology. As the 
tumour progresses, the bone destruction it causes will become
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visible on the radiograph as an osteolytic lesion.* In 
these circumstances bone reaction is considerable, and the 
bone scan is also strongly positive. If the tumour does 
not progress calcium will be laid down during the healing 
process in such quantities that sclerotic areas will be
visible on the radiograph. At this stage both
investigations are positive. Eventually, if the lesion 
heals completely, there will be extensive calcification
producing a dense appearance on the radiograph. At
this stage the bone scan may appear normal.
As the bone scan depends on the metabolic reaction 
of the bone, it is clear that if there is absent or little 
bone reaction to tumour invasion, the scan may be normal 
or near normal despite radiological evidence of bone 
destruction. This occurs infrequently but is more likely 
to be found in some cases of myeloma (Leonard et al , 1981), 
.in some cases of rapidly growing anaplastic carcinoma or 
conversely in cases of indolent tumours such as thyroid 
cancer (Charkes 1970). If bone destruction is extensive 
(Goergen et a l , 1974), or if bone metabolism is modified 
by radiotherapy (Cox 1974) a "cold" area may be seen, 
corresponding to the area of diminished bone activity.
Similarly, in the metabolic bone disorders a 
considerable change in bone calcium may occur without 
detectable change on the radiograph. If there is net 
balance between bone formation and bone resorption, 
albeit if both are increased, then these changes may
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theoretically never be revealed by radiology (De Nardo 
1966) . Radioactive tracer techniques may circumvent 
these difficulties since they depend only upon increased 
bone turnover regardless of the net calcium balance.
It is clear, however, that the techniques of 
skeletal radiology and scintigraphy are in many instances 
complementary and maximum diagnostic information can be 
obtained by performing both studies.
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Paper 7. A comparison of bone scanning and radiology in 
the evaluation of patients with metabolic bone 
disease (1980)
Clinical Radiology 31: 321-326
I Fogelman, D Carr
Purpose of Investigation
The purpose of this study was to compare the relative 
sensitivity of bone scanning and radiology in the diagnosis 
of metabolic bone disease. Eighty patients with metabolic 
bone disorders were studied, and the bone scans and radiographs 
were each read independently without the observers being 
aware of the specific clinical diagnoses.
Oinical Radiology (1980) 31, 321-326  
© 1980 Royal College of Radiologists
0009-9260/80/00090321 ^02.00
A Comparison of Bone Scanning and Radiology in the 
Evaluation of Patients with Metabolic Bone Disease
IGNAC FOGELMAN and DENIS CARR*
University Departments o f  Medicine and Nuclear Medicine, Royal Infirmary, Glasgow, "^Department o f  
Radiology, Western Infirmary, Glasgow
Bone scans and radiographs were evaluated in 80 patients with metabolic bone disease (27 with osteoporosis, 
14 with primary hyperparathyroidism, 24 with renal osteodystrophy and 15 with osteomalacia). The bone 
scan did not suggest a metabolic bone disorder in any of 27 patients with histologically proven osteoporosis. 
In 22 (81%) patients radiographs were reported as showing osteoporosis. In 19 (70%) vertebral fractures were 
seen on X-ray while these were noted in 11 (41%) patients on the bone scan. Vertebral fractures were usually 
visualised on the bone scan when these had occurred less than one year previously. In primary hyperpara­
thyroidism the bone scan was suggestive of a metabolic bone disorder in 7 of 14 (50%) patients, while radio­
graphs were reported as showing evidence of hyperparathyroidism in three (21%) cases. The bone scan 
suggested the presence of a metabolic bone disorder in all 24 patients with renal osteodystrophy and 15 
patients with osteomalacia while the correct diagnosis was obtained in 14 (58%) and nine (60%) of these 
patients on X-ray. It is concluded that the bone scan is the more sensitive investigation in patients with osteo­
malacia, primary hyperparathyroidism and renal osteodystrophy. For osteoporosis radiology is the investi­
gation of choice but the bone scan may be of value in assessing the duration of vertebral collapse.
Bone scanning is now established as a sensitive means 
of detecting skeletal métastasés and its superiority 
over radiology is well recognised (Citrin et al, 1977). 
Recently there has been considerable interest in the 
use of bone scanning in metabolic bone disease (Sy, 
1974; Sy and Mittal, 1975; Rosenthal and Kaye, 1975; 
Weigmann et al, 1977; Krishnamurthy et al, 1977; 
Fogelman et al, 1977a, 1978, 1979. Fogelman and 
Citrin, 1980) and although focal abnormalities may 
not be seen, certain recognisable patterns of bone 
scan abnormality are becoming apparent in these 
conditions (Fogelman et al, 1977a, 1979). However, 
there is only limited information available as to the 
value of radioisotopic imaging compared with routine 
radiology in the various metabolic bone disorders. 
In this study 80 patients with metabolic bone disease 
had a gamma-camera bone scan performed using a 
standard technique, and a conventional radiological 
skeletal survey was also obtained. The bone scans and 
radiographs were assessed independently and in a 
random order by two observers (scans, I.F.; radio­
graphs, D.C.) who were unaware of the clinical 
diagnoses.
METHODS
Eighty patients (27 witli osteoporosis, 14 with 
primary hyperparathyroidism, 24 with renal osteo­
dystrophy, and 15 with osteomalacia) were studied.
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The diagnosis of primary hyperparathyroidism was 
established in all patients by the finding of elevated 
serum calcium levels with elevated or inappropriate 
plasma parathyroid hormone levels. In addition, 11 
of the 14 patients had parathyroid tumours removed. 
In the osteoporosis, osteomalacia and renal osteodys­
trophy groups, the diagnosis was established by 
routine biochemistry and radiology and, in addition, 
transilial bone biopsies were performed in all 80 
patients to obtain histological confirmation of the 
diagnoses.
Bone Scan
Each patient was scanned 4 h  after the intravenous 
injection of 15mCi of technetium-99 m hydroxye- 
thylidene-diphosphonate (HEDP). Details of the tech­
nique employed have been described elsewhere 
(Fogelman 1978).
Radiological Skeletal Survey
In all patients the radiographic skeletal survey 
comprised antero-posterior, and lateral views of skull, 
antero-posterior and lateral views of the cervical, 
dorsal and lumbar spine. A postero-anterior radio­
graph of chest, antero-posterior views of the pelvis 
and views of the long bones and hands were also 
obtained.
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RESULTS
The scan and radiograph were read independently 
without any knowledge of the clinical diagnosis 
although both observers were aware that the study 
group consisted of patients with metabolic bone 
disease. The studies were reported and a diagnosis 
was suggested if it was felt that this was indicated. 
In addition, any abnormalities observed were charted 
on skeletal maps.
The bone scans were assessed for the presence of 
seven metabolic features that have previously been 
shown to be characteristic of metabolic bone dis­
orders. These features are (a) increased tracer uptake 
by the axial skeleton, (b) by the long bones, (c) by 
the wrists, (d) prominence of the calvarium and 
mandible (Fig. 1), (e) beading of the costochondral 
junctions (Fig. 2), (f) a ‘tie’ sternum, and (g) faint or 
absent kidney images.
Each of these features was scored in the following 
way: 0, normal; 1, abnormal, and 2, strikingly abnor­
mal, and the metabolic index (total score for the 
seven features) for each patient was calculated (Fogel­
man et ai, 1979). For the purpose of this study a 
metabolic index of over 4, i.e. 5 or above, was taken 
as abnormal. The skeletal surveys were assessed for 
the standard radiological features associated with 
metabolic bone disease (Hodson, 1975).
The results of the two investigations were com­
pared and related to the clinical status of the patient 
where relevant.
The results for the various patient groups will be 
presented separately. We have accepted the radio­
graph as the standard skeletal investigation as it is the 
universally available technique against which any new 
development must be judged and also the radiograph 
may allow a specific diagnosis to be made due to the 
anatomical details displayed. In contrast the bone 
scan presents a non-specific abnormality, namely 
increased tracer uptake which may be seen with 
virtually all bone pathology. Therefore, while radio­
logy often suggests a specific diagnosis, in interpreting 
the bone scan we can often only say that the appear­
ances are suggestive of a metabolic bone disorder.
Osteoporosis
The bone scan was not suggestive of a metabolic 
bone disorder in any of the 27 patients with histo­
logically proven osteoporosis. In 22 (81%) cases the 
radiographs were reported as showing osteoporosis. 
In 19 (70%) patients vertebral fractures were seen on 
X-ray while these were noted in 11 (41%) patients on 
the bone scan. In eight (30%) cases the bone scan 
underestimated the extent of vertebral collapse which
(a) ib)
Fig. 1 — Lateral view of skull on bone scan — (a) normal, (6) showing increased tracer uptake by calvarium with prominent 
mandible in patient with primary hyperparathyroidism.
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ia) (b)
Fig. 2 -  Anterior views of thorax — (a) normal, (6) showing ‘beading’ of costochondral junctions in patient with osteomalacia.
was seen on X-ray. The relationship of scan evidence 
of vertebral fracture to the history of the most recent 
severe episode of acute back pain is shown in Table 1. 
Generally vertebral fractures were visualised on the 
bone scan when less than one year from the time of 
fracture although this was not always the case. Renal 
images were seen in all patients on the bone scans.
Primary Hyperparathyroidism
The bone scan was suggestive of a metabolic bone 
disorder in 7 of 14 (50%) patients with primary 
hyperparathyroidism while radiographs were reported 
as showing evidence of hyperparathyroidism in three 
(21%) cases. In only one patient were the renal 
images not visualised on the bone scan.
Renal Osteodystrophy
The bone scan was suggestive of a metabolic bone 
disorder in all 24 patients with renal osteodystrophy 
while radiographs were reported as showing hyper­
parathyroidism or renal osteodystrophy in 14 (58%) 
cases. The renal images were not visualised in 20 
(83%) patients on the bone scan.
Osteomalacia
The bone scan was suggestive of a metabolic bone 
disorder in all 15 patients with osteomalacia while 
radiographs were reported as showing osteomalacia 
in nine (60%) cases. Ten patients had pseudo-fractures
present and there were 24 sites involved in these 
patients. Nineteen (79%) sites were detected on the 
bone scan while 14 (58%) were seen on X-ray. The 
ribs were the most frequently involved site (90%), 
then femur (70%), pelvis (40%), scapula (20%) and 
fibula and forearm (10%). Absent kidney images on 
the bone scan were noted in two patients, and both 
of these cases had multiple hot spots present which 
were interpreted as pseudo-fractures.
DISCUSSION
Bone scanning provides a highly sensitive means of 
detecting skeletal pathology but abnormalities tend 
to be non-specific. The bone scan in Paget’s disease or 
if skeletal métastasés are present shows focal abnor­
malities but in osteomalacia, primary hyperparathy­
roidism and renal osteodystrophy where the whole 
skeleton is involved by a metabolic process, these 
may not be seen. However, recognisable patterns of 
abnormality may be apparent and by giving a 
numerical score to seven metabolic features on the 
bone scan we have derived a metabolic index for 
metabolic bone diseases (Fogelman et ai, 1979). An 
abnormal value suggests that a metabolic bone dis­
order may be present but seldom can allow a definite 
diagnosis. In osteoporosis there is usually only a very 
gradual change in bone volume that occurs over many 
years and in keeping with this the bone scan appear­
ances are usually normal. However, when bones 
become so abnormally brittle that pathological 
fracture with vertebral collapse occurs then this
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Table 1 — Osteoporotic patients with radiological evidence 
of vertebral collapse
Patient History (duration since acute episode
o f  severe back pain)
(a) Scan +ve
1 Eight months
2 Three months
3 Chronic pain only
4 Chronic pain only
5 Four months
6 One month
7 14 months
8 Four months
9 No back pain
10 Chronic pain only
11 12 months
(b) Scan -ve
1 14 months
2 Chronic pain only
3 Chronic pain only
4 Chronic pain -  seven years since 
acute episode
5 Chronic pain -  IVi years since acute 
episode
6 Chronic pain only
7 12 months -  long history of chronic 
pain previously
8 Three months -  long history of 
chronic pain previously
appears on the bone scan as a focal area of increased 
tracer uptake and the scan appearances are charac­
teristic (Fogelman and Citrin, 1980).
In the present study the bone scan did not suggest
the presence of a metabolic bone disorder in any of 
the 27 patients with histologically proven osteo­
porosis. Radiographs were reported as showing 
osteoporosis in 22 (81%) patients. In 19 (70%) 
patients vertebral fractures were seen on X-ray while 
these were noted in 11 (41%) patients on the bone 
scan. In addition, the bone scan underestimated the 
extent of vertebral collapse in eight patients (Fig. 3). 
Generally vertebral fractures were visualised on the 
bone scan when an acute episode of severe back pain 
had occurred less than one year previously although 
this was not always the case (Table 1). One patient 
who gave a history of an acute episode of severe back 
pain three months prior to scaiming had a negative 
bone scan but this patient also gave a history of long­
standing chronic back pain prior to the acute episode. 
It may be that the ‘acute’ episode represented an 
exacerbation of her chronic condition rather than 
further vertebral collapse.
The bone scan was suggestive of a metabolic bone 
disorder in seven of 14 (50%) patients with primary 
hyperparathyroidism while X-rays were reported as 
showing evidence of hyperparathyroidism in three 
(21%) cases. The renal images were not visualised in 
one case and in this instance the scan appearances 
could have been misinterpreted as those of renal 
osteodystrophy (see later). With the availability of 
parathyroid hormone assays the diagnosis of primary 
hyperparathyroidism is being made more frequently 
and, indeed, much earlier than previously. In the 
majority of cases there will be no radiological or
(a) (b)
Fig. 3 -  (a) Bone scan image of posterior thoracic spine showing a single area of linearly increased tracer uptake in mid-spine 
in keeping with history of an acute episode of back pain four months previously. Lateral X-ray of spine (b) shows several 
collapsed vertebrae.
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Fig. 4 — Multiple hot spots in ribs (representing pseudo­
fractures) in patient with osteomalacia. These were not seen 
on routine radiology although two pseudo-fractures in the 
pelvis were detected.
biochemical evidence of skeletal involvement and 
there may be little evidence of skeletal disease even 
when bone biopsies are performed. It is, therefore, to 
be expected that the bone scan will be normal in 
many cases of primary hyperparathyroidism but this 
test still provides a more sensitive indicator of meta­
bolic bone disease than routine radiology (Sy, 1974; 
Krishnamurthy et al, 1977).
The bone scan was suggestive of a metabolic bone 
disorder in all 24 patients with renal osteodystrophy 
while radiographs were reported as showing hyper­
parathyroidism or renal osteodystrophy in 14 (58%) 
cases. Renal images were not visualised in 20 (83%) 
patients. Sy and Mittal (1975) graded seven areas on 
the bone scans of 14 chronic dialysis patients on a 
scale 0 —4+ and found that the bone scan was 
abnormal in 13 (93%) patients; however, only four 
(29%) of these patients showed resorptive changes on 
radiographs. Olgaard et al (1976) studied 30 patients 
on haemodialysis and classified their bone scans into 
four groups according to the degree of increased 
tracer uptake in the lower limbs. They found 90% of 
the bone scans but only 33% of X-rays abnormal. 
Cavalli et al (1976) studied 43 patients with chronic 
renal disease (34 on dialysis, nine on maintenance 
therapy) and found that the bone scans indicated that 
88% had skeletal disease, wliile radiographs were 
abnormal in 56%. De Graaf et al (1977) studied 30 
dialysis patients and found that the bone scan was 
positive in 80% while radiographs showed skeletal 
disease in 14%. It therefore seems that the bone
scan provides a sensitive means of detecting skeletal 
involvement in patients with chronic renal failure.
The bone scan was suggestive of a metabolic bone 
disorder in all 15 patients with osteomalacia while 
X-rays were reported as osteomalacia in 19 (60%) 
cases. Absent kidney images were noted in the bone 
scans in two patients and both of these had multiple 
hot spots on the bone scans which were interpreted 
as pseudo-fractures. Ten patients had pseudo-fractures 
present and there were 24 sites involved. Nineteen 
(79%) of these were detected on the bone scan while 
14 (58%) were seen on X-ray. The most frequently 
involved sites were ribs (90%), femur (70%), pelvis 
(40%), and scapula (20%). Pseudo-fractures of the 
ribs were clearly seen on the bone scan (Fig. 4) but 
were often not seen on an initial chest X-ray although 
many but not all were later decided if selected rib 
views were obtained. Generally the bone scan pro­
vides the superior test for detecting pseudo-fractures 
(Fogelman et al, 1977b; Macfarlane et al, 1977); 
however, we found that these were missed on one 
occasion in the pelvis due to the symmetry of the 
lesions in the pubic rami and on another occasion 
were mised due to poor technique where overlapping 
views of the skeleton did not include the upper 
femora. In two further patients pseudo-fractures of 
the upper femora although present were not initially 
recognised on the bone scan because of the symmetry 
of the lesions. There is also the theoretical possibility 
of bladder activity obscuring lesions in the pelvis.
In the present study many of the patients with 
renal osteodystrophy and osteomalacia were severe 
examples of disease and one would not expect the 
bone scan to be abnormal in 100% of cases when 
‘milder’ disease was studied. However, in this selected 
population the bone scan undoubtedly proved 
superior to conventional radiology. The scan appear­
ances in osteomalacia, primary hyperparathyroidism 
and renal osteodystrophy are often non-specific 
although an elevated metabolic index together with 
absent kidney images is strongly suggestive of renal 
osteodystrophy and focal abnormalities (particularly 
when predominantly in the ribs) on a ‘metabolic’ 
scan raise the probability of osteomalacia.
The relative sensitivities of bone scanning and 
radiology in the various patient groups are shown in 
Table 2. It should be noted that while an assessment 
of the metabolic features on the bone scan did not 
suggest the presence of a metabolic bone disorder 
in any of the patients studied with osteoporosis, if 
the non-metabolic feature of linearly increased tracer 
uptake in the spine, representing vertebral collapse, is 
included (which would suggest the presence of osteo­
porosis) then the sensitivity rises to 41%. In the 
evaluation of patients with hyperparathyroidism
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Table 2 — Comparison of X-ray and scan sensitivity
Disease X-ray Scan
(%) (%}
Osteoporosis 81 0 (41)*
Primary hyperparathyroidism 21 50
Renal osteodystrophy 58 100
Osteomalacia 60 100
*If the non-metabolic bone scan feature of vertebral 
collapse (which would suggest the presence of osteoporosis) 
is included then sensitivity rises to 41%.
magnification radiographs of the hands, either by 
optical magnification (Meema, 1977) or using direct 
radiograpliic magnification (Carr et al, 1980) may 
increase the radiological sensitivity but these tech­
niques are not yet widely available.
It is concluded that the bone scan is the more 
sensitive investigation in patients with osteomalacia, 
renal osteodystrophy and primary hyperparathy­
roidism and should be performed prior to X-ray. In 
osteoporosis radiology is the investigation of choice 
but the bone scan may be of value in assessing the 
duration of vertebral collapse and perhaps alerting 
an observer to tlie presence of an underlying 
condition wlrich is responsible for accelerated bone 
loss, e.g, primary hyperparathyroidism or thyrotoxi­
cosis.
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Comment
This investigation presents the only comparative study 
of radiographs and bone scans in a group of patients with 
various metabolic bone diseases. Any previous reports 
relating to the metabolic bone disorders have simply 
evaluated radiographs and scans in a single condition, and 
then only in renal osteodystrophy and primary hyperpara­
thyroidism. In the present study all radiographs and scans 
were read independently without the observers having any 
knowledge of the specific diagnoses.
Utilising the presence of metabolic features on the 
scan image as a means of identifying metabolic bone disease, 
the bone scan was shown to be superior to radiology in primary 
hyperparathyroidism, renal osteodystrophy and osteomalacia. 
However the scan appearances are non-specific and simply 
allow identification of increased bone turnover, whether 
related to metabolic bone disease or to other causes. It 
is clear that radiology can on occasion show specific 
changes, but on the basis of the present findings it would 
appear that if the bone scan does not suggest the presence 
of a metabolic disorder, then radiology will almost certainly 
be negative. Thus in the initial assessment of the above 
disorders the bone scan should be the imaging investigation 
of choice and radiology reserved for obtaining supplementary 
information when required.
59 .
In osteoporosis, however, evaluation of the bone 
scan for metabolic features is of very little value in 
the identification of disease, and radiology remains the 
investigation of choice. Clearly when the appearances of 
benign vertebral collapse are seen on the scan this suggests 
a diagnosis of osteoporosis and in these cases there was 
usually a history of fracture occurring within the previous 
year. It is thus suggested that the bone scan may be 
helpful in evaluating the time interval since collapse 
occurred. In addition, the bone scan may also be of value 
as a general screening test in those patients with osteoporosis 
but in whom the clinical picture or biochemical investigations 
are somewhat atypical. Here the scan may on occasion allow 
identification of otherwise unsuspected pathology such as 
malignancy, Paget's disease or osteomalacia.
It is of interest that all the bone scan studies to 
date in the field of metabolic disease have utilised the 
"older" bone scanning agents such as Tc-99m polyphosphate, 
pyrophosphate or hydroxyethylidene diphosphonate. The 
possibility of metabolic features being less apparent with 
the newer imaging agents has previously been commented upon 
in chapter 2 and this topic will be more fully dealt with 
in chapter 5. Thus there is a clear need for further 
studies to be carried out in metabolic bone disease 
comparing radiology with bone scans obtained with the newer 
diphosphonate scanning agents.
\60 .
Paper 8. A comparison of bone scanning and radiology in 
the assessment of patients with symptomatic 
Paget's disease (1980)
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Purpose of Investigation
This study was designed to compare the relative 
sensitivities of radiology and bone scanning in the detection 
of lesions in patients with symptomatic Paget's disease.
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Abstract. Bone scans and X-rays from 23 subjects 
with symptomatic Paget’s disease were evaluated. 
One-hundred and twenty-seven sites of Pagetoid in­
volvement were found, of which 120 (94.5%) were 
recognised on the bone scan as compared to 94 (74%) 
on X-ray. The anatomical distribution and relation­
ship of lesions on scan and X-ray to the patient’s symp­
toms are also discussed.
It is concluded that the bone scan is more sensitive 
than radiology in detecting Paget’s disease and only 
rarely will a lesion that is seen on X-ray not be visual­
ised by scanning.
Introduction
Paget’s disease affecting the skeleton is common with 
an incidence of approximately 4% in hospital patients 
over the age of 40 years (Collins, 1956). The bone 
scan appearances in this condition are often charac­
teristic (Serafini, 1976) and it is well recognised that 
the scan is more sensitive than radiographic examina­
tion in the detection of metabolically active disease 
(Serafini, 1976; Shirazi et al., 1974; Khairi et al., 
1974; Lavender et al., 1977; Vellenga et al., 1976).
In the present study, Technetium-99m diphos­
phonate bone scans and radiological skeletal surveys 
were obtained in 23 patients with symptomatic Pa­
get’s disease. The incidence, anatomical distribution 
and relationship of lesions on scan and X-ray to the 
patient’s symptoms are discussed.
Patients and Methods
Twenty-three patients with symptomatic Paget's disease were stud­
ied. Clinical details arc shown in Table 1.
Bone Scans. Bone scans were obtained in each patient 4 h after 
the intravenous injection of 15mCi of Technetium-99m hydroxy­
ethy lidene diphosphonate (HEDP). Details o f  the technique em­
ployed have been described elsewhere (Fogelman ct al., 1978).
Radiological Skeletal Survey.'i. In all patients, the radiographic skel­
etal survey comprised antero-posterior and lateral views of the 
skull, antero-posterior and lateral views of the cervical, dorsal
Table 1. Paget’s disease
Patient Age Alkaline Predominant
and phosphatase elinical
sex (normal 
80-280 U/1)
complaints
1. GH 69 F 380 U/1 Pain lumbar spine and pelvis
2. SA 61 F 942 U/1 Pain femur
3. WO 51 M 717 U/1 Pain tibia
4. .1C 42 F 626 U/1 Pain lumbar spine, pelvis 
and femur
5. .IMcl 57 M 781 U/1 Pain femur
6. M M cD 60 F 448 U/1 Pain sacrum, pelvis and femur
7. AB 49 M 325 U/1 Pain tibia
8. FMcC 41 M 2,255 U/1 Pain thoracic spine
9. ME 65 F 2,268 U/1 Pain tibia
10. JO’B 62 M 2.967 U/1 Pain tibia
11. .IG 55 M 639 U/1 Pain tibia
12. lO 60 F 494 U/1 Pain lumbar spine
13. ET 48 M 3.171 U/1 Pain tibia
14. MR 66 F 786 U/1 Headache
15. DL 56 M 2,012 U/1 Pain in chest
16. JC 73 F 1,506 U/1 Pain thoracic, lumbar spine 
and femur
17, CF 78 F 2,318 U/1 Pain lumbar spine, pelvis 
and femur
18. FM 69 F 1,413 U/1 Pain lumbar spine and tibia
19. .IM 72 M 2,928 U/1 Pain lumbar spine and sacrum
20. MF 74 F 1,693 U/1 Pain lumbar spine and tibia
21. JD 73 F 1,740 U/1 Pain lumbar spine, pelvis 
and femur
22. Cl 73 F 5,825 U/1 Pain lumbar spine, pelvis 
and femur
23. .IG 70 M 1,187 U/1 Pain lumbar spine, pelvis, 
tibia and humerus
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Table 2. Comparison o f sites of involvement on bone scan and X-ray in Paget's disease
Skull Spine" Pelvis^ Femur Tibia Scapula Humerus M iscella­ Total
C D L S
neous
Lesions seen 
on X-ray
6 - 7 15 1 27 22 9 - 4 3 94
Lesions seen 
on bone scan
9 1 12 17 2 25 22 10 7 5 10 120
l esions seen on 
X-ray only
- — - — 1 4 2 — — 7
Lesions seen on 
bone scan only
3 1 5 2 2 2 2 1 7 1 7 33
Patients with 
symptomatic sites
1 — 2 12 2 8 8 9 — 1 3 46
Lesions in the long bones and scapula are counted as two when bilateral
' involvement o f any area o f spine in a single subject is counted as one lesion while the number of affected vertebrae in that 
area is not considered
*’ The pelvis is considered as two separate areas, ie. right and left hemi-pelvis
Table 3. Sites of involvement in 23 patients with Paget's disease
Spine - 18 patients (78.3%)
Cervical - 1 (4.4%)
Thoracic - 12 (52.2%)
Lumbar - 17 (73.9%)
Sacrum - 3 (13.0%)
Pelvis - 16 patients (69.6%)
Femur - 15 patients (65.3%)
Tibia - 10 patients (43.6%)
Skull - 9 patients (39.1%)
Scapula - 6 patients (26.1%)
Humerus - 4 patients (17.4%)
Clavicle - 2 patients (8.7%)
Rib - 2 patients (8.7%)
Metacarpal - 2 patients (8.7%)
Patella - 1 patient (4.4%)
Forearm - 1 patient (4.4%)
Mandible - 1 patient (4.4%)
and lumbar spine. A postero-anterior radiograph of chest, antero­
posterior views o f the pelvis, and views of the long bones and 
hands were also obtained.
Comparison of Results. The bone scans and X-rays from the present 
study were included with others obtained from patients with var­
ious metabolic bone disorders (Fogelman and Carr, 1980). All 
the studies were assessed independently and in a random order 
by 2 observers (Scans-IF. X-rays DC) who were unaware of the 
clinical diagnoses. All abnormalities noted were charted on skeletal 
maps.
Results
Twenty-three patients with Paget's disease were stud­
ied and 127 sites of involvement were found. One-
Fig. I. X-ray (A) and bone scan (B) showing Pagetoid involement 
of the left tibia
hundred and twenty (94.5%) sites were recognised 
on the bone scan as compared to 94 (74%) on X-ray. 
There was agreement between the bone scan and X- 
ray in 87 (67.5%) sites. Four (17.4%) patients had 
monostotic Paget's disease, in 2 cases affecting the 
tibia, in I the femur and in I the skull.
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Fig. 2. X-ray (A) and scan (B) showing Pagetoid involvement of the left 1st proximal phalynx and distal radius
The comparisoti of the distribution of sites of Pa­
getoid involvement seen on bone scan and X-ray is 
shown in Table 2. while the relative incidence of sites 
affected in individual patients in shown in Table 3.
Discussion
The main feature on the bone scan in Paget's disease 
is tnarkedly increased uptake of tracer, which is usual­
ly uniformly distributed throughout most or all of 
the affected bone. Distortion or expansion of the bone 
is commonly seen (Figs. 1, 2). When polyostotic Pa­
get's disease is present, there is seldom any doubt 
as to the correct diagnosis, so much so that it is 
often possible to differentiate co-existing Paget's di­
sease and metastatic disease (Citrin and McKillop. 
1978). When monostotic Paget's disease is present 
it may be difficult to differentiate this from other 
pathology and particularly from a sclerotic lesion in 
the spine, eg. from carcinoma of the prostate, but 
usually even the appearance of a single lesion is so 
characteristic as to be highly suggestive of Paget's 
disease (Fig. 3).
In Paget's disease it has been shown that bone 
scanning is more sensitive than radiology in the detec­
tion of lesions (Shirazi et al., 1974; Khairi et al., 1974) 
and our study confirms these findings. In 23 patients 
with symptomatic disease we have found 127 sites 
of Pagetoid involvement and 12 (94.5%) of these sites 
were detected by the bone scan whereas 94 (74%) 
were seen on X-ray. In addition, in 6 patients the 
extent of disease affecting a long bone was underesti­
mated by radiology. Although 33 sites were not pre-
Fig. 3. Bone scan showing Pagetoid involvement of a single mid- 
thoracic vertebrae. Note the uniform distribution of tracer through­
out the whole of the affected vertebrae and that the spinous process 
is clearly seen
sent on X-ray (Table 2), approximately one-third of 
these involved areas which are difficult to evaluate 
with standard radiographic views, eg. scapulae, ribs 
(Fig. 4) and sternum (Milstein et al., 1974) and the 
bone scan was particularly valuable in detecting such
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Fig. 4. Bone scan view of posterior right shoulder showing Pagetoid 
involvement of scapula and two ribs
lesions. Other X-ray negative sites included the spine, 
pelvis, femur, tibia and humerus.
It is often difficult to classify Paget's disease into 
lytic, blastic and sclerotic phases by radiology as has 
been suggested by other workers (Khairi et al., 1973) 
as there is usually a mixed picture present in any 
patient and occasionally this is the case even in the 
same bone. While we did not initially classify the 
radiological features, we did revise those X-rays from 
patients where lesions were missed on the bone scan 
and in all cases, sclerotic changes were found (Fig. 5).
The sites of Pagetoid involvement are shown in 
Table 3. The relative incidence is similar to that re­
ported in other series (Shirazi et al., 1974; Vellenga 
et al., 1976) but we have found the spine rather than 
pelvis to be the most commonly involved site. We 
were somewhat surprised at the frequency of involve­
ment of the scapula (26%) but this finding is in agree­
ment with other reported series (Shirazi et al., 1974; 
Wellman et al., 1977). We believe that the incidence 
of scapular involvement remains largely unrecognised 
because this area is seldom symptomatic and will of­
ten be missed on routine radiology (Miller et al., 
1974). Monostotic Paget’s disease was found in 4 pa­
tients (17.4%) but this may not accurately reflect the 
general incidence in the population as we are dealing 
with a selected series of patients referred with sympto­
matic disease.
The areas of symptomatic Paget's disease are sum­
marised in Table 2. The most common sites were 
spine in 13 patients, tibia in 9 patients and pelvis and 
femur both 8 patients, i.e. in the weight bearing areas 
(Wellman et al., 1977). Although headaches have been 
reported to be a characteristic feature of Paget’s di­
sease (Ibbertson et al., 1979) of the 9 patients with 
skull involvement, only one specifically complained 
of this. Overall there was good accordance between
Fig. 5. X-ray (A) and scan (B) 
of anterior pelvis. There is 
striking Pagetoid involvement 
which is apparent on X-ray 
but not seen on scan
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the sites of patients’ pain and X-ray and scan findings, 
although in 4 of the 23 patients no correlation was 
found. There seems to be general agreement that 
symptomatic lesions usually appear strongly positive 
on the bone scan (Shirazi et al., 1974; Khairi et al., 
1973) but only 36% of the lesions seen in the present 
study were found to be symptomatic. We have found 
that all 4 sites visualised on one study only (33 on 
the bone scan, 7 on X-ray), were asymptomatic. How­
ever, Khairi studied 27 patients with Paget’s disease 
and found that all 19 lesions visualised on X-ray but 
not on the bone scan were asymptomatic but that 
15 of the 21 lesions seen on the scan and not on 
X-ray were symptomatic (Khairi et al., 1974).
In conclusion, we have shown that the bone scan 
is more sensitive than radiology in detecting Paget’s 
disease and only rarely will a lesion that is seen on 
X-ray not be visualised on scanning. This phenome­
non was limited to the sclerotic lesion in agreement 
with other groups (Shirazi et al., 1974; Khairi et al., 
1973). In addition to its sensitivity, the bone sean 
provides adequate visualisation of the whole skeleton 
and is easier to perform and interpret than a radiolog­
ical skeletal survey.
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Comment
This study essentially confirms previous reports 
that the bone scan will identify many more sites of 
Pagetoid involvement than routine radiology. It is 
suggested that this is due to the combination of greater 
sensitivity for disease and the improved visualisation of 
the total skeleton obtained with bone scanning. It is 
extremely uncommon for any lesion seen on a radiograph 
not to be detected on a scan, and this is limited to the 
sclerotic metabolically inactive lesion. Symptomatic 
lesions appear strongly positive on the bone scan but it 
was found that only 36% of all lesions detected by the 
bone scan were symptomatic.
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SUMMARY 
CHAPTER 3.
A COMPARISON OF SKELETAL SCINTIGRAPHY AND RADIOLOGY IN 
METABOLIC BONE DISEASE
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This chapter deals with comparisons of bone scanning 
and radiology in metabolic bone disease and Paget's disease. 
Initially the different principles and mechanisms relating 
to lesion detection with both radiology and bone scan are 
discussed.
Paper 7 describes the only investigation to date 
comparing radiology and bone scanning in metabolic bone 
disorders. All radiographs and scans were independently 
evaluated without prior knowledge of the specific diagnoses 
and it was found that the scan was more sensitive in 
identifying patients with primary hyperparathyroidism, 
renal osteodystrophy and osteomalacia. In osteoporosis 
radiology remains the investigation of choice although it 
was found that the bone scan may be of some value in 
indicating the time interval since vertebral collapse, as 
the intense tracer uptal^e at the site of collapse gradually 
disappears over a 1-2 year period.
Paper 8 presents the results of a study comparing 
radiology and bone scanning in patients with symptomatic 
Paget's disease. The findings confirm previous reports 
that the bone scan is more sensitive than radiology for 
detecting sites of Pagetoid involvement.
64
It is noted that all bone scan studies to date 
in metabolic bone disease have used ’older’ bone scanning 
agents, and it is possible that with the new diphosphonates 
which have higher skeletal affinity, metabolic features 
may be less apparent. It is clear that further comparative 
studies between bone scanning and radiology require to be 
carried out. This is not the case in Paget's disease for 
here focal pathology is present and this is easily identified 
on the scan image, regardless of which radiopharmaceutical 
is used.
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CHAPTER 4.
QUANTITATION OF 24-HOUR WHOLE-BODY RETENTION OF 
TECHNETIUM-99m DIPHOSPHONATE - A TRACER TECHNIQUE 
FOR THE ASSESSMENT OF SKELETAL METABOLISM
6 6  .
Following a review of the use and limitations of 
established radioactive tracer techniques, four papers 
(9-12) are presented which deal with the development 
and validation of a new test , 24-hour whole-body retention 
of technetium-99m diphosphonate, for the measurement of 
skeletal metabolism.
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THE HISTORY OF RADIONUCLIDE TRACER TECHNIQUES 
IN THE EVALUATION OF SKELETAL METABOLISM 
The earliest indication that radionuclides could 
accumulate in the skeleton originated from observations 
in painters of luminous watch dials who developed bone 
necrosis, osteomyelitis and bone tumours following chronic 
exposure to radium (Blum 1924, Hoffman 1924). It was 
initially thought that this radionuclide was taken up by 
reticuloendothelial cells, until autoradiography of human 
post mortem material revealed that the bone itself was 
radioactive (Mart land 1926). Nevertheless, it was widely 
believed that bone was metabolically inactive until 
Chiewitz and Hevesy (1935) demonstrated incorporation of 
P-32 phosphate into the skeleton of adult rats. This was 
the first use of an artificially produced radionuclide in 
the study of skeletal metabolism, and in addition to finding 
deposition of P-32 in bone, its distribution in other organs 
and excretion in both urine and faeces were studied.
Walke (1940) described the physical characteristics 
of Ca-45 and suggested its use as a tracer in biological 
studies. The first animal experiments using Ca-45 were 
reported by Campbell and Greenberg (1940) who measured its 
absorption and excretion in a rat. The first report.
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however, of the use of Ca-45 in humans.was from Beilin and 
Laszlo (1953) who administered Ca-45 intravenously to 
patients with malignancy and measured its blood clearance 
and excretion. They suggested that such studies might 
yield useful information on skeletal metabolism. This 
paper has been followed by a great many others (Anderson 
et al, 1956; Krane et a l , 1956; Bronner et a l , 1956;
Fink and Laszlo, 1957; Comar et al, 1957; Spencer et al , 
1957; 1960; Mazzuoli et a l , 1958; Dow and Stanbury, 1960)
which have simply expanded these original observations, with 
the same or different radionuclides, without however adding 
any theoretical basis as to how one might obtain an accurate 
measurement of skeletal metabolism.
While bone crystals are extremely small, they have a 
huge total surface area and yet this surface appears to 
have such little contact with body fluids that the vast 
bulk of skeletal mineral has to be considered separate from 
and effectively non-exchangeable with the calcium of the 
body fluids (Neuman and Neuman, 1953; 1957). It has been
suggested that in normal adults injected tracer mixes with 
only 1% or less of the estimated total body calcium 
(Heaney 1963). Although several early papers proposed that 
processes other than exchange were required to explain 
observed bone tracer behaviour (Norris and Kisieleski, 1948) 
it was Carlsson (1951) who first provided the conceptual 
basis on which most subsequent calcium kinetic data is 
based. He suggested that the tracer content of bone
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represented two distinct and essentially independent 
components: (a) an exchangeable calcium fraction in
which tracer concentration, by definition, must change 
in parallel with that of the body fluids, and (b) 
that associated with bone accretion, in which tracer 
is removed from body fluids and deposited irreversibly 
in the skeleton during new bone formation.
ASSESSMENT OF SKELETAL METABOLISM WITH RADIOCALCIUM 
Bone Remodelling
While growth ceases with skeletal maturity, the 
skeleton remains a metabolically active organ with 
remodelling of bone continuing throughout life. By this 
means both the mass and architecture of bone can be altered. 
Essentially remodelling is ttfe term used to describe the 
sequential occurrence of a wave of cellular activity which 
is initiated by osteoclastic bone resorption, then osteoblasts 
refill the resorbed area with osteoid and this is 
subsequently mineralised (Frost 1963). Remodelling is not 
a generalised process, and talées place at localised sites.
Why this should be so is not known, nor is the stimulus 
which may commence the sequence recognised. However it 
is likely that remodelling is necessary to repair damaged 
tissue such as sites of micro-fracture (Frost 1973), and 
may have a role to play in altering bony trabeculae in 
response to mechanical stress (Doyle et al, 1970;
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Aloia et al, 1978). Certainly at any one time there are 
many active sites throughout the skeleton and it has been 
suggested that a healthy adult remodels approximately 10% . 
of the skeleton annually (Aaron 1976).
Clearly if a subject is in calcium balance the rate 
of bone resorption and formation must be equal, but if 
one is losing bone then the rate of resorption must 
exceed that of formation. While alterations in skeletal 
metabolism occur in many diseases it has been observed 
that the rates of bone resorption and formation change in 
the same direction, although not necessarily to the same 
degree (Harris and Heaney, 1969).
Calcium Metabolism
Calcium is found in the body in bone, extracellular 
fluids and soft tissues. From the body fluids calcium 
may enter the skeleton in two ways; either by exchanging 
with other calcium ions on exposed surfaces of bone crystals 
or by deposition into new bone crystals as these are formed. 
The first or exchange process occurs rapidly and extensively 
and this has been confirmed in studies with bone labelled 
in vitro (Amprino 1952; Lacroix 1952) and in bone cell 
culture studies (Lengemann 1957). The exchange process, 
however, is clearly not the only one for new bone is 
constantly being formed to keep pace with resorption.
In addition, autoradiographic studies have shown that
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injected radionuclides are initially deposited widely 
throughout an animal's skeleton, but later remain where 
deposited in deeper bone (Tutt et a l , 1952; Jowsey et a l ,
1953; Bauer 1954). Bauer and Carlsson (1955) injected 
both P-32 and Ca-45 into rats, and over the next five 
days obtained serial measurements of each in plasma and 
bone. From these results they computed the rate of 
deposition of calcium and phosphorus in various parts of 
the skeleton. Good agreement was obtained between the 
two sets of data. It was found that for the first 24-48 
hours after injection, tracer uptake by bone was rapid, 
presumably due to the summation of exchange and deposition; 
but thereafter mixing or exchange with surface bone was 
evidently completed, and the rate remained steady, reflecting 
the rate of incorporation of tracer into deeper bone. Such 
findings suggest that surface bone and body fluids are in 
equilibrium and these two fractions of body calcium may thus 
be regarded as comprising a single pool or mass of exchangeable 
calcium.
It is convenient to consider the body's calcium as 
existing in two main pools, the exchangeable calcium pool 
and deep bone. The exchangeable pool receives calcium 
from intestinal absorption and bone resorption, while 
calcium is lost from it by urinary and faecal excretion, 
as well as by deposition into deep bone.
72.
Calcium Kinetic Measurements
One method of measuring skeletal metabolism, and perhaps 
the only generally accepted one available at the present time 
is to label the calcium atoms entering bone with radiocalcium 
and so distinguish them from the calcium atoms coming out. 
There are several ways in which this can be accomplished 
but most methods are variations of the same theme.
Essentially an injection of radiocalcium (Ca-47 or Ca-45) is 
given intravenously and plasma decay curves and whole-body 
retention of tracer estimated over a period of time, usually 
in the order of two weeks. The plasma decay curve is 
obtained from radioactivity measurements at various time 
intervals following injection and the retention curve 
either by collecting excreta or by counting the retention 
of tracer in a whole-body counter. Several mathematical 
approaches based on these primary sets of data are then 
possible and have been reviewed by Heaney (1963), Marshall 
(1964) and Wendeberg (1965). A relatively simple and 
straightforward calculation may be obtained from the postulate 
of Bauer et al (1961) that the amount of activity in the 
skeleton at any given time is the sum of the amount deposited 
by new bone mineralisation and the amount that has entered 
by exchange. From this the basic equation R == E + A is 
derived, where R = activity retained, E is activity in the 
exchangeable pool and A is activity deposited by accretion
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(bone mineralisation). As there are two unknowns (E and A ) , 
two equations can be written at different time intervals 
following administration of the dose to determine the two 
unknowns. The times chosen are of great importance since 
during much of the first week or so after injection the 
fall of activity of tracer in plasma is relatively rapid, 
almost certainly due to exchange processes, and any 
calculation of mineralisation rates would tend to over­
estimate the true value until these processes have reached 
equilibrium. To avoid this, measurement should be made as 
late as possible, but if too late other problems arise.
Firstly the rapid decay of Ca-47 may make it impossible to 
measure activity, and secondly and in practical terms much 
more important, if resorption of labelled bone were to occur, 
this would release tracer into the exchangeable pool and 
render the whole measurement meaningless. Nordin (1967) 
has suggested that measurements should be made at 7 or 11, and 
14 days after injection, but much controversy exists 
(Heaney 1963) and the optimal times remain speculative. 
Alternative procedures for the calculation of bone mineral­
isation rate from the isotopic data include drawing a line 
through the most linear part of the plasma decay curve, 
extrapolating back to zero time and calculating the exchangeable 
calcium pool size from the reciprocal of the intercept.
Total turnover is calculated from the rate of fall of plasma 
specific activity multiplied by this pool and if urinary
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calcium and endogenous faecal calcium are subtracted from 
the turnover, this yields the bone mineralisation rate 
(Noràin 196 7).
Limitations of Calcium Kinetic Measurements
The conceptual basis for calcium kinetic studies is 
complex and Heaney (1963) has suggested that the extreme 
simplifications necessary for diagnostic purposes may 
negate the value of these techniques. He also stated that 
the field of calcium kinetics is sufficiently complex that 
with very little effort it could be made totally 
incomprehensible. The accretion rate and exchangeable 
calcium pool size have both been defined on a mathematical 
or kinetic basis and while it is argued that such measurements 
are of great importance in the overall understanding of 
the metabolic bone diseases, nevertheless their physiological 
significance is not immediately apparent and measurements 
have little direct clinical significance (Dymling 1971).
Values for accretion rate in patients with metabolic bone 
disease, for example, tend to show large overlap with values 
from control subjects (Dymling 1962; Nordin et al, 1976).
Calcium kinetic techniques have further practical 
disadvantages, for they are laborious to perform, are 
expensive, and utilise significant amounts of radioactivity.
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Furthermore when balance techniques are used, collection of 
excreta is necessary, and it is recognised that many 
additional sources of error may be introduced (Reifenstein 
et al, 1945; Isaksson and Sjogren, 1967). In addition, 
prolonged periods of in-patient hospitalisation are 
required for calcium kinetic studies and for these reasons 
such tests have been less often performed in recent years.
OTHER TRACER TECHNIQUES FOR ASSESSMENT 
OF SKELETAL METABOLISM
A . Continuous Infusion of Calcium-45
In view of the complexity and other problems related 
to the calcium kinetic techniques, Rich et al (1961) 
investigated the possibility of using the distribution of 
radiocalcium delivered by constant intravenous infusion as 
a means of reflecting skeletal metabolism in metabolic bone 
disease. Each infusion was delivered over a period of 1.7 
to 3.3 hours and during this time the specific activity of 
plasma calcium was found to increase at a constant rate, which 
made it possible to calculate the amount of calcium with which 
the administered Ca-45 appeared to mix. It was suggested 
that this test principally reflected alterations in bone 
formation which made available a larger area of bone 
surface for exchange reactions. The results of the Ca-45
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infusion test were found to be similar in all normal 
subjects and appeared to vary characteristically in states 
of altered skeletal metabolism such as Paget's disease, 
primary hyperparathyroidism and osteomalacia. However, 
unexpectedly high results for available calcium were 
found in three patients with senile osteoporosis and this 
finding could not be adequately explained.
Haymovitz and Horwith (1964) evaluated the Ca-45 
infusion technique in a larger group of patients with 
metabolic bone disease. They obtained similar results 
to Rich et al (1961) but found that the majority of patients 
with osteoporosis had normal values for the test . They 
suggested that the technique may be useful in elucidating 
the pathogenesis of bone disease.
The radiocalcium infusion technique, while relatively 
simple to carry out, was not however shown to provide a 
sensitive measure of altered skeletal metabolism in 
individual patients and this test is no longer performed.
B . Tracer Techniques using non-radioactive substances
(i) Stable Strontium
Fraser et al (1960) and Eisenberg and Gordon (1961) 
described techniques for estimating the rate of skeletal 
deposition of calcium using stable strontium as a tracer.
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After an intravenous dose of strontium, its concentration in 
serum and urine was measured over the next six days. From 
the rate of decline of these concentrations it was possible 
to calculate the rate of movement of strontium out of the 
body fluids into urine and bone. It was suggested that 
this technique provided a sensitive means of identifying 
patients with increased bone turnover and that it may be 
of particular value as an aid to the diagnosis of primary 
hyperparathyroidism or osteomalacia (Fraser et al, 1960). 
However to carry out this test patients were required to 
take fixed calcium diets for three or more days prior to 
the commencement of the study (Fraser et al, 1960) and 
multiple blood and urine samples (with inevitable uncertainties 
as to whether the urine collections were complete) were 
obtained over the six day period. A small but significant 
amount of strontium (approximately 8-16%) is excreted by 
the faeces and this was not corrected for.
A similar test using stable strontium, which measures 
the 24-hour strontium space, has also been suggested as a 
valuable index of exchangeable calcium (Nadarajah et al,
1968; Thalassinos et al, 1970). Here the strontium space 
result is expressed in plasma units, and this calculation 
requires the assumption that plasma is 5% of body weight 
expressed in kilograms. To carry out the above studies
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facilites for measuring strontium are required and in 
practice these tests are no longer performed.
(ii) Calcium Infusion Tests
The use of calcium infusions in the diagnosis of 
metabolic bone disease was first suggested by Schilling 
and Laszlo (1951) who argued that the amount of calcium 
appearing in the urine after a standard infusion should be 
inversely related to the avidity of the skeleton for 
calcium. Since that time many groups have published data 
on various aspects of calcium infusions with only limited success 
in clinical practice (McCance and Widdowson, 1939; Baylor 
et al, 1950; Howard et al, 1953; Kyle et al, 1954;
Spencer et al, 1954; Goldman and Bassett, 1954). However 
Nordin and Fraser (1956) described a standard procedure 
utilising a four hour calcium infusion and they considered 
this test to be of diagnostic value for osteomalacia.
Essentially the net output of calcium following infusion is 
expressed as a percentage of the administered dose after 
deduction of a basal excretion figure calculated from the 
previous 24 hours' urinary output of calcium.
This test is inconvenient to perform as it requires the 
patient to take a low calcium diet for three days prior to 
study, with urine collections over the following 48 hours.
There is the further disadvantage that calcium infusions 
are not without risk in patients with hypercalcaemia and
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the usefulness of this test in clinical practic has not 
been substantiated (Bhandarkar and Nordin, 1962).
ADVANTAGES OF TECHNETIUM-99m DIPHOSPHONATE UPTAKE 
AS A MEASURE OF SKELETAL METABOLISM 
The vast bulk of skeletal mineral has such little 
contact with body fluids that it is effectively unavailable 
for exchange reactions, and surface phenomena dominate the 
chemical behaviour of bone due to the enormous surface area 
of the bone crystals (Neuman and Neuman, 1953). It is 
believed that alterations in the bone surface available 
for exchange reactions are directly proportional to the 
level of skeletal metabolism (Fraser et al, 1960). Bone 
that is actively remodelling thus appears to be more 
accessible than resting bone for exchange with calcium 
(or bone seeking radiopharmaceuticals) in the circulating 
body fluids (Heaney 1976). A means of quantitating such 
alterations in skeletal affinity for tracer may therefore 
provide a valuable measure of skeletal metabolism in 
clinical practice.
Tc-99m diphosphonate is an avid bone seeking compound 
which has been shown to adsorb onto the surface of bone 
crystals (Francis 1969) (see chapter 1). Tc-99m 
diphosphonate is rapidly cleared from the soft tissues 
and excreted via the urinary tract, and because of this it 
is possible to measure skeletal retention of tracer at
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relatively early times following injection. A direct 
measure of skeletal avidity for this bone seeking 
radiopharmaceutical can thus be obtained. This is not 
possible with radiocalcium because of excreted activity in 
the bowel and all the values obtained relating to skeletal 
avidity of tracer, such as mineralisation rates, are derived 
from indirect data. While quantitation of skeletal uptake 
of Tc-99m diphosphonate is not strictly comparable with the 
other more elaborate calcium kinetic techniques, the 
magnitude of bone remodelling is nevertheless clearly 
reflected. In addition quantitation of Tc-99m diphosphonate 
requires no patient preparation, is simple and quick to 
perform, is inexpensive and uses extremely small amounts of 
radioactivity.
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Pap er  9 .  The u se  o f  w h o le -b o d y  r e t e n t i o n  o f  Tc-99m
diphosphonate in the diagnosis of metabolic 
bone disease (1978)
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Purpose of Investigation
In chapter 2 it was emphasised that quantitation of 
skeletal uptake of radiopharmaceutical may provide a 
sensitive measure of accelerated bone turnover. A semi- 
quantitative scoring system based on the presence of metabolic 
features on the bone scan image and the technique of 
measuring bone to soft-tissue ratios from the scan were 
described and critically evaluated. It was apparent, 
however, that these techniques did not provide a sensitive 
means of identifying altered skeletal metabolism in 
individual subjects, and a large degree of overlap was found 
between results from patients with metabolic bone disease 
and control subjects.
The present study arose from my desire to obtain a more 
accurate means of quantitating total skeletal uptake of 
radiopharmaceutical. Utilising a standard shadow-shield 
whole-body monitor, sequential measurements of whole-body 
retention of Tc-99m hydroxyethylidene diphosphonate (WBR) 
were obtained over 24 hours in 4 patients with osteoporosis,
82 .
11 with renal osteodystrophy, 7 with osteomalacia, 5 with 
primary hyperparathyroidism, 10 with Paget's disease and
12 healthy volunteer subjects.
It is recognised that diphosphonate is either largely 
taken up by the skeleton or else excreted via the urinary 
tract. Normally, approximately 70% of an intravenous dose 
of Tc-99m hydroxyethylidene diphosphonate will be excreted 
via the urinary tract within 4-6 hours of injection. I 
therefore suggested that if the majority of the non-skeletal 
activity were excreted then a whole-body count would 
effectively provide a skeletal count. The purpose of this 
study was to assess whether WBR measurements could provide 
a sensitive measure of skeletal metabolism.
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The Use of Whole-Body Retention of Tc-99m 
Diphosphonate in the Diagnosis of 
Metabolic Bone Disease
Ign ac  F o g e lm a n , R o d n ey  G . B essent, John  G . Turner, D enn is L. C itrin*, la in  T. B o y le ,
a n d  W illia m  R. G re ig
Royal Infirmary, Glasgow, G4 OSF, Scotland
The lim ited  role o f bone scanning in the diagnosis of m etabolic bone  
disease m ight he considerably im proved  by accurate quantification o f shele- 
tal uptake o f the radiopharm aceutical. Using a standard shadow-shield  
whole-body m onitor, we have m easured whole-body retention (W B R ) of 
Tc-99m  HEDP up to 24  hr in 11 patients with renal osteodystrophy ( mean  
W BR 8 8 .6 %  at 24  hr)^ in ten patients with PagePs disease ( mean 5 6 .9 % )   ^
in seven patients w ith osteom alacia (m ean  4 0 .7 % );  in five patien ts with  
prim ary hyperparathyroidism  (m ean  5 0 .7 % );  in four patients w ith osteo­
porosis (m ean  2 1 .2 % );  and in 12  norm als (m ean  1 9 ,2 % ) . The osteo­
porotic  group could not be differentiated from  the norm al group, but the  
other groups were significantly different from  the norm al group at 24  hr 
( p  <i 0 ,0 0 2 ) , and each individual resu lt for the 24-hr W BR of Tc-99m  
HEDP in these groups lay outside our norm al range. This test m ay, there­
fore, provide a sensitive means o f detecting conditions with increased bone 
turnover. W e obtained m easurem ents o f plasm a activity o f Tc-99m  HEDP 
in these patients up to 24  hr, and 4-hr bone to soft-tissue ratios from  bone- 
scan images, but little  additional in form ation  resulted.
J Nucl Med 19: 270-275, 1978
There has been recent interest in the use of bone lem of standardizing the “soft tissue,” since counts
scanning in metabolic bone disease, and there emerge per unit area vary with vascularity and muscle bulk,
certain patterns of abnormality that may aid in the In an attempt to quantify total skeletal uptake of 
diagnosis of these disorders {1 -5 ). Nevertheless, the radiopharmaceuticals, we have measured the whole-
scan appearances are often nonspecific and are of body retention (W BR) of Tc-99m hydroxyethyli-
limited use in those cases that present the most dif- dene diphosphonate (H ED P) sequentially over 24
ficulties in clinical practice. Because of the great hr in patients with Paget’s disease and other meta­
affinity of bone for the phosphate and phosphonate bolic bone disorders. We also measured bone to soft-
tracers, quantification of their skeletal uptake may tissue ratios from the bone scans in these patients,
have a useful role in the detection of metabolic dis­
orders. Simple quantification of the bone scan has
been P ^ e d  by measuring the bone to soft-tissue ^  ^ revision accepted Nov. 3, 1977.
ratio (5 ), but this is a relatively crude method as p„ contact: Ignac Fogclman, Dept, o f Nuclear
the small area of bone selected may not reflect a Medicine, Royal Infirmary, Glasgow 0 4  OSF, Scotland
small yet significant change in the total skeletal u p - ^ D e p t ,  of Nuclear Medicine and Division of 
. 1 f  , r  Clinical Oncology, University of Wisconsin Hospitals, Madi-take o f  radiopharmaceutical. There is also the prob- son, WI 53706.
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galliuni-67 and scintigraphic im aging. /  7 / j /e c /D /j  130; 1 2 5 -  7. H aaga JR, A lfida RJ, H avrilla TR, et al; CT de-
131, 1974 tection and aspiration o f  abdom inal abscesses. A m  J Roent-
5 . K u m a r  B, C o le m a n  RE, A l d e r s o n  PO: G allium  ci- 128: 4 6 5 -4 7 4  1977
trate (*”G a) im aging in patients with suspected inflam m atory
processes. Arch Surg  1 10: 1237-1242 , 1975 B uff e r PB, Sc h o r R, A sh b y D , et al: C om parison
6. H o p k in s  GB, M e n d e  CW : G aiIium -67 and subphrenic G a-67 citrate im ages obtained w ith rectilinear scanner 
abscesses, is delayed scintigraphy necessary? J N u c l  M e d  and large-field Anger cam era. J N u cl  M e d  18: 5 3 8 -5 4 1 , 
16: 6 0 9 -6 1 1 ,1 9 7 5  1977
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and this communication describes our findings (Ta­
ble 2 ).
Each patient was given 50 /iCi of Tc99m HEDP 
by i.v. injection and the whole-body count was meas­
ured at 5 min, and at 2, 4, 6, 8, and 24 hr, using a 
standard shadow-shield whole-body monitor (6 ). 
Whole-body retention of radiopharmaceutical was 
calculated, after appropriate background subtrac­
tion, by taking the 5-min count as 100% and cor­
recting thereafter for radioactive decay. In addition, 
10-ml blood samples (20-ml at 24 hr) were col­
lected by venepuncture at the time of each whole- 
body count and plasma radioactivity was measured 
in an automatic gamma counter. Results were ex­
pressed as a percentage of injected activity per litre 
plasma, using a fraction of the injected material as 
a standard.
The above measurements were made in; (a) ten 
patients with Paget’s disease (age range 47—78 yr, 
symptomatic, and with extensive radiologic and 
bone-scan evidence of disease); (b) four with os­
teoporosis (age range 51-72 yr, symptomatic, and 
with vertebral crush fractures); (c) five with pri­
mary hyperparathyroidism (age range 51-80 yr, 
three having parathyroid adenomas, subsequently 
removed, and two having hypercalcaemia with ele­
vated parathormone levels); (d) seven with osteo­
malacia (age range 15-68 yr, all having bone and 
muscle pain and having had bone-biopsy evidence 
of osteomalacia); (e) 11 with renal osteodystrophy 
(age range 15—55 yr, creatinine clearance range 
5-35 m l/m in, all with biochemical and bone-biopsy 
evidence of renal osteodystrophy); and (f) 12 
healthy volunteers with no evidence of bone disease 
(age range 19-31 yr).
Bone scintigrams were performed with Tc-99m 
HEDP in all patients, using a gamma camera with 
high-resolution, medium-sensitivity collimator. In ad­
dition, all images were recorded and stored in a mini­
computer. The pictures were stored for later re- 
trievel and processing on computer magnetic tape. 
Bone to soft-tissue ratios were measured by using the
computer to define regions of interest around the L2 
vertebra or, in the case of Paget’s disease, an in­
volved vertebra. An adjacent soft-tissue area clear 
of bone and renal activity was similarly defined (Fig.
1). The computer was used to derive mean counts 
per unit area for each region, and the simple ratio 
of these two results is defined as the bone to soft- 
tissue ratio.
In 35 patients bone to soft-tissue ratios were meas­
ured but in two patients (one with Paget’s disease 
and one with primary hyperparathyroidism) the 
stored images were “lost.” Bone to soft-tissue ratios 
were also measured in a control group of 80 women 
with breast carcinoma without clinical suspicion of 
bone métastasés, and with bone scans considered 
completely normal.
Differences between groups for any parameter 
were tested using the Wilcoxon rank-sum test which 
— unlike the Student t-test— makes no assumptions 
about the distribution of values for the populations 
being compared.
RESULTS AND DISCUSSION
Table 1 shows the mean values for plasma Tc-99m 
activity at each sampling time for the various groups 
of patients. The renal osteodystrophy group was sig­
nificantly higher than the normal and Paget’s groups 
at all times, but with greatest significance at 24 hr 
(p <  0.01 and p < 0.002, respectively). The pri­
mary hyperparathyroidism group also differed sig­
nificantly from the normal and Paget’s groups up 
to 8 hr (p < 0.01), but there was no significant dif­
ference at 24 hr. The osteomalacia group was sig­
nificantly different from the normal group at 24 hr 
only (p <  0 .02). At 4 and 6 hr there was marginal 
significance (p <  0.05) in the difference between 
the osteomalacia and primary hyperparathyroidism 
groups. There was also marginal significance in the 
difference between the osteoporotic and normal 
groups at 24 hr (p < 0.05). Although these differ­
ences exist between the various group averages, 
there is marked overlap of individual plasma results
TABLE 1. MEAN VALUES FOR PLASMA ACTIVITY OF Tc-99m 
(% INJECTED ACTIVITY/LITRE PLASMA ±  1 s.d.)
HEDP
5 min 2 hr 4  hr 6 hr 8 hr 24 hr
O steo p o ro sis  {N =  4) 20 .0  d :  4 .48 3 .78  ±  0 .8 4 1.99 ±  0 .48 1.33 ±  0.32 0 .96  ±  0 .25 0 .43  ±  0 .12
Renal o s te o d y s tro p h y  (N = 11) 16.38 ±  3.98 4.01 ±  1.57 2.6  ±  1.11 1.83 ±  0.91 1.78 ±  0 .78 0.64  ±  0.42
P a g e t 's  d is e a s e  (N =  10) 16 .35  ±  4 .09 2 .23  ±  0.93 1.2 ± 0 . 5 1 0 .79  ±  0 .27 0.58  ±  0.13 0 .25  ±  0 .05
O ste o m a la c ia  (N =  7) 20 .44  ±  3 .48 2.89  ±  0 .84 1.54 ±  0 .54 1.03 ±  0.42 0 .94  ±  0 .35 0 .4 9  ±  0 .16
Prim ary  h y p e rp a ra th y ro id ism  
(N =  7)
21 .6  ± 5 . 5 6 5.21 ±  1.62 2 .89  ±  1.13 1 .86  ±  0.82 1.44 ±  0 .67 0 .52 ±  0 .24
N orm als  (N =  10) 15.24  ±  2.68 2.78 ±  0 .65 1.46  ±  0 .4 0 .98  ±  0 .29 0.73  ±  0 .23 0 .29  ±  0 .07
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FIG. 1. M onochrom e  r e p re s en ta t io n  of co lor TV im a g e  of 
Iwmbo sacra l  sp in e ,  showing  reg io n s  d e f ined  fo r  “ b o n e "  a n d  "soft-  
t i s su e"  act iv ity  m easu rem en ts .
between all groups; accordingly— with the possible 
exception of the osteoporotic group— measurement 
of plasma activity does not provide diagnostic infor­
mation beyond that derived from the measurement 
of 24-hr WBR of Tc-99m HEDP (discussed later).
The distribution of the bone to soft-tissue ratios 
is shown in Fig. 2. The primary hyperparathyroidism 
patients are indistinguishable from the normal group, 
as previous workers have found (5 ). The osteo­
malacic and renal osteodystrophy groups are both 
significantly different from the normal group (p <  
0.001). However, there is an appreciable overlap 
between each of these groups and the normal range, 
rendering a normal result in an individual patient of
no value. The bone to soft-tissue ratios for the 
Paget’s group all lie above the normal range. In all 
these patients, however, the diagnosis was obvious 
from the bone-scan appearance [patients with Paget’s 
disease usually have characteristic bone-scans (7 )]  
and the area of bone for the bone to soft-tissue ratio 
was deliberately chosen as an affected area. Note fur­
ther that our bone to soft-tissue ratios are of no value 
in those situations that often provide the greatest dif­
ficulty clinically— namely, primary hyperparathyroid­
ism and osteoporosis.
The measurement of the bone to soft-tissue ratio 
is a crude means of quantifying skeletal uptake of a 
tracer, and although elevated values confirm in­
creased skeletal uptake, normal values do not ex­
clude this.
Figure 3 plots the mean whole-body retention 
against time for the different groups, up to the end 
of our study at 24 hr. The continuous curves were 
derived from a least-squares fit of the data to a 
double exponential function, using an iterative pro­
cedure. Intergroup differences are most striking at 
24 hr (Fig. 3 ), but the osteoporosis curve lies close 
to the normal. The 24-hr value for whole-body re­
tention of Tc-99m HEDP is a more convenient meas­
urement than the 8-hr value. Also, the 24-hr value 
is not subject to error from failure to empty the 
bladder, which may cause artificially high values in 
the earlier hours of study. The technetium either is 
taken up by the skeleton or is almost totally excreted 
by the kidneys (S ); in fact, almost 70% of an i.v. 
dose of Tc-99m HEDP is normally excreted through 
the urinary tract within 6 hr of injection (9 ). There­
fore, by 24 hr the body burden of Tc-99m HEDP 
represents almost entirely skeletal uptake.
B o n e  so ft t i s s u e  ratio
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O s te o p o ro s is R enal P a g e t s O s te o m a la c ia 1^ H y p e rp a ra -
O s te o d y s tro p h y th y ro id ism
FIG. 2. Dis tr ibution of 4-tir b o n e / s o f t -  
t is sue ratios.
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TABLE 2 . M E A N VALUES FOR 2 4 -H R  W B R O F T c-9 9 m  HEDP (%  INJECTED 
A N D  4-H R  B O N E TO SOFT-TISSUE RA TIO S ±  1 s .d .
ACTIVITY ±  1 s .d .) .
No.
M ean  24 -h r 
WBR ±  1 s .d .
D ifference from 
norm al g ro u p
M ean  4 -h r b o n e  to so ft-tissue  
ra tio  ±  1 s .d .
O steo p o ro sis 4 21.2  ±  1.7 N ot s ign ifican t 3 .43  ±  0 .39
Renal o s teo d y s tro p h y n 88 .6  ±  10.5 p <  0 .002 6 .29  ±  1.6
P a g e t’s 10 56 .9  ± 1 3 . 1 p <  0 .002 10 .87  ±  3 .79
O steo m a la c ia 7 4 0 .7  ±  8 .0 p  <  0 .002 6 .06  ±  1.85
Prim ary  h y p erparafhy ro id isn" 5 5 0 .7  ±  14.6 p <  0 .002 3 .7 6  ±  0 .26
N orm als 12 19.2 ±  1.7 4 .0 5  ±  0 .69
The control group had a mean 24-hr whole-body 
Tc-99m HEDP of 19.18% ±  1.73 (1 s.d.), this 
being significantly different from the groups with 
Paget’s disease, osteomalacia, primary hyperpara­
thyroidism, and renal osteodystrophy (Table 2 ).
Figure 4 shows that in these groups all results for 
24-hr WBR of Tc-99m HEDP in individual patients 
lay outside our normal range. The osteoporotic 
group could not be differentiated from the controls, 
but since there were only four patients in this group, 
it requires further study.
The 24-hr whole-body retention of Tc-99m HEDP 
in the renal osteodystrophy group (mean 88.6% ±  
10.5) was much higher than in all other groups (p <  
0.002). Although very high values for WBR of 
Tc-99m HEDP can be expected in any patient unable 
to excrete the tracer due to severe renal impairment 
(e.g., in acute renal failure, obstructive uropathy, or 
end-stage chronic renal failure), we find that in our 
patients with renal osteodystrophy the high reten­
tions were largely due to increased skeletal uptake 
of the tracer. This was shown by elevated bone to 
soft-tissue ratios (Fig. 2) and the high-contrast scin­
tigrams (Fig. 5). On the other hand, two patients
with acute renal failure, who previously had normal 
renal function, had low bone to soft-tissue ratios (2.0 
and 2.6 against the normal of 4.05 ±  0.69) and 
their bone images were of poor quality due to high 
soft-tissue background (Fig. 5 ). These patients with 
previously normal bones were anuric, and their WBR 
of Tc-99m HEDP (although not measured) must 
have been 100%. Although increased soft-tissue 
retention no doubt made some contribution to the 
high WBR in our patients with renal osteodystrophy, 
the increased skeletal uptake appears to be the domi­
nant factor.
A high WBR of Tc-99m HEDP cannot differen­
tiate between uraemic patients with significant renal 
osteodystrophy and those with other forms of severe 
renal impairment, but the bone scintigram clearly 
shows the high bone uptake and low soft-tissue back­
ground typical of renal osteodystrophy.
Whereas the 24-hr whole-body retention of Tc- 
99m HEDP in the Paget’s group showed marginal 
significance in its difference from the primary hyper­
parathyroidism group (p <  0.05), neither group 
differed significantly from the group with osteoma­
lacia. Moreover, the scatter of individual results in
FIG. 3. M ean w h o le -b o d y  re fen flons  
o f Tc-99m HEDP up to  24  hr.
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FIG. 4. Dis tr ibution of in d iv idua l  24- 
hr w h o le -b o d y  re ten t ions  of Tc-99m HEDP.
these groups was such that no diagnostic value could 
be attached to them. However, they show clear de­
marcation between normal and abnormal, and when 
the diagnosis is already established or strongly sus­
pected (as is often the case), the knowledge that the 
result is either higher or lower than the group mean 
may provide additional information as to the severity 
of the disease.
Elevated values for 24-hr whole-body retention 
of Tc-99m HEDP have also been found in two pa­
tients in whom primary hyperparathyroidism was 
suspected, but definite confirmation of diagnosis has 
not yet been obtained. In each case transileal bone 
biopsies were abnormal, showing increased bone 
resorption in keeping with hyperparathyroidism. 
Therefore, in every case where we have found an 
elevated value for 24-hr whole-body retention of 
Tc-99m HEDP this could be correlated with condi­
tions known to cause increased bone turnover (Table
2) or else there was histological evidence of in­
creased bone turnover. The measurement of whole- 
body Tc-99m HEDP may therefore provide a sen­
sitive means of detecting conditions with rapid bone 
turnover. It can be used as a screening test for vari­
ous metabolic bone disorders, and in particular for 
primary hyperparathyroidism, which at times can 
present a considerable diagnostic problem {10). 
Although patients with osteoporosis seem to have
results in the normal range, this test may help to 
differentiate those cases where rapid bone loss is 
due to an underlying condition such as thyrotoxi­
cosis. Also, it may be that plasma activity of Tc-99m 
HEDP at 24 hr may be of some help in diagnosing 
osteoporosis, since a marginally significant difference 
(p < 0.05) has been found between this group and 
the normals, and an elevated plasma result would 
tend to support the diagnosis of osteoporosis.
As indicated in the discussion on renal osteodys­
trophy, a knowledge of renal status is essential when 
one is interpreting the WBR of Tc-99m HEDP. All 
patients in the present study, except those with renal 
osteodystrophy, had normal renal function.
The use of a whole-body monitor to calculate the 
24-hr whole-body retention of Tc-99m HEDP pro­
vides an overall measurement of skeletal retention 
of radiopharmaceutical as contrasted with measure­
ment of the bone to soft-tissue ratio, which uses only 
a small and perhaps nonrepresentative area of bone. 
Measurement of whole-body retention is a simple 
noninvasive test that provides accurate and repro­
ducible results ( /  /  ). It can be performed as an out­
patient investigation. Very small amounts of radio­
activity are used and this test can therefore be re­
peated safely. This may be of use when one is fol­
lowing the progression of disease or monitoring the 
effect of treatment.
FIG. 5. Bone scin t ipho tos  of lumbo- 
socrol sp ine ,  pos ter io r  view. (A) Chronic  
rena l  fa i lu re .  N o te  h igh  skele ta l  u p ta k e  of 
t racer .  Kidney im ages  a r e  not s een .  (B) 
Acute  rena l  fa i lu re .  Poor-qual i ty  im a g e  du e  
to  high  ti s sue  b a c k g ro u n d .
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Fatty Acid Accumulation and Abnormal Lipid 
Deposition in Peripheral and Border Zones 
of Experimental Myocardial Infarcts
D avid  W . B ilheim er, L. M axim ilian  Buja, R obert W . P ark ey , Frederick  J. B onte ,
a n d  J a m es T. W illerson
University of Texas (Southwestern) Medical School, Dallas, Texas
Twenty-eight dogs w ith acute anterior m yocardial infarcts due to p rox i­
m al occlusion of the left an terior descending coronary artery (L A D ) were  
studied at various periods follow ing the occlusion to determ ine: ( a )  the  
tim e  course and location of abnorm al lip id  accum ulation a fter infarction,
( b )  the degree o f muscle-cell in jury associated w ith  increased lip id  deposi­
tion, and ( c )  w hether uptake o f fa tty  acid from  the circulating fa t poo l 
contributes to lip id  accum ulation in certain m yocardial regions. The find­
ings show that m yocardial lip id  accum ulation begins as early as 6  hr after  
proxim al LAD occlusion. The increased lip id  deposition  occurs as non­
m em brane-bound lip id  droplets in m uscle cells w ith and w ithout ultra- 
structural evidence o f irreversib le in jury. Analysis o f tissue u ptake of 
intravenously in jected  oleic acid conjugated w ith album in revealed
relatively selective concentration of label in  the peripheral and border re­
gions o f the infarct, but occasionally even the central subendocardial portion  
of the infarct concentrated the fa tty  acid. Thin-layer chrom atography showed  
that m ost o f the label was associated w ith  the trig lyceride fraction  when  
the radiolabeled fa tty  acid was in jected  6  or 2 4  hr a fter LAD occlusion.
These m yocardial cellular and topographical alterations w ill have to be 
considered when labeled fa tty  acids are used for im aging acute m yocardial 
infarcts a n d /o r  if a ttem pts are m ade to iden tify  m yocardial fat-laden cells 
scintigraphically.
J Nucl Med 19: 276-283, 1978
During our studies of experimental myocardial in- the “fat” came from circulating plasma lipids or
farction, we have observed, in border-zone regions from the internal metabolism of these cells (2 ).
of canine myocardial infarcts, the presence of promi- Since that time fatty acids have been implicated in
nent, fine vacuolization of muscle cells, suggesting the genesis of cardiac arrhythmias and myocardial
the accumulation of lipid droplets in these cells (1) .  depression in patients and experimental animals with
These findings are consistent with the observations acute myocardial infarcts (5 -5 ) . It has also been
made over 20 years ago by W artman and associates, suggested that decreased fatty acid uptake occurs in
who demonstrated that neutral lipid droplets, stained regions of acutely ischemic myocardium, and efforts
with oil-red-O, were present in “viable” myocardial 
fibers within and around an area of experimental _______
myocardial infarction ( 2 ) .  They believed that this Received July 12, 1977; revision accepted Sept. 23, 1977.
material accumulated only in reversibly damaged For reprints contact: Jaines T. Willerson, Ischemic I^ art
?  Center, L 5 .134, The University o f Texas Health Science Ctr.,
myocardial cells and were uncertain as to whether 5323 Harry Hines Blvd., Dallas, T X  75235.
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Comment
This paper describes what I believe to be an important 
new, and sensitive test for the assessment of skeletal 
metabolism. At the time of publication the Journal of 
Nuclear Medicine invited Dr R A Holmes to write a 
teaching editorial "Quantification of skeletal Tc-99ra 
labelled phosphates to detect metabolic bone disease"
(Holmes 1978) discussing this paper.
In the present study it was found that patients with 
osteomalacia, primary hyperparathyroidism, renal 
osteodystrophy and Paget's disease, could be clearly 
differentiated from a control population. In addition 
it was found that each individual patient's result in 
these groups lay outside the control range. While blood 
samples were taken for Tc-99m counting at the time of 
each WBR measurement, these results did not provide any 
additional diagnostic information.
The results of WBR from patients with renal osteo­
dystrophy are difficult to interpret because of the severe 
renal impairment present in these cases. Although these 
patients had severe bone disease it is nevertheless impossible 
to separate that proportion of the total WBR due to bone 
uptake from that due to soft-tissue retention. These
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findings, however, emphasise the point that one must always 
be aware of renal function when interpreting WBR results.
The use of WBR in Paget's disease may also appear 
questionable - as this diagnosis is usually simply made on 
the basis of clinical, biochemical and scintigraphic or 
radiological evidence. However, if a screening test were ’■ 
required to identify or exclude Paget's disease, then WBR 
utilises considerably less radioactivity than a bone scan 
(approximately l/300th of the dose). Also a WBR result 
provides a quantitative measure of tracer uptake which is 
likely to reflect severity of disease. In addition, WBR 
is a simple method for accurately documenting alterations in 
skeletal metabolism in sequential patient studies (a theme 
developed more fully in chapter 6) and several groups have 
subsequently suggested that quantitation of diphosphonate 
uptal^e by bone may accurately document the effect of therapy 
in Paget's disease (Espinasse et al, 1981; Vattimo et al,1981) 
While the number of patients studied with primary 
hyperparathyroidism and osteomalacia are small, these 
preliminary results appear to suggest that WBR may be a 
sensitive means of differentiating patients with these 
conditions from normal subjects. Certainly, in clinical 
practice, if osteomalacia or primary hyperparathyroidism 
are suspected additional information indicating whether the 
disease is present or not would be useful. If osteomalacia 
is taken as an example, this condition may be suspected in
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various clinical settings, for example, in an Asian 
population, in subjects receiving anticonvulsant therapy 
or in elderly women who present with a femoral neck 
fracture. However, the only way at present to exclude 
osteomalacia, once suspected, is to perform a bone biopsy.
If a normal WBR result were shown to exclude osteomalacia 
then clearly many patients would be spared an invasive test. 
Similarly I believe that a normal WBR result makes a 
diagnosis of primary hyperparathyroidism extremely unlikely, 
although in this case I expect that eventually a small 
amount of overlap between patients with very mild disease 
and normal subjects will be found.
It is clear, however, that an elevated WBR result is 
of no differential diagnostic value and in general if the 
diagnosis is not apparent , then a bone scan should be 
obtained to image the distribution of tracer.
It may be argued that useful WBR measurements could be 
obtained earlier than 24 hours after injection. However 
I believe that at 4 hours there is too much patient variability 
as regards urinary clearance of tracer. While this may also 
apply to both 6 and 8 hours after injection there are 
further difficulties with the scheduling of studies, as 
measurements would have to be obtained late in the afternoon 
or early in the evening, and thus the number of patients
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that could be studied would be limited. Twenty-four 
hours after injection is free from the problem of patient 
compliance as regards adequately emptying the bladder, and 
patients can be given appointments throughout the whole 
working day. This does mean, however, that a patient is 
required to attend for study on two consecutive days 
(each visit is approximately 20 minutes), but this has not 
been found to be a problem in practice.
Measurement of 24-hour whole-body retention of 
diphosphonate is essentially a very simple test, which uses 
extremely low amounts of radioactivity and appears to 
provide a sensitive measure of increased bone turnover. 
However the problem of assessing the extent to which WBR 
truly reflects skeletal metabolism is a very real one, for 
at the present time there is no satisfactory means available 
to measure skeletal metabolism accurately. Commonly used 
biochemical tests such as serum alkaline phosphatase or 
urinary hydroxyproline excretion, while generally believed 
to reflect skeletal metabolism do not precisely measure this, 
and the results of these investigations show a huge overlap 
between patients with metabolic bone disease and control 
subjects (Nordin et al, 1976). The subject of calcium 
kinetic studies has been discussed previously in this 
chapter. While these tests appear to provide a
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mathematically derived measure of skeletal metabolism, 
they are extremely inconvenient to perform and results 
once again show a large degree of overlap between patients 
and control subjects. Bone biopsy with histomorphometric 
analysis, is an invasive test, but does provide a direct 
means of assessing skeletal metabolism. Unfortunately 
only a very small area of bone can be sampled and the 
extent to which this is representative of the whole 
skeleton and, therefore, of total skeletal metabolism, is 
unclear.
Thus there is no external standard by which to compare 
V/BR performance as a measure of skeletal metabolism.
While the data presented in this thesis does support the 
belief that WBR accurately reflects skeletal metabolic 
activity and provides a sensitive means of identifying 
patients with increased bone turnover, the mechanism by 
which diphosphonate localises in bone is nevertheless not 
fully understood. It would, therefore, appear as so often 
occurs in medicine, the application of a new technique may 
precede a full understanding of the precise mechanisms 
involved. Validation of the WBR technique will depend upon 
independent confirmation of its results as well as its 
general usefulness in clinical practice.
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Paper 10. Accuracy of 24 hour whole-body (skeletal) 
retention of diphosphonate measurements 
European Journal of Nuclear Medicine (in press)
I Fogelman, R G Bessent, J E Scullion,
G F Cuthbert
Purpose of Investigation
Initial experience with 24-hour whole-body retention 
of diphosphonate (WBR) measurements had shown that the 
technique held considerable promise for providing a 
sensitive measure of increased bone turnover. Nevertheless, 
the reproducibility of the technique, the accuracy and 
possible sources of error in WBR measurements had not 
previously been studied and are now reported.
Accuracy of 24 Hour Whole-Body (Skeletal) Retention 
of Diphosphon ate Measurements 
I Fogelman, R G Ressent, J E Scullion, G F Cuthbert
SUMMARY
We have shown that 24 hour whole-body retention (WBR) 
of diphosphonate is a valuable test for the assessment of 
skeletal metabolism. However, the reproducibility, accuracy 
and possible sources of error in WBR measurements have not 
previously been studied.
In 21 paired studies the technique was found to be 
highly reproducible (r = 0.998, p<0.0001). The coefficient 
of variation for whole-body counts on day 1 was 0.1% and on 
day 2, 1.1%. A phantom was used to assess the possible
error introduced by redistribution of tracer. The net 
whole-body count of the phantom representing the 24 hour 
distribution was 98% of that of a uniform phantom. Ten 
subjects were counted twice within a few minutes to study 
the effect of repositioning, and showed a mean difference 
between counts of only 0.8%.
Eleven subjects with traumatic fractures were studied 
to assess the possible contribution of focal lesions to WBR. 
It was found that 9 subjects had normal values for WBR, 
while 2 had minimally elevated results. Twenty patients 
with renal disease but no apparent skeletal disease were 
also studied to assess the possible contribution of soft-
2 .
tissue retention to WBR. A significant correlation between 
serum creatinine and WBR was found (r = 0.72, p <0.001).
However WBR results were always normal when serum creatinine 
values were <130 pmol/l.
It is suggested that WBR measurement is accurate and the 
technique is highly reproducible. The presence of a focal 
lesion is unlikely to affect a WBR result significantly and 
if serum creatinine is in the normal range then an elevated 
WBR result can be assumed to reflect increased skeletal 
metabolism without further concern as to renal function. 
INTRODUCTION
Twenty-four hour whole-body retention (WBR) of diphosphonate 
has been shown to be a sensitive measure of skeletal metabolism 
(1-5). This test has considerable potential for widespread 
application as a screening procedure in the identification of 
patients with increased bone turnover (3). In order to 
assess the accuracy of WBR measurements we have studied the 
reproducibility of the technique and have also examined 
the following sources of error:-
1. Statistical counting errors.
2. Redistribution of tracer within the body, between the 
initial and 24-hour whole-body count.
3. Repositioning of subjects on whole-body monitor couch.
4. Unsuspected focal lesions, such as fractures, causing 
locally increased tracer retention.
3 .
5. Reduced excretion of tracer not taken up by the skeleton 
as a result of poor renal function.
M E T H O D S
Measurement of 24-hour WBR
Each subject was given an intravenous bolus of SOyCi of 
99m Tc-HEDP* and the initial whole-body count was begun at five minutes 
after injection, using a scanning-couch, shadow-shield, whole-body monitor 
(WBM) with two opposed 12.5 x 7.5 cm scintillation detectors 
1.0 m apart. The pulse height analyser window was set to 
cover the energy range 115-165 KeV and energy setting and 
counting sensitivity were checked with a standard source at 
the start of each day. The scanning speed was controlled to 
within 0.2% over the normal scan time of 1000s by tachometer 
feedback to the thyristor-controlled, D-C drive motor. To 
correct for any small difference in speed from day to day, 
two microswitches caused a digital timer to record to a precision 
of 0.1% the time taken for the couch to move a fixed distance 
of 141 cm, corresponding to the passage of the subject's trunk 
and thighs between the two detectors. This time was used to 
normalise the net counts on each occasion.
The presence of the subject increases the background 
reading of the WBM because of scattering. Since this back­
ground cannot be measured directly at 24 hours a control study 
was carried out with 50 non-radioactive subjects of various
* Procter & Gamble "Os te os c an"
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builds, to measure the ratio between the background count 
with the subject on and off the monitor. The mean ratio 
was 1.35 with a standard deviation 0.025 and this factor 
was used to estimate the subject background from that 
measured by the empty monitor.
After correcting the normalised net counts for radio­
active decay the ratio between the 24-hour and initial 
whole-body counts gives the 24-hour whole-body retention 
of 99m Tc-HEDP.
Reproducibility
WBR measurements were obtained on two separate occasions 
in 21 subjects (10 normal and 11 with metabolic bone disease). 
For 14 subjects repeat studies were within 4 weeks of each 
other, for 3 subjects within 5 to 8 weeks, and for the remaining 
4, within 11 to 19 weeks (table 1),
Redistribution
The effect on the whole-body count of change in tracer 
distribution from uniformly vascular on day 1 to skeletal on 
day 2 was studied using a 65 Kg phantom* composed of 9 water- 
filled elliptical cylinders assembled to represent the body 
tissue distribution (6). After measuring the background 
count with the phantom in position the appropriate fraction 
of 50 yCi of 99m Tc-pertechnetate was added to each cylinder 
to give a uniform concentration of activity throughout the 
phantom and a lOOOs count was taken. After this activity
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had decayed considerably overnight the phantom was flushed 
out and refilled with tap water and the background measured.
99m Tc-pertechnetate was then added to simulate the 24-hour 
skeletal distribution of 99m-TC“HEDP. Since most of the 
skeletal uptake and blood clearance of HE DP occurs by 4 hours (7) , 
the relative activities in different parts of the skeleton 
at 24 hours were estimated by quantitating count rates within 
regions of interest on all views of standard 4-hour, normal 
skeleton scans. Neglecting limb activity the percentage 
distribution found was: skull 15%, pelvis 42%, spine 31%, 
sternum 12%. The appropriate percentages of 50 yCi were 
added uniformly to the pelvic and head sections of the 
phantom but the spinal and sternal activities were placed in 
sealed tubes of suitable dimensions, fixed in position inside 
the water-filled thorax section of the phantom. The 
remaining sections were non-active and a lOOOs count was made.
The activities used on the two occasions were compared by 
counting three aliquots of each initial dose on a gamma 
counter and correcting for decay to the time of the correspond­
ing phantom count.
Repositioning
Although the whole-body monitor geometry gives very 
uniform response, small errors in the measured ratio of the. 
two whole-body counts may occur if subjects are in different 
positions on the monitor couch on the two occasions. They 
are normally positioned with feet at a standard mark and as
6 .
nearly as possible on the centre line of the couch. The 
effects of repositioning was investigated n 10 subjects 
who were each counted 3 times in quick succession. For 
counts 1 and 2 the subjects were positioned normally, 
having got off the monitor in between. For count 3 the 
subject was moved as far sideways as the couch would allow. 
Background was subtracted from each count which was then 
corrected for decay.
Control Values for Whole-Body Retention
Control values for WBR were obtained from a group of 
98 male and 152 female normal volunteers (age range 20-67 
years) . The control WBR at any age was obtained from the 
median results for a five-year span centred on the age in 
question for each sex.
Focal Le s i on s
WBR was measured in 11 male subjects, otherwise normal, 
who had sustained traumatic fractures two to ten days 
previously. Clinical details and WBR results from these 
subjects are shown in Table 2. Serum calcium, phosphate, 
alkaline phosphatase and creatinine were normal in all cases. 
Reduced Excretion of Tracer
WBR was measured in 20 subjects with established renal 
disease but with no clinical, biochemical (serum calcium, 
phosphate and alkaline phosphatase were normal) or radiological 
evidence of skeletal disease. All had serum creatinine levels 
not greater than 2 Oi) ymol/1 (normal <120 ymol/l) (Table 3) .
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R E S U L T S
Counting Statistics
Gross counts on day 1 were approximately 10^ and on day 2 
for a normal subject 2 x lo"^  with subject backgrounds of 
about 5,000 counts. Thus the coefficient of variation of 
day 1 counts was 0.1% and on day 2 it was 1.1%. In addition 
the method used to estimate the patient background on day 2
has a coefficient of variation of 2% or 100 counts in addition
to the statistical counting error. Thus the total coefficient 
of variation on the derived net counts for day 2 was 1.25% 
while errors in the day 1 measurements are insignificant. 
Reproducibility
Measured WBR covered a wide range of 17 to 87%, The 
linear correlation coefficient between the repeat measurements 
was 0.998 with a regression line (Fig 1) :
WBR^ (%) = WBR^ X 0.99 + 0.22.
The mean difference in percentage whole-body retention 
between the 21 repeated studies was -0.01% WBR with a standard 
deviation of 1.21% WBR. No results which were normal on 
one occasion become abnormal on repeat.
Redistribution
After making the corrections described above the net 
whole-body count from the phantom representing the 24-hour 
distribution was 97.95% that of the uniform phantom. The 
net counts were over 700,000 giving negligible statistical 
error.
REPOSITIONING
The mean difference between the two counts for ten 
subjects with the patient correctly repositioned was 0.80% + 
0.66% S.D. The greatest difference for one subject was 
2.52% but the next largest was only 1%. The mean difference 
between the first two counts and the third, where the 
subject was displaced sideways, was 4.8% + 2.0% S.D. with a 
greatest reduction of 7.8%. These latter results are for 
extreme mispositioning of the subject. For normal practice 
the effect of repositioning is likely to contribute an error 
of not more than 2.1% to the 24 hour WBR i.e. a result of 
(2o + 0.4%) for a normal subject.
Control Population
The overall median WBR for the 98 male controls was 
19.3% with 2.5 and 97.5 percentiles of 14.0% and 25.3% 
respectively. For the 152 female controls the corresponding 
results were 18.5%, 12.3% and 25.9%.
Traumatic Focal Lesions
WBR ranged from 14.0% to 27.0% of which only two were 
just above the 97,5 percentile of the male controls with 
values of 26.5% and 27.0%. Comparison of individual whole- 
body retentions with the median control values for males of 
the same age (five year band) using the Wilcoxon test for 
pair differences showed no significant difference from 
normal for the group.
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R e d u c e d  E x c r e t i o n  of T r a c e r
Measured WBR in the group with mild renal impairment 
ranged up to 57% with 10 of the 20 results above the control 
97.5 percentile for their sex. However, these all 
corresponded to serum creatinine values above the normal 
maximum of 120 ymol/1 (Fig 2) .
There was a significant linear correlation coefficient 
between WBR and serum creatinine of 0.72 (p<0.001) with
regression line; creatinine (ymol/1) = WBR (%) x 4.77 - 5.0. 
Using the Spearman test there was also a significant correlation 
between WBR and parathyroid hormone (R = 0.65, p <0.005) . 
Comparison of the WBR of the 12 subjects with serum creatinine 
greater than 12 O ymol/l using the Wilcoxon test for pair 
differences showed them to be significantly greater than the 
median 5-year control values for the same age and sex (p<0.005) . 
However, the WBR for the eight subjects with normal serum 
creatinine were not significantly different from control values 
(p>0.05) .
DISCUSSION 
Technical Factors
Errors in counting at 24 hours and background estimation 
indicate that there is a 95% probability of the derived 
24-hour WBR being within 2,5% of the true value, that is, a 
result of approximately (20 + 0.5)% for a normal subject.
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Because of the close speed control of the monitor and timing 
of the important part of the scan time to 0.1%, errors from 
this cause are negligible. Changes in monitor sensitivity are 
checked and corrected daily by counting a standard. Patient 
repositioning on the couch, within the limits normally 
achieved, contributes a mean error of about 2% to the measured 
WBR i.e. 0.4% in 20%.
The redistribution results indicate, within the limits 
of the model, that redistribution within a subject of normal 
build will cause a systematic error producing a result that 
is 98% of the true value. Other technical factors include 
the proportion of- unbound activity in the injected 99m Tc-HEDP 
and the injection technique. No check was made on binding 
but the pertechnetate was added to the HEDP vial not more 
than two hours before use and this method has previously 
given extremely consistent quality, with low-background 
images over several thousand gamma camera skeletal surveys.
At injection blood was drawn back to ensure that the needle 
tip was truly intravascular.
The reproducibility studies indicate that 95% of repeat 
studies will be within a range of difference of 2.5% WBR.
Since statistical considerations would suggest a similar 
range of difference there is little error to be ascribed 
to physiological changes between WBR measurements even for 
those made 19 weeks apart. There was no correlation found 
between the time interval between repeat studies and the 
size of the difference found.
1 1
Clinical Factors
If WBR is to be widely applied and used to screen 
population for high bone turnover it is important to be 
aware of both the effect of renal impairment, and focal 
lesions due to trauma or fracture, on WBR results.
Patients with osteoporosis often have crush vertebral 
fractures present and if these were to lead to a marked 
increase in WBR then patients could be falsely considered 
to have high skeletal turnover. In the 11 patients studied 
with traumatic fractures it is clear that a single fracture 
or even multiple fractures do not necessarily and indeed 
are unlikely to lead to an elevation of whole-body retention 
outwith the normal range. While nine patients had normal 
values for WBR, seven of these had values which were less 
than or equal to 20%, and only two had elevated results 
which were only just outwith the normal range at 26.5 and 27.0' 
The two patients with vertebral fractures had unequivocally 
normal results for WBR at 14.3 and 21.7%. Thus where WBR 
is significantly elevated in such patients it is likely that 
a diffuse skeletal problem is indeed present. However, 
elevated values for WBR, particularly in the elderly, are 
also found in Paget's disease or in widespread metastatic 
involvement of the skeleton. To clarify such situations 
we would recommend obtaining a bone scan in any patient with 
an elevated WBR result, to image the distribution of tracer 
throughout the skeleton.
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In those patients with established renal disease but 
with no apparent skeletal involvement a significant positive 
correlation between the serum creatinine and WBR values was 
found. No patient had an abnormal result for WBR with a 
serum creatinine value below 130 ymol/l but above this 
level WBR was generally (but not always) elevated. Where 
WBR was elevated it was not possible to separate the two 
main potential contributing factors, i.e. renal impairment 
leading to (1) soft-tissue retention of tracer or (2) skeletal 
disease. While those patients with elevated WBR had normal
biochemistry it is possible that they had unsuspected 
skeletal disease. However the correlation between elevated 
serum creatinine and abnormal WBR indicates direct dependence 
upon renal function and the elevated WBR results probably 
reflect soft-tissue retention of tracer. It is clearly 
important to be aware of renal function when interpreting 
WBR data. Nevertheless we find that if serum creatinine 
is in the normal range then an elevated WBR result can be 
accepted as reflecting increased skeletal metabolism without 
further concern as to renal function.
Whole-body retention measurements are therefore not 
subject to large technical errors and are not significantly 
affected by the presence of focal abnormalities. The test 
is simple to perform, is non-invasive using very low 
activity, and requires only two brief out-patient attendances. 
Because of the narrow range of results found in normal 
subjects 24-hour whole-body retention of diphosphonate has
13
promise of providing a simple and sensitive screening 
test for increased bone turnover.
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t a b l e
REPRODUCIBILITY STUDIES
Time Interval
Patient* Age Sex WBR
(%)
WBR
(%)
Between : 
(week:
1 2 8 M 2 1.1 2 0 . 7 8 19
2 24 M 2 1.86 20.24 3
3 2 3 F 19 .2 19 . 94 2
4 24 M 19 . 49 1 8 .  4 6
5 31 M 2 1 . 6 5 2 1 . 8 9 1
6 2 3 M 17.62 17.97 2
7 41 M 2 0 . 2 2 2 1 . 5 2 15
8 52 M 18. 77 19.33 11
9 31 M 17.2 1 9 . 6 3 8
10 40 M 2 3 . 8 2 2 2 . 5 8 5
11 5 8 F 35 o 3 3 6 . 6 7 1
12 20 M 83 . 3 8 1 . 6 6 1
13 59 M 30.22 29.41 1
14 75 F 85 . 9 87 . 1 4
15 49 M 50 . 66 49 .55 1
16 75 F 32.74 34.27 3
17 6 1 F 27 .09 2 6.58 15
18 56 F 35 .41 3 3.58 1
19 55 F 32 .08 31.23 3
20 47 F 32.78 3 3.57 2
2 1 59 F 35 .94 36 . 27 2
Patients 1-10 Normal subjects.
P atients 11-2 1 Metabolic Bone disease.
T A B L E  2 
PATIENTS WITH TRAUMATIC FRACTURE
P atien t Age Site of Fracture WBR %
1 36 Os Calais 2 0.26
2 49 -Lumbar vertebra 2 14.31
3 42 Right 2nd“5th ribs
Right scapula 18.22
Right fibula
4 39 Right 2nd metacarpal 26.98
and medial cuneiform
5 49 Left 6th rib 2 0.4
6 30 Lumbar vertebra 2 21.7
7 4 9 Left 10th and 11th
rib 2 6.45
8 41 Right 9th-llth ribs 14.0
9 54 Left Bth-lOth ribs 22.43
10 27 Left 5th-8th ribs 17.46
Right humerus
11 47 Left ankle 19.49
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Comment
This series of investigations illustrate that 
measurements of 24-hour whole-body retention of diphosphonate 
(WBR) are highly reproducible and are not subject to 
significant technical errors. Redistribution of radio­
isotope from an initially vascular compartment on the 
first day, to a predominantly skeletal one on the second 
day was evaluated using phantom studies. The net whole- 
body count of the phantom representing 24-hour distribution 
of tracer was 98% of the uniform phantom. This is a small 
systematic error which could be corrected for if required, 
but in practice we do not do this. Repositioning of 
subjects o n the whole-body monitor couch within the limits 
normally achieved was not found to cause any significant 
error.
It was considered important to ascertain whether the 
presence of focal lesions in the skeleton, which on occasion 
may be present, for example due to degenerative disease 
or trauma, could affect WBR results. WBR measurements 
were thus obtained in subjects who had sustained traumatic 
fractures but were otherwise healthy. The results from 
this study suggested that such fractures (which have higher 
tracer uptake than degenerative disease) are extremely 
unlikely to elevate WBR results outside the normal range.
It would have been desirable to have repeated these 
measurements after the fractures had healed, to document
90 .
whether any alterations in WBR had occurred, but this 
unfortunately was not possible. Some WBR measurements 
have been carried out previously in patients with skeletal 
métastasés (with documented focal disease) and many of these 
subjects had normal results for WBR (Citrin D L, personal 
communication). WBR was elevated only when extensive 
skeletal involvement by tumour was present, supporting the 
view that the presence of several focal lesions will not 
elevate WBR outside the normal range.
The question of whether mild renal impairment might 
influence WBR results was also studied. It was shown that 
in patients with established renal disease , TOR was always 
in the normal range if the serum creatinine was <d.30pmol/l 
(normal £ 120). Once again it is uncertain whether WBR 
was elevated in these subjects within the normal range, 
although no difference in patient results was found when 
compared with age matched controls. Thus an elevated WBR 
result cannot be explained on the basis of impaired renal 
function if serum creatinine is within the normal range. 
However, it should be noted that a significant correlation 
was found between serum creatinine values and WBR results, 
and it would, therefore, appear that with deteriorating 
renal function, WBR has a direct dependence on the degree 
of renal impairment with a corresponding increase in soft- 
tissue retention of tracer.
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Paper 11. Age-related alterations in skeletal metabolism 
24-hr whole-body retention of diphosphonate 
studies in 250 normal subjects: Concise
communications (1982)
Journal of Nuclear Medicine 23; 296-300
I Fogelman, R G Bessent
Purpose of Investigation
The purpose of the present study was to analyse the 
results for 24-hour whole-body retention of diphosphonate 
from the first 250 healthy volunteer subjects studied to 
assess whether there was any age or sex dependence.
Age-Related Alterations in Skeletal Metabolism— 24-hr Whole-Body Retention 
of Diphosphonate in 250 Normal Subjects: Concise Communication
Ignac Fogelman and Rodney Bessent 
Royal Infirmary, Glasgow, Scotland
Tw enty-four-hour m easurem ents of w hole-body retention (W B R ) of T c -99m  di­
phosphonate (a  sensitive m easure of ske le ta l m etabolism ) have been obtained in 
250 healthy volunteer subjects. W BR values w ere  found to fall from the age of 20 
yr until 35 yr and then in m en to rise linearly thereafter. W om en showed a sim ilar 
pattern initially but there w as a m arked  rise in W BR corresponding to the m eno­
pausal years. Our results lend support to the belief that skeleta l m etabolism  in­
creases with age. It is suggested that som e im balance must a lw ays exist betw een  
resorption and form ation in bone, w ith net loss of bone m ineral, and increasing lev­
els of skeletal m etabolism  will exaggerate  this im balance and acce le ra te  the rate  
of bone loss.
J Nucl Med 23: 296-300,1982
Alterations in skeletal metabolism with age and 
those occurring at the time of the menopause are of ob­
vious importance with regard to bone loss and the de­
velopment of osteoporosis. Until recently, however, there 
was no satisfactory technique for the assessment of 
skeletal metabolism. While bone histomorphometry can 
provide relevant data, bone biopsy is an invasive proce­
dure that yields information pertinent to only a small 
area of bone and thus may not reflect changes in the 
skeleton as a whole (7). In addition, there is often dis­
agreement regarding the interpretation of age-related 
changes seen in histological sections (2). Alterations in 
skeletal metabolism may also be deduced from changes 
in the rate of bone loss. This is usually assessed by mea­
suring the mineral content of bone (by photon absorp­
tiometry), either in cross-sectional studies over a wide 
age range or in individual subjects in whom sequential 
studies are performed. However, it is necessary to per­
form sequential studies in individual patients for at least 
2-3 yr to obtain data reflecting rates of bone loss (J). 
Moreover, measurements of bone mineral content are 
usually made at the radius, and ehanges there may not
Received July 14, 1981; revision accepted Oct. 27, 1981,
For reprints contact: Ignac Fogelman, BSc, MB, ChB, MRCP, 
Dept, of Medicine, Royal Infirmary, Glasgow, G4 OSF, Scotland.
accurately reflect change throughout the entire skel­
eton.
With the introduction of the current bone-seeking 
radiopharmaceuticals (the technetium-99m-Iabeled 
diphosphonates), agents extremely sensitive to skeletal 
abnormality are now available, and their uptake in bone 
is thought to reflect osteoblastic activity and to a lesser 
extent skeletal vascularity (4). Skeletal uptake of tracer 
therefore reflects skeletal metabolism, and we have 
previously shown by using a whole-body monitor that 
measurement of 24-hr whole-body retention of Tc-99m 
diphosphonate provides a simple, sensitive measure of 
skeletal metabolism (5,6). This communication presents 
our results with this technique in 250 healthy volunteer 
subjects in the age range 20-70 yr.
PATIENTS
Two hundred and fifty healthy volunteer subjects were 
studied (Table 1). There was no history of associated 
skeletal, renal, or malabsorptive disease.
METHODS
Measurement of whole-body retention (WBR) of 
Tc-99m diphosphonate. Each subject was given an in-
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TABLE 1. MEDIAN AND 
BIOCHEMICAL
FULL RANGE OF 
RESULTS
Serum Median Range
Calcium* (mmoi/l)
(normal 2.2-2.6)
Male (N =  77) 2.4 2.2-2 .6
Fem ale (N =  130) 2.4 2.2-2 .6
Ail 2.4 2.2-2 .6
Albumin (g/L)
(normal 35-55)
Male (77) 47 40-55
Fem ale (130) 46 39-53
All 46 39-55
Aik. phosphatase (U/l)
(normal 80-280)
Male (73) 187 96-280
Female (128) 163 87-275
All 168 87-280
Creatinine (jumol/l)
(normal 35-120)
Male (74) 90 60-120
Female (122) 80 40-120
All 80 40-120
• Individual serum calcium values were corrected for the 
corresponding serum albumin by a  procedure described by 
imrie et al. (23).
travenous bolus of 50 ixCi of Tc-99m hydroxyethylidene 
diphosphonate (HEDP) and the WBR at 24 hr was 
measured using a shadow-shield whole-body monitor as 
previously described (5).
Biochemistry. As a general screen for skeletal or renal 
disease, serum calcium, alkaline phosphatase, albumin.
NORMAL 24 hour WBR OF Tc-99m HEDP
I
o
I
!
Î
Age ai-25 26-30 31-35 36-40 41-45 46-50 51-55 56-60 61-65 66-70 71-75 
n.1lY 6i"11 14 10 9 19 17 16 4 32 15 21 8 23 12 7 8 1 3 0
FIG. 1. Whole-body retention results in 5-yr groupings In 250 normal 
subjects.
and creatinine values were obtained in 90% of all subjects 
over 30 yr of age. All results for these parameters (Table 
1 ) were in the normal range.
RESULTS
Figure 1 shows the results for 24-hr whole-body re­
tention (WBR) of HEDP obtained in the study popu­
lation, divided on the basis of 5-yr age groupings and sex. 
Median values for WBR with 95% confidence range are 
presented in Table 2. The only significant difference in 
values between male and female was for the 41-45 yr 
group (p <  0.05), but the male group was small with only 
four results available, so no great weight should be placed 
on this result.
Table 3 indicates where significant differences in 
WBR occur between the 5-yr age groupings within the 
male and female groups separately. For males, all age 
groups from 26 to 50, except those from 41-45, have 
significantly lower WBR than those over 60. This is not 
the case for the eight in the 21-25-yr group, whose WBR 
is a little higher than those between 26 and 50. These 
results suggest a male pattern of WBR falling from ad­
TABLE 2. 
OF SEX
WHOLE-BODY RETENTION RESULTS IN 250 NORMAL SUBJECTS, DIVIDED ON THE BASIS 
AND 5 YR AGE GROUPINGS, WITH MEDIAN AND 95%  CONFIDENCE RANGE OF THE
MEDIAN VALUES
Male Female
Age Median Median
range WBR 95%  Confidence WBR 95%  Confidence
(yr) No. (% ) range (%) No. (%) range (%)
21-25 8 20.67 16.10-23.70 11 18.86 15.20-20.30
26-30 14 19.52 17.10-21.70 11 17.26 14.80-21.90
31-35 9 17.42 15.50-21.70 10 15.20 14.50-17.30
36-40 17 18.27 15.40-19.40 19 16.0 15.00-16.60
41-45 4 19.72 — 16 17.02 15.60-19.50
46-50 15 19.07 17.20-20.30 32 18.61 16.70-21.40
51-55 8 20.56 18.80-25.30 21 22.1 18.40-24.70
56-60 12 20.76 18.01-23.80 23 21.58 19.70-23.70
61-65 8 23.36 16.30-25.30 7 21.06 17.80-26.70
66-70 3 23.54 — 1 19.41 —
71-75 — . 1 23.52
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TABLE 3. COMPARISON OF WHOLE-BODY RETENTION RESULTS BETWEEN 5-YR AGE GROUPINGS
WITHIN THE MALE AND FEMALE GROUPS
Male
Age 21-25 26-30 31-35 36-40 41-45 46-50 51-55 56-60 61-65 66-70
P < 0 . 0 5  
P <  0.02
P <  0.05 
P <  0.05 
P <  0.01
P <  0.02 
P <  0.01 
P <  0.02
P <  0.02 
P <  0.02
P <  0.01 
P <  0.001 
P <  0.001 
P <  0.005
P <  0.001 
P <  0.001 
P <  0.001 
P <  0.001
P <  0.02 
P <  0.02 
P <  0.02 
P <  0.05 
P <  0.05
P <  0.001 
P <  0.001 
P < 0 . 0 1
P <  0.02 
P <  0.02
Female
olescence to about age 35 and then rising gently there­
after.
In women by contrast, groups from 51-60 have sig­
nificantly higher WBR than all younger groups. In the 
adjacent group (ages 61-65), they have higher WBR 
than in the 31 -45 groups, and the 46-50 group is higher 
than the 31-40 groups. This demonstrates the pattern 
of WBR again falling from adolescence to about 35 
followed by an initial gentle rise, but this is markedly 
accelerated during the menopausal years of 46-55.
DISCUSSION
Skeletal uptake of diphosphonate is predominantly 
related to sites of new bone formation and is thought to 
be dependent upon osteoblastic activity {4). Measure­
ments of 24-hr whole-body retention (WBR) of di­
phosphate thus reflect bone formation. In the context of 
bone remodeling, however, osteoblastic activity always 
follows osteoclastic activity (7) and it is recognized that 
with alterations in skeletal metabolism, rates of bone 
formation and resorjltion change in the same direction, 
although not necessarily to the same degree {3,8). WBR 
measurements will therefore also reflect bone resorption. 
Nevertheless, an absolute loss of bone can occur only 
because of an imbalance between formation and re­
sorption, and WBR will be unable to quantitate this 
difference.
The results from our WBR studies suggest that in both 
men and women there is a fall in skeletal metabolism 
from 20 yr of age until approximately 35. Thereafter in 
men there is a nearly linear increase in skeletal metab­
olism until age 65. We have not studied enough subjects 
over age 65 to be confident of the variation of WBR in 
old age. While WBR results in women initially follow a 
similar pattern, there is a marked rise in skeletal me­
tabolism at about 55 yr of age, presumably related to the
menopause. While the falling values for WBR between 
ages 20 and 35 are unexplained. Frost (7) has shown a 
very similar pattern of change with age in active osteoid 
seams (reflecting bone formation) and osteoclastic ac­
tivity (reflecting bone resorption) in human rib biopsies. 
Frost suggests that “some important change in internal 
regulation of bone remodelling becomes apparent at age 
thirty-five.” In addition, it has been suggested that bone 
mineral content is at a maximum in both men and 
women at age 35 {9), and this would be in keeping with 
our findings if the rise in WBR after 35 yr of age indi­
cates the time at which bone loss commences.
While it is widely believed that skeletal metabolism 
increases with age {10-12), there is nevertheless some 
conflicting evidence in the literature. Certainly bone loss 
appears to commence at around 30 yr of age {7,13,14) 
and the rate of loss seems to increase steadily thereafter. 
In women there is an additional accelerated phase of 
bone loss that occurs following the menopause 
{ I I ,13-15).  This is the pattern of results shown with 
WBR. Heaney et al. {11,16), using simultaneous ra­
diocalcium kinetics and external calcium balance tech­
niques, studied a group of women at 5-yr intervals before 
and after menopause and showed that skeletal metabo­
lism increases after menopause. It has also been dem­
onstrated that parathyroid levels increase with age {12), 
and this may be of considerable importance to the control 
of skeletal metabolism, although this has yet to be 
proven. Other suggested factors affecting control of 
skeletal metabolism may be decreased calcium absorp­
tion (77), a reduction in physical activity {IS),  or a fall 
in sex-hormone levels (79), all of which occur with 
aging.
The major area of dispute relating to changes in 
skeletal metabolism with age evolves from the published 
results of quantitative analysis of bone histology. While 
Frost (7) and Jowsey {10) have found an increase in both
298 THE JOURNAL OF NUCLEAR MEDICINE
__________CLINICAL SCIENCES
DIAGNOSTIC NUCLEAR MEDICINE
resorption and formation with age, other groups have 
been unable to confirm such changes {20,21). Studies 
on normal bone have generally been carried out on rel­
atively small numbers of subjects, and there is a clear 
need for the indices of formation and resorption to be 
studied in a sufficiently large population with adequate 
numbers in all decades.
Taking the mean WBR at each year of age between 
20 and 45 for males and females separately in a paired 
comparison, we find a small yet significant difference (p 
< 0.05) in values for WBR between men and women. 
This difference is small, however, approximately 1% in 
20% WBR, and although unexplained, it may reflect 
differences in hormonal control of skeletal metabolism. 
Differences in height and weight exist between the male 
and female groups, but we were unable to find any cor­
relation between height or weight and WBR in the 133 
subjects (86 female, 47 male) for whom these data were 
available. Moreover, within each age decade there was 
no correlation at all between height and WBR or weight 
and WBR for males or females. Furthermore, there was 
no correlation between the mean WBR and mean height 
or mean weight for each 5-yr age range in males or fe­
males: Women in the 36-40- and the 51-55- yr groups 
were significantly shorter than in most other groups, but 
the former does not match the minimum in the curve of 
WBR against age, and the latter is in the region of high 
WBR (Fig. 1). There were no significant differences 
between female weights in the 5-yr age groups. For the 
males the 31-35 group was significantly lighter than the 
21-25 group (p <  0.05), but there were no other differ­
ences, Thus we conclude that weight and height are not 
significant factors in the behavior of WBR.
Large individuals may be expected to have their blood 
volume and skeletal mass increased in proportion to their 
total mass when compared with smaller individuals. It 
is therefore likely that relative blood flow to the skeleton 
and the percentage of the bone surface that is metabol- 
ically active would be independent of body size. Since 
W BR reflects the percentage of injected activity ad­
sorbed onto the bone surface, this will provide a measure 
of skeletal metabolism that is unaffected by the size of 
the individual.
Accurate interpretation of WBR data depends upon 
normal renal function, and it is well recognized that the 
latter deteriorates with age. However, the changing 
trends in WBR noted in our studies occurred at relatively 
early ages (less than 55 yr) when age-related renal im­
pairment is almost certainly not a factor. In addition, 
renal function was checked, giving normal values for 
serum creatinine in all subjects. We have previously 
shown that if serum creatinine is within the normal 
range, there is no abnormality of WBR, even in patients 
with established renal disease, when these are compared 
with age-matched controls {22),
On the basis of our results, we propose a simple hy­
pothesis relating alterations in skeletal metabolism to the 
changes in bone mineral content that occur with age. 
Whereas skeletal growth stops by the age of 18 to 20 yr, 
osteoblastic activity appears to continue falling from the 
high adolescent levels (when bone modeling and re­
modeling coexist) until the mid 30s. Perhaps this is due 
to a prolonged period of withdrawal of growth stimuli 
before bone remodeling alone remains. Thereafter, bone 
resorption is the only drive to bone formation. After 
about age 35, the rate of resorption appears to increase 
following, perhaps, parathyroid hormone secretion, re­
duction in physical activity, falling sex hormone levels, 
or other factors as yet unknown. There will be a resulting 
increase in rate of bone formation, as detected by WBR, 
but it is probable that it will not quite match the increase 
in rate of resorption. For example, if there is a simple 
linear feedback system, causing the formation rate to 
increase in proportion to the difference between re­
sorption and formation rates, then there must always 
remain a small imbalance between the two rates to 
provide the “error signal” that is necessary to maintain 
an increased formation rate. Thus we suggest that there 
will always be some imbalance between resorption and 
formation associated with bone remodeling, with a net 
loss of bone mineral. Consequently, once bone remod­
eling is established there is negative calcium balance, but 
initially this may be small and not detectable by standard 
techniques. Increases in skeletal metabolism with age, 
or following the menopause, will exaggerate the differ­
ence between resorption and formation and accelerate 
the rate of bone-mineral loss. In short, increases in 
skeletal metabolism lead to an increasing calcium debt 
that cannot be repaid, resulting in irreversible bone 
loss.
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Comment
As stated in the paper clear age-related trends exist 
for the results of 24-hour whole-body retention of 
diphosphonate (WBR) in normal adult subjects. A male 
pattern of falling WBR values from 20 years of age to 
35 years, with a gentle, approximately linear rise 
thereafter was seen. In females a similar pattern of 
results was found initially but a more marked rise in WBR 
occurred between 46 to 50 years of age, which I believe 
is related to accelerated bone turnover following the 
menopause.
While all the clinical studies to date suggest that 
TOR does accurately reflect alterations in skeletal 
metabolism (see chapter 6), the exact mechanism and site of 
diphosphonate localisation in bone is not fully understood. 
It is therefore true to state that we do not know what 
precisely WBR is measuring. Thus it is necessary to 
question whether the results obtained in the present study 
could be artefactual in any way. Factors such as the 
individual's height and weight, and minor alterations in 
renal function of individual subjects are discussed fully 
in the paper, and although considered unimportant clearly 
cannot be absolutely excluded as contributing to the changes 
noted. However, large numbers of subjects were studied in
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all age groups and the pattern of WBR results between 
the years 20 and 45 is very similar for both men and women.
It is not surprising to find a sharper rise in WBR results 
for women thereafter due to the known increase in bone 
turnover which occurs following the menopause. All the 
trends in WBR results described are occurring in the 
age range 20 to 50 years, when age-related alterations 
in renal function are very unlikely to affect results.
In addition the overall pattern of results is similar 
to data published by Frost (1963) based on historaorphometric 
analysis of bone biopsy sections from human ribs (figure 3). 
It should be noted, however, that bone at this site is 
predominantly cortical whereas trabecular bone is more 
active metabolically. Nevertheless the great majority 
of bone in the body is cortical and its relative contribution 
to total skeletal metabolism is not known.
It is of interest to note that the mean WBR value 
for the study group as a whole (250 subjects) is 19.2% +
3.5% (ISD). The first publication relating to TOR in 
1978 (paper 9) reported 12 normal subjects and the mean 
WBR was 19.2% + 1.7%. In 1980 (paper 16) a control 
group of 111 subjects was reported and the mean WBR was 
19.4% + 3.4%. The mean results for WBR are therefore 
remarkably consistent with a relatively small value for
94,
Figure 3
a) Alterations with age 
in osteoclastic 
activity from 139 
human rib biopsies.
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(From H M Frost, Bone Remodelling Dynamics, 1963.
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the standard deviation. This presents a narrow control 
range for normal subjects and facilitates identification 
of abnormality, although as illustrated in the present 
paper any result requires to be related to age-matched 
controls.
On the basis of the results obtained in this study 
a simple hypothesis has been proposed relating alterations 
in skeletal metabolism with age, to changes in bone 
mineral content. It is generally accepted that there is 
"coupling" between bone resorption and bone formation, and 
it is believed that in early adult life the skeleton is 
in calcium balance (implying bone resorption and formation 
are equal). It is now suggested that if bone resorption 
and formation are linked along the lines of a simple 
linear feedback system, then once bone remodelling is 
established, and bone resorption is the only stimulus 
to bone formation, then there must always be some imbalance 
between resorption and formation to provide the "error 
signal" necessary to maintain bone formation. Thus a 
net negative calcium balance must always exist but will 
be small until the fourth decade when levels of skeletal 
metabolism are relatively low, and this calcium loss may
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not be detectable by standard analytical techniques. 
The results of the present study suggest that skeletal 
metabolism rises throughout most of adult life, and 
any rises in skeletal metabolism with age or related 
to disease will exaggerate differences between bone 
resorption and formation leading to an increasingly 
negative calcium balance, and bone loss.
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Paper 12. Measurement of 24-hour whole-body retention 
of Tc-99m HEDP by a gamma camera (1981)
Journal of Nuclear Medicine 22 : 542-545
W Martin, I Pogelman, R G Bessent
Purpose of Investigation
While I considered that the 24-hour whole-body retention 
of diphosphonate (WBR) technique had considerable potential 
for application in clinical practice, I nevertheless 
realised that whole-body monitors are not widely available 
and this would limit the possible use of the WBR technique 
to relatively few centres. The purpose of the present 
investigation was therefore to assess whether WBR 
measurements could be obtained with a gamma camera (which 
is widely available) and compare results with those 
obtained with the whole-body monitor.
Measurement of 24-Hour Whole-Body Retention of Tc-99m HEDP by a Gamma
Camera
W illiam Martin, Ignac Fogelman, and Rodney G, Bessent 
Dept, of Clinical Physics and Bio-engineering and Royal Infirmary, Glasgow, Scotland
M e a s u r e m e n t  of 2 4 - h r  w h o l e - b o d y  r e te n t io n  of T c - 9 9 m  HEDP, u s in g  a s h a d o w -  
sh ie ld ,  w h o l e - b o d y  m o nito r ,  h a s  b e e n  s h o w n  to  b e  a s e n s i t i v e  m e a s u r e  of s k e l e t a l  
m e t a b o l i s m  a n d  of v a l u e  in th e  d i a g n o s i s  of  m e t a b o l i c  b o n e  d i s e a s e .  A n e w  m e t h o d  
of m e a s u r i n g  t h e  r e te n t io n  u s in g  a g a m m a  c a m e r a ,  w ith  a s c a n n in g  ( f i sh ta i l )  c o l l i ­
m a to r  a n d  p a t ie n t  p l a c e d  at 2 .3  m  d i s t a n c e ,  h a s  b e e n  e v a lu a t e d  in 18  p a t i e n t s  
u n d e r g o in g  ro u t in e  b o n e  s c a n s .  T h e  p a t i e n t s  a l s o  h a d  w h o le - b o d y  r e te n t io n  m e a ­
s u r e d  u s in g  t h e  w h o l e - b o d y  m o n ito r  (W B M ),  a n d  t h e  t w o  m e t h o d s  c o r r e l a t e d  w e l l ,  
y ie ld in g  a r e g r e s s i o n  l in e  G C %  =  —0 . 8 2  + 0 . 9 8  W B M % , r = 0 . 9 7 5 ,  p <  0 . 0 0 1 .  T h e  
l im ita t io n s  to,  a n d  r e p e a ta b i l i ty  of, t h e  g a m m a - c a m e r a  m e a s u r e m e n t s  a r e  d i s ­
c u s s e d .  T his  w o rk  s h o w s  th a t  m e a s u r e m e n t s  of w h o l e - b o d y  r e te n t io n  c a n  b e  o b ­
ta in e d  in a n y  n u c le a r  m e d i c i n e  d e p a r t m e n t  p o s s e s s i n g  a g a m m a  c a m e r a  w ith  a  
s u i t a b le  c o ll im a to r .
J NucI Med 22; 5 4 2 - 5 4 5 ,  1981
B one  sc a n n in g  w ith  the t c c h n c t iu m -la b e lc d  d ip hos-  
p h o n a le s  has proved so m e w h a t  d i sa p p o in t in g  in the a s ­
s e s s m e n t  o f  pat ien ts  w ith  m e ta b o l ic  bon e  d i sea se ,  s in ce  
sca n  a pp earances  are often apparently  norm al w hen  the  
sk e le to n  is d if fu se ly  involved ( / - 5 ) .  In su ch  ca ses  an  
a w a r e n e s s  o f  a b n o rm a l i ty  d ep en d s  upon a su b ject iv e  
im p ress io n  o f  increased tracer up take  th r o u g h o u t  the  
skeleton. A ccu ra te  quantitation o f  tracer uptake by bone  
is required  for a posit ive  id en t i f ica t io n  o f  increased  
sk e le ta l  m e ta b o l ic  ac t iv ity .  M e a s u r e m e n t  o f  24 -hr  
w h o le -b o d y  retention ( W B R )  o f  T c - 9 9 m  d ip h o sp h o n a te  
( T c - H E D P )  is a new  te ch n iq u e  by w h ich  total sk e le ta l  
uptake  o f  tracer is obtained. W e  have sh ow n that patients  
w ith  pr im ary  hyp erparathyroid ism , o s te o m a la c ia ,  renal  
o s te o d y s tr o p h y ,  and P a g e t ’s d ise a se  c a n  be c lea r ly  d i f ­
fere n t ia ted  from  a control  pop u la t ion  by this t e c h n iq u e  
( 5 - 7 ) .
W h o le - b o d y  retention  o f  d ip h o sp h o n a te  provides a
Received Aug. 20, 1980; revision accepted Oct. 31, 1980.
For reprints contact: William Marlin, FhO, West of Scotland Health 
hoards. Dept, of Clinical Physics and Bio-Fiiginecring, I I W, Graham 
St., Glasgow, G4 91,F Scotland.
sim ple  and sensitive m easure o f  skeletal m etabolism , and  
potentia l ly  has widespread application in clinical practice  
( 5 - 9 ) .  H ow ever ,  since whole-body m onitors ( W B M )  are  
not w id e ly  av a i la b le ,  the m e a n s  to perform  su ch  s tu d ies  
app ear  to be limited to on ly  a few centres ( /  ). T h is  is not 
the case, and this com m u nicat ion  describes how accurate  
m e a su r e m e n t  o f  24-hr W B R  o f T c - l  l E D P  m a y  be m ade  
using a g a m m a  cam era with a suitable  collim ator,  which  
m a k e s  the technique  availab le  in m ost nuclear  m ed ic in e  
d e p a r tm e n ts .
VIATI  RI AF. S  A N D  Ml  T t l O D S
E ig h te en  patients  with  su sp ec ted  a b n o rm a l i t ie s  o f  
sk e le ta l  m e ta b o l is m  were  g iven  15 m Ci o f  T c - H E D P *  
by in travenous injection as part o f  a standard  bone scan.  
D ia g n o s e s  were: P a g et’s d isease ,  six; osteoporosis ,  four; 
pr im a ry  h y p er p a r a th y r o id ism ,  three; renal o s t e o d y s ­
tro p h y ,  one; th y ro to x ic ,  one; u n es ta b l ish cd ,  three.  T h e  
w h ole -bod y  count was m easured 5 - 1 5  min after injection  
by p o s it io n in g  the patient  2.3  m from a w id c -f ie ld  
g a m m a  c a m e r a  fitted with the “ f i sh ta i l” c o l l im a to r  
n o r m a l ly  used for w h o le -b o d y  im a g in g  w ith  a sc a n n in g
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g a m m a  c a m e r a .  T h is  c o l l lm a lo r  is paralle l  in one  d i ­
m ension and diverging in the other. W h e n  the coll im ator  
fa c e  is v er t ica l ,  this  g iv es  a f ield o f  v iew  o f  0 .3 5  m  
( F W U M )  horizontally  and 2.5 m vertically at a d istance  
o f  2 .3 m , w h e r e  p a t ie n ts  co u ld  be a c c u r a te ly  po s it io n ed  
s ta n d in g  a g a in s t  the  wall  o f  the room . T h is  e n a b le d  a 
rather distorted im a g e  o f  the whole  patient to be obtained  
by the  g a m m a  c a m e r a .  A n ter io r ,  poster ior,  and lateral  
view s o f  30 sec  each were  acquired, typically  yield ing 120 
K c o u n ts  per \ ie\v a n ter io r ly  and poster ior ly ,  w ith  100  
K counts  per v iew laterally, using the T c - 9 9 m  photopeak  
w ith  a 20% w in d o w .  T h e  anter ior  and poster ior  v iew s  
w ere  then repeated .  T h e se  m e a su r em e n ts  were  carefu l ly  
r ep ea te d  at 24  hr, w ith  10 0 - s e c  t im in g ,  g iv in g  a p p r o x i ­
m a te ly  5 K c o u n ts  (not  in c lu d in g  b a c k g r o u n d )  for p a ­
tients with a normal w hole -body  retention o f  20%. U s in g  
a p p ro p r ia te  b a c k g r o u n d ,  w h ich  w a s  m e a su r ed  on both  
d a y s ,  and d e c a y  co rr ec t io n s ,  the 2 4 -h r  W B R  o f  T c-
1 l E D P  w a s  ca lcu la ted .  W ith in  18 d ays  o f  the bone  scan,  
e a c h  su b je c t  a lso  had a 2 4 -h r  W B R  o f  T c - H E D P  m e a ­
sured in the standard  w a y  us in g  the w h o le -b o d y  m onitor  
an d  an a c t iv i ty  o f  50  fxC'i ( 5 ) .  O n  the w h o le -b o d y  m o n ­
itor, p a t ie n ts  lie  on a ta b le  and pass b e tw e e n  d e te c to r s  
a b o v e  an d  b e lo w  them . T h u s  the  m e a n  o f  the an ter ior  
an d  pos ter ior  v iew s,  as m e a su r ed  w ith  the g a m m a  
c a m e r a ,  is best  for c o m p a r iso n  w ith  the  w h o le -b o d y  
m o n i t o r ’s results.
Rl-:SL 1 T S
F igu re  IA  plots the 2 4 -h r  W B R  for 18 pa tients ,  as  
m e a su r e d  by g a m m a  c a m er a  ( m e a n  o f  the  tw o  anter ior  
and tw o  posterior v iew s) ,  aga inst  the results ob ta ined  on 
the W B M .  T h e  ind iv idual v a lu e s  for the var ious d i a g ­
no ses  as m e a su red  on the  w h o le -b o d y  m onitor  were  
con s is te n t  with  those reported previously  ( 5 ) .  T h e  m ea n
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FIG. 1. (A) R esu lts  of 24-hr w h o le-b od y  reten tion , m easu red  a s  
m ean  of anterior and posterior counts from gam m a cam era, against 
resu lt a s  m ea su red  by w h o le-b od y  sh a d o w -sh ie ld  m onitor. (B) R e­
peatab ility  o f g a m m a -ca m era  WBR resu lts  from  tw o  anterior and  
tw o posterior v iew s. (C) results of WBR m easured from lateral v iew s  
with g am m a ca m era , v e r su s  resu lts  m ea su red  from anterior and 
p oster ior  v ie w s . P atien ts with P a g e t’s  d is e a s e  are indicated with 
a  P.
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TABLE 1. APPROXIMATE PARAMETERS FOR GE MAXICAMERA tl (WIDE FIELD) AND OHIO NUCLEAR 
STANDARD-FIELD GAMMA CAMERA, AS USED TO MEASURE WHOLE-BODY RETENTION*
C am era C ollim ator
Area of 
crystal 
(cm^)
Field of view  
at 2 m^ 
(cm )
Background
(c o u n t/s e c )
Sensitiv ity  to 
point so u r ce  (2 m) 
(cps/AiCi)
Sensitiv ity  to 
patient (2 m) 
(cps/juCi)
W ide-field  sca n n in g 1090 2 4 0  X 34 30 0 .6 6 3 0 .2 7 0
W ide-fleld  n on e 1590 5 2 5 52 21
Standard diverging 5 4 6 circle , 185 cm  diam . 12 0 .1 9 2 0 .0 7 8
Standard n on e 9 1 8 29 0 37 15
A 20%  w indow  w a s  cen tered  on T c-99m  ph otopeak .
' Initial sen sitiv ity  m ea su rem en ts  w ere  m ade at 2 m and patient s tu d ies  al 2 .3  m for c o n v e n ie n c e . R esu lts  at the two d is ta n ce s
w e re  not s ign ifican tly  d ifferent.
p e r c e n ta g e  d i f f e r e n c e  b e tw een  the results  is 7.6% and a 
l e a s t - sq u a r c s  l inear  regression g iv es  G C%  =  —0 .8 2  +
0 .9 8  W B M % , r =  0 .9 7 5 ,  p <  0 .001 .  T h e  tw o  m ethods for 
m e a su r in g  W B R  a g ree  well  and sh o w  that a g a m m a  
c a m e r a  ca n  be used to m e a su r e  W B R  sa t is fa c to r i ly  in 
p a t ie n ts  u n d e rg o in g  routine  bone scans.  T h e  results  
o b ta in e d  on the  w h o le -b o d y  m onitor  tend to be h igher  
than those  with the g a m m a  cam era ,  probably  due to the  
d i f fe re n t  d e te c to r  g e o m e tr ie s ,  but the  var ia t ions  in the  
results arc not s ignificant.  Figure 1 B show s the variation  
o f  24-hr  W B R  m easured  w hen  the patient is repositioned  
in the posterior and anterior views. R epeatab il ity  is good,  
the m ea n  percent d i f f e r e n c e  b e tw e en  the results  be ing  
3.3%. F igure  1C ind ica tes  the results obta ined  for 24-hr  
W B R  as m easured by the lateral against the anterior and  
posterior views. T h e  results again  agree  well,  but as can  
be seen  in all three g ra p h s ,  the  pat ien ts  w ith  P a g e t ’s 
disease  tend to sh o w  the grea te st  d ifferences .  T h is  is due  
to the focal up take  o f  T c - H E D P  in these  patients ,  w h ich  
leads to s ignificant redistribution betw een  the D a y  1 and  
D a y  2 m e a su r e m e n ts .  In the  c a se  o f  the pat ien t  with  
nearly  100% W B R  m ea su r ed  la tera lly  in Fig.  1C, the  
s ide  o f  o ne  f ibu la  took up an u n u su a l ly  high proportion  
o f  the dose  causing  the variation between the results (see  
D isc u s s io n ) .
D I S C U S S I O N
T h e r e  are several  factors to be con s id ered  w h en  us ing  
a g a m m a  c a m e r a  for 2 4 -h r  W B R :  (a )  the c o u n t  rate  
response  o f  the g a m m a  c a m era ;  (b )  b a c k g r o u n d  count  
rate; (c)  sensit ivity and uniform ity  o f  the collimator; and  
(d )  red is tr ibution  o f  r a d io p h a rm a c eu t ic a l  in the p a ­
tient.
N o r m a l  p a t ien ts  retain  a p p r o x im a te ly  20% o f  the  
in jected  H E D P  at 24  hr; th u s  a p p r o x im a te ly  1 / 8 0 t h  o f  
the in jected  a c t iv i ty  rem a in s  at that  t im e.  T h is ,  a lo n g  
with  the se n s it iv i ty  o f  the  g a m m a  ca m er a  and the  
background count rate (T a b le  1 ), provides the l im itations  
to the in jected  d o se  from  s ta t i s t ica l  c o n s id e r a t io n s  
(A p p e n d ix ) .  S in c e  the g a m m a  c a m er a  is ap p ro x im a te ly
8 0  t im es  m ore  sens it ive  \\ ithout a co l l im a to r  (T a b le  1 ), 
this m ig h t  be th o u g h t  to present a better  m e th o d  o f  
m e a su r in g  W B R ,  even th o u g h  the b a c k g r o u n d  is in ­
c rea sed  by a factor o f  17.5. H o w e v er ,  for pat ien ts  
un derg o in g  routine bone scans , the initial m e a su r em e n t  
after  the injection o f  15 m C i o f  T c - H E D P  results in the  
c a m e r a 's  b e in g  operated  in its non l in ear  co u n t  rate re­
sp o n se  reg ion on D a y  I . S im p le  c o u n t-r a te  correc t io ns ,  
su ch  as can  be d e te rm in e d  by a s ta n d a rd  p h a n to m  with  
w ater  sca tter ing ,  are inapplicab le  du e  to the w el l-k now n  
pro b lem s o f  sc a t ter in g  w ith in  the patient ,  pu lse  p ileup,  
source  g eom etry  variations, and scattered radiation from  
aro u n d  the  roorn, all a f f e c t in g  the p u lsc -h e ig h t  d is tr i ­
bution  at high count  rates (1 0  12) .  T h e s e  e f fe c t s  vary  
c o n s id e r a b ly  from patient  to pat ien t ,  and cou ld  be c o r ­
rected  for o n ly  by us ing  p h a n to m s  with properties  
identica l  to those o f  e a ch  ind iv idual  patient.
U s e  o f  the fishtail co l l im a to r  enab les  the initial count  
rate on D a y  1 to be within the linear count-ra te  response  
o f  the c a m e r a ,  as well as red u c in g  the  b a ck g ro u n d .  T h e  
pulsc-height distribution from the patients is also similar  
on both d a y s  du e  to the e l im in a t io n  o f  m u c h  o f  the  
sca t ter e d  radiation .  T h e  var) ing sens it iv i ty  o f  the  c o l l i ­
m ator  in the d iv erg in g  (v e r t ica l )  d irec t ion  is rela t ive ly  
un im p o rta n t ,  s ince  only  red is tr ibution  o f  ra d io p h a r ­
m a c e u t ic a l  a f f e c t s  results ,  and the initial v ascu lar  d i s ­
tr ibution  on D a y  1 has s im i la r  g e o m e t r y  to the D a y  2 
bone distr ibution, T h is  problem  is m ost  obvious in cases  
w ith  foca l  a b n o r m a l i t ie s  su ch  as  P a g e t ’s d is e a se  (a s  
m en t io n e d  e a r l ier ) ,  w h ere  c o n s id e r a b le  c h a n g e s  in d i s ­
tr ibution o f  r a d io p h a rm a c eu t ic a l  occur. In su ch  c a ses ,  
how ever ,  the 24 -hr  W B R  is m a r k e d ly  increased  ( 5 ) ,  
y ie ld in g  c lear  d ist in ct ion  from  the norm al g ro u p  o f  p a ­
tients (Fig.  I ). T he  large patient-to-cam era  distance  (2.3  
m ) red uces  the e f fe c ts  o f  c h a n g e s  in so u r c e - to -d c te c to r  
d is ta n ce ,  b es id es  w h ich  p a t ien ts  can  be a c c u r a te ly  re­
p os it ion ed .
If  a bone  scan  is not required ,  but on ly  a m easure  o f  
sk ele ta l  m eta b o l ism ,  24-hr  W B R  could  be m easured  by  
a g a m m a  c a m e r a  us ing  a co n s id e r a b ly  lower a c t iv i ty  
than  15 m C i.  If one  needs to m e a su r e  a norm al 24 -hr
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W B R  lo a precision  o f  5% [i.e .,  result =  ( 2 0  ±  1)%] 
w ith in  a total t im e  on D a y  2 o f  1000  see  for patient  and  
b a c k g r o u n d  m e a su r e m e n ts ,  then s ta t i s t ica l  c o n s id e r ­
a t io n s  ( A p p e n d ix )  sh o w  that an a c t iv ity  o f  2 m C i  could  
be used. 1 lere  a g a in  use  o f  the g a m m a  c a m e r a  w itho u t  
a co l l im a to r  is not pract ica l ,  s in ce  the  m u c h  higher  
b a ck g ro u n d ,  with s ig n i f ica n t  f lu c tu a t io n s  w ith in  a nu ­
clear m edicine departm ent,  requires a D a y  1 activity that 
w o u ld  ca u se  no n l in ea r  o pera t io n  o f  the c a m er a .  E v a lu ­
a t ion  o f  W B R  at a sh orter  t im e interval (e .g . ,  6 or 8 hr) 
m ig h t  be a su ita b le  a d d it io n  to this test ( 5 ) ,  s ince  even  
at this time W B R  is a m easure  reflecting skeletal uptake,  
a l th o u g h  in c o m p le te  and varia ole ex cr e t io n  o f  non-  
sk ele la l  T c - H E D P  w o u ld  affec t  the result.  M oreover ,  if  
there were any uncertainty , the result could  be confirm ed  
by a m easurem ent at 24  hr. N o t e  again that considerably  
low er  ac t iv it ies  c o u ld  be used  if a 6, 8, or even  a 12-hr  
result  were used as s ta n da rd .
A l th o u g h  the f ishta il  co l l im a to r  has  des ira b le  prop­
ert ies ,  W B R  co u ld  a lso  be m e a su red  us in g  a g a m m a  
c a m er a  w ith  a n y  c o l l im a to r  c a p a b le  o f  in c lu d in g  the  
w h o le  body  in its f ield o f  v iew  at a rea so n a b le  d is ta n ce .  
For e x a m p le ,  a 2 5 -c m  c a m er a  d e tec to r  w ith  a c o n v e n ­
tional diverging co ll im ator  can be used (T ab le  1), taking  
a c co u n t  o f  the factors  a lre a d y  d iscussed .
C O N C L U S I O N
W e  have sh ow n that m ea su r em e n t  o f  24 -hr  W B R  can  
be m ade using a g a m m a  cam era  and could be used cither  
independently  or in addition to standard bone scans. This  
test provides a sens it ive  m easure  o f  skeletal  m etab o l ism  
( 5 - 7 )  and is s im p le ,  non invas ive ,  has  g o o d  rep ro d u c ­
ib ility ,  and can be per fo rm ed  in a n y  nu clear  m e d ic in e  
d e p a r tm en t  po sse ss in g  a g a m m a  c a m e r a  w ith  su ita b le  
c o ll im a to r .
F O O T N O T E
Oslcoscan, Procter and Gamble, Cincinnati, OH.
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A P P E N D I X
Statistical accuracy of the measurement of 24-hr WBR by a 
^aiiinia camera. The random error in a normal WBR of 20% will 
be estimated a.s a worst case. On injection of 15 mCi Tc-I lEDP  
and the patient positioned at 2.3 m from the camera, typical an­
terior and posterior count rates are 4000 cps for the IGE camera 
with fishtail collimator, these being well within the linear range.
The background conn I rate (B) is typically 30 cps. At 24-hr, with 
a normal patient, the net anterior and posterior cotint rates arc I /5 
X I /  16 X 4000 = 30 cps (C), to which background (which must 
be counted correctly on both days) will be added (S = C +  B). 
Only the second-day measurement has significant random 
error.
The standard deviation (cr) in the measurement of C, the net cps 
from the patient (C = S -  B) is
V  t y  t nLs G
which for ty = tij = 100 sec, as was used in this investigation, 
yields
"so , 30 ,
Thus the fractional error in C is: 1.03 /30  = 2%. and the probable 
range of 24-hr WBR is (20 ± 0.4)% for a normal patient. It must 
be emphasi/cd again that there are other, systematic, sources of 
error, such as those invohcd in repositioning both patient and 
camera, photopeak variation, etc.. but steps can be taken to min- 
im i/c these.
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Comment
This study illustrates clearly that a gamma camera 
with a suitable collimator can be used to obtain a 24-hour 
whole-body retention of diphosphonate (WBR) measurement. 
Extremely good correlation was found between results 
obtained in this way and those obtained with the standard 
whole-body monitor (WBM). While the amount of radioactivity 
required for V/BR is somewhat higher than with the WBM 
(approximately 2mCi compared with 50 pCi) it is still a 
very small dose and considerably less than for a bone scan 
(approximately 15 mCi). If a bone scan is being performed 
anyway, then a WBR measurement can be obtained as an 
extension of that study with no extra radioactivity required.
WBR measurements are easily obtained using a gamma 
camera, the technique is reproducible and in addition results 
correlate well with those from the WBM. It is concluded 
that WBR can be measured in any nuclear medicine department 
possessing a gamma camera with a suitable collimator.
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SUMMARY 
CHAPTER 4
QUANTITATION OE 24-HOUR WHOLE-BODY RETENTION OE 
TECHNETIUM-99m DIPHOSPHONATE - A TRACER TECHNIQUE 
EOR THE ASSESSMENT OE SKELETAL METABOLISM
100 .
Chapter 4 commences with a review of the historical 
aspects of the use of radioactive tracer techniques in the 
assessment of skeletal metabolism. The complexity of 
radiocalcium measurements and their lack of diagnostic 
value is emphasised. The development and validation of 
the technique of 24-hour whole-body retention of technetium- 
99m diphosphonate (WBR) as a measure of skeletal uptake of 
tracer, and as a means of identifying increased bone turnover 
is then described. The analysis and evaluation of WBR 
results in 250 healthy volunteer subjects is presented and 
it is also shown that the WBR technique can be carried out 
in any nuclear medicine department possessing a gamma camera.
Paper 9 is the original publication relating to the 
WBR technique and it introduces the concept that measurements 
of 24-hour whole-body retention of diphosphonate may provide 
a sensitive index of altered skeletal metabolism. Initial 
studies demonstrate that patients with osteomalacia, 
primary hyperparathyroidism, renal osteodystrophy and 
Paget's disease can be clearly differentiated from control 
subjects. While the exact site and mechanism of 
diphosphonate localisation in bone is not known, it is 
nevertheless suggested that in spite of these uncertainties
loi .
the WBR technique may have great potential value in clinical 
practice due to its proven ability to identify patients with 
increased bone turnover. Several studies relating to the 
accuracy of the WBR technique are detailed in paper 10 and 
it is seen that the test is highly reproducible and not 
subject to any significant technical errors. In addition 
the results from further studies assessing whether the 
presence of focal lesions in bone or minor impairment of 
renal function may affect WBR are presented. It is 
concluded that these clinical factors are unlikely to 
affect WBR to any significant extent. While the possibility 
of these factors contributing to minor alterations in WBR 
cannot be excluded, it is shown that they are extremely 
unlikely to elevate a TOR result outside the normal range.
An analysis of results of WBR in 250 healthy volunteer 
subjects is presented in paper 11, A clear age-related 
pattern of results is shown. In men there is a fall in 
WBR results between the ages of 25 to 35 years with a gentle, 
approximately linear rise thereafter. In women a similar 
pattern of TOR results is seen although there is a sharper 
rise at around 50 years of age which is thought to be 
related to increased bone turnover following the menopause.
102 .
On the basis of the findings in this study a hypothesis 
relating alterations in skeletal metabolism to age-related 
bone loss is presented.
This chapter concludes with a comparative study of 
WBR measurements obtained with a gamma camera and with 
the standard whole-body monitor (WBM) technique (paper 12) 
The relevance of this study is that there are relatively 
few centres which have WBM's while gamma cameras are 
widely available. An extremely good correlation was 
found between results obtained with the two techniques 
and it is concluded that WBR measurements can be obtained 
in any nuclear medicine department possessing a gamma 
camera.
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CHAPTER 5
COMPARISON OF THE AVAILABLE DIPHOSPHONATE 
BONE SCANNING AGENTS
104
This chapter consists of three papers (13-15) 
which relate to the evaluation of various diphosphonate 
bone scanning agents in clinical practice. Striking 
differences in skeletal affinity between these agents 
are found and the implications of these results in both 
benign and malignant disease are discussed.
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Paper 13. A clinical comparison of Tc-99m HEDP and 
Tc-99m MDP in the detection of bone 
métastasés: Concise communication (1979)
Journal of Nuclear Medicine 20: 98-101
I Fogelman, D L Citrin, J H McKillop,
J G Turner, R G Bessent, W R Greig
Purpose of Investigation
The purpose of this investigation was to evaluate a 
new bone scanning agent, Tc-99m methylene diphosphonate, 
and compare this with Tc-99m hydroxyethylidene diphosphonate 
in the detection of bone métastasés in patients with known 
malignancy.
A Clinical Comparison of Tc-99m HEDP and Tc-99m MDP 
in the Detection ot Bone Métastasés:
Concise Communication
I, Fogelman, D. L, Citrin, J. H. McKillop, J. G. Turner, R. G. Bessent, and W. R. Greig
Glasgow Royal  Infirmary, Glasgow, Scotland, and University o f  Wisconsin Hospitals, Madison,
Wisconsin
We have compared bone scintigrams made with Tc-99m-tagged HEDP (l-hydroxy- 
ethylidene diphosphonate) and MDP (methylene diphosphonate), the former at 4 hr 
after injection, the latter at both 2 and 4 hr. In 17 patients with skeletal métastasés, 
there was no significant difference in lesion count or scan quality between the 4-hr 
images. The tumor-to-bone ratio (TIB) was significantly higher with Tc-HEDP 
(p <  0.02). Lesion detection rate and TIB ratios were both lower with Tc-MDP at 2 
hr when compared with the 4-hr values for both Tc-HEDP (p <  0.02, p  <  0.005) and 
Tc-MDP (p <  0.02, p  <  0.01). The 4-hr Tc-MDP scan was of significantly higher 
quality than the 2 hr Tc-MDP scan (p <  0.01). Although Tc-HEDP produces a higher 
TIB ratio at 4 hr, the present study does not suggest that either agent is superior in 
clinical practice.
J NucI Med 20: 98-101, 1979
Since the introduction of the Tc“99m-labeled 
phosphate and diphosphonate bone-scanning agents, 
it has been generally accepted that of the available 
agents the diphosphonates are the most satisfactory 
( i-6 ). Two diphosphonates are in routine clinical 
use at present, Tc-99m hydroxyethylidene diphos­
phonate (Tc-HEDP) and Tc-99m methylene diphos­
phonate (Tc-MDP). The soft-tissue clearance is ap­
parently more rapid with Tc-MDP than with Tc- 
HEDP. For this reason it has been suggested that 
scans may be obtained with Tc-MDP 2 hr after 
injection, and that Tc-MDP is therefore the agent 
of choice (5). A recent clinical comparison of the 
two agents has also suggested that Tc-MDP is su­
perior to Tc-HEDP (7).
In this report we describe a comparison of 4-hr
Received July 14, 1978; revision accepted Sept. 26, 1978.
For reprints contact: I. Fogelman, Dept, of Nuclear Medicine, 
Glasgow Royal Infirmary, Glasgow G4 OSF, Scotland.
bone scans obtained with Tc-HEDP and Tc-MDP 
in 17 patients with bone métastasés. Additionally, 
a comparison has been made between the 2-hr and 
4-hr bone scans with Tc-MDP.
PATIENTS AND METHODS
Seventeen patients with bone métastasés (Table 
1) were studied on two occasions. A radionuclide 
bone scan was obtained 4 hr after the i.v. injection 
of 15 mCi of Tc-HEDP*. Approximately one week 
later a repeat study was performed 2 and 4 hours 
after the injection of 15 mCi of Tc-MDPt. During 
the period between the paired studies no patient 
received specific chemotherapy or radiotherapy.
Bone scans were obtained by recording multiple 
views of the skeleton on Polaroid film using a 
gamma camera fitted with a high-resolution me- 
dium-sensitivity collimator. Spinal views were ob­
tained with 500,000 counts, and all others with 
100,000 counts. In addition, all scintigrams were 
recorded and stored on a minicomputer by means
Reprinted from the JOURNAL OF NUCLEAR MEDICINE, 
February, 1979, Volume 20, Number 2, Pages 98-101.
of Laben analog-to-digital converters. Subsequent 
analysis of the digitized computer images permitted 
calculation of bone to soft-tissue ratios (B/ST) by 
selecting regions of interest around lumbar vertebra 
2 and an adjacent soft-tissue area clear of renal 
activity (5). Similarly tumor-to-bone ratios (T/B) 
were measured as ratios of activity in tumor-in­
volved bone to activity in corresponding normal 
bone.
The bone images were evaluated independently 
by three observers, (DLC, JHMcK, JGT), without 
knowledge of patient details or the ratiotracer used. 
The overall quality of scan image was recorded on 
a scale of 1-3:1 was considered poor quality, 2 
average quality, and 3 a very good-quality image. 
In addition each physician recorded the total num­
ber of focal abnormalities identified in each patient.
All statistical comparisons between Tc-MDP and 
Tc-HEDP were performed using a paired Wilcoxon 
test, since each patient was studied with both 
agents.
RESULTS
The correlation between the lesion counts ob­
tained by the three independent observers was very 
good for all studies, the correlation coefficient (r) 
ranging from 0.84-0.96 (p <  0.001, in all cases). 
Regarding image-quality assessment, there was 
fairly good correlation for both 4-hr studies (r rang­
ing from 0.49-0.76, p <  0.05 in all cases). In the
2-hr Tc-MDP study, however, two observers cor­
related well with each other (r =  0.60, p <  0.01) 
but not with the third observer (r = 0.17 and 0.45, 
p >  0.05).
Iihage-quality score (Table 1). Overall there was 
no significant difference in quality between the 4- 
hr images obtained with Tc-HEDP and both the 2- 
hr and 4-hr Tc-MDP images. There was, however, 
a significant improvement in quality between the 
images obtained with Tc-MDP at 2 and 4 hr (p <  
0 .01).
Lesion counts (Table 2). There was no significant 
difference between the number of bone lesions 
(métastasés) identified on the 4-hr Tc-HEDP and 
Tc-MDP scans. The 2-hr Tc-MDP scans gave sig­
nificantly fewer identifiable lesions than did the 4- 
hr studies with either Tc-MDP (p <  0.02) or Tc- 
HEDP (p <  0.02).
Bone-to-soft-tissue ratios (Table 3). There was no 
significant difference in B/ST ratios between the 4- 
hr Tc-HEDP study and either the 2- or 4-hr Tc- 
MDP study. However, a significant increase in B/ 
ST ratio was noted between 2- and 4-hr Tc-MDP 
studies (p <  0.05).
Tumor-to-bone ratios (Table 4). The T/B ratios ob­
tained with Tc-HEDP were significantly higher than 
those obtained in both the 2-hr Tc-MDP (p <  0.005) 
and 4-hr MDP study (p <  0.02). In addition, there 
was a significant increase from 2 to 4 hr in the Tc- 
MDP studies (p <  0.01).
TABLE 1. PATIENT CHARACTERISTICS AND OVERALL SCAN IMAGE QUALITY SCORE*
Patient
No. Age Sex
Prim ary
Site
HEDP 
(4 hr)
MDP
(2 hr)
MDP 
(4 hr)
1 62 F B reast 2.2 1.7 1.5
2 75 F B reast 2.0 2.0 2.0
3 46 F B reast 2.0 2.2 2.5
4 58 F B ladder 2.5 2.2 2.7
5 53 M Lung 1.5 1.2 1.2
6 72 F B reast 1.0 1.0 1.7
7 83 M P rosta te 2.5 2.5 2.5
8 55 F B reast 1.3 1.7 1.7
9 47 F B reast 3.0 2.7 3.0
10 71 M P rosta te 2.0 1.7 1.7
11 42 F B reast 1.7 1.7 2.3
12 72 F B reast 1.0 2.3 2.7
13 49 F B reast 2.3 2.3 2.3
14 57 F B reast 2.7 2.0 2.7
15 58 F B reast 2.0 2.0 2.0
16 41 F B reast 2.3 2.0 3.0
17 64 F B reast 1.3 1.0 1.7
M ean ±  s.d. 2.0 ±  0.6 1.9 ±  0.5 2.2 ±  C
NSD^ p <  0.01**
NSD**
* Mean of th ree  ind ep en d en t observers.
** R esu lts of com parison  by paired W ilcoxon te s t; NSD =  no sign ifican t difference.
DISCUSSION
The clinical superiority of the Tc-99m diphos­
phonate vectors H ED P and MDP, when compared 
with pyrophosphate and the polyphosphates in
TABLE 2. NUMBER OF BONE LESIONS COUNTED*
Patient HEDP MDP MDP
No. (4 hr) (2 hr) (4 hr)
1 15.0 14.7 16.3
2 2.0 2.0 2.0
3 13.3 11.7 14.3
4 28.0 28.3 29.0
5 3.7 4.3 6.0
6 4.3 4.7 4.7
7 29.7 22.7 25.7
8 9.7 10.0 12.3
9 21.3 14.0 16.7
10 17.7 16.0 12.3
11 8.7 8.3 8.7
12 9.7 8.0 9.0
13 12.7 12.7 14.4
14 13.3 12.0 13.0
15 3.0 2.3 2.0
16 3.0 2.0 2.7
17 17.3 16.7 17.7
Mean ±  s.d. 12.5 ±  8.4 11.2 ±  7.3 12.2 ±  7.7
V —V------- "
p <  0.02** p <  0.02**
NSD**
* Mean of three independent observers.
** Results of comparison by paired Wilcoxon test;
NSD = no significant difference.
terms of quality of scan image and lesion detection 
rate, is now generally accepted. Since the early 
work demonstrating that MDP has a slightly faster 
blood clearance than HEDP, it has been suggested 
that the former is the preferred agent for routine 
clinical studies ( i ) . Of particular importance in this 
respect has been the suggestion that a time interval 
of only 2 hr between injection and scanning is re­
quired with MDP, compared with 3 to 4 hr with 
HEDP (5). This suggestion, however, was made by 
Subramanian (3) on the basis of studies of blood 
clearance in only six healthy volunteers without 
bone disease, and was not based on any data re­
garding either the visualization or quantitation of 
bone lesions. A clinical comparison of MDP and 
HEDP has been performed in 11 volunteers and 20 
patients (7). On the basis of faster blood clearance, 
improved quality of scan image and higher bone to 
soft-tissue ratios, the authors concluded that MDP 
was the preferred radiopharmaceutical for bone im­
aging. However, only seven of their patients had 
skeletal m étastasés and in these cases no lesions 
identified with one compound were missed with the 
other. Also no quantitative data were presented 
regarding tumor-to-bone ratios.
The results of the present work, performed as a 
critical paired study of patients with unequivocal 
bone m étastasés, have shown no major difference 
between the 4-hr HEDP and MDP scans in terms 
of overall image quality, number of lesions de-
Patient HEDP MDP MDP
No. (4 hr) (2 hr) (4 hr)
1 5.8 4.7 5.2
2 5.7 6.5 6.8
3 5.3 4.2 5.2
4 4.1 2.8 2.7
5 3.2 2.5 3.8
6 2.9 3.1 4.7
7 7.7 5.1 5.4
8 4.5 3.3 4.1
9 7.0 6.8 8.2
10 4.1 5.5 4.5
11 4.9 6.0 6.0
12 2.7 2.9 2.4
13 12.1 9.9 10.9
14 4.0 4.4 5.5
15 4.7 4.1 5.3
16 4.0 4.7 4.7
17 3.5 3.9 3.3
Mean ±  s.d. 5.07 ±  2.26 4.72 ±  1.85 5.22 ±  2.04
NSD* p <  0.05*
''--------- --Hr.-- y--------------- ^
NSD*
* Results of comparison by paired Wilcoxon test;
NSD = no significant difference.
TABLE 4.
Patient HEDP MDP MDP
No. (4 hr) (2 hr) (4 hr)
1 2.0 1.9 1.7
2 2.1 2.0 2.2
3 1.7 1.7 1.8
4 2.1 2.4 2.8
5 2.6 1.8 1.9
6 2.7 2.2 2.2
7 2.2 2.0 2.0
8 1.8 1.7 1.7
9 2.3 2.0 2.1
10 4.5 3.2 3.9
11 3.3 2.5 3.0
12 5.3 3.7 4.1
13 1.5 1.6 1.7
14 2.3 1.8 1.9
15 1.4 1.4 1.3
16 1.8 1.6 1.6
17 1.9 1.6 1.8
Mean ±  s.d 2.45 ±  1.03 2.05 ± 0.61 2.2 ± 0.78
p <  0.005* p <  0.01*
p <  0.02*
* Results of comparison by paired Wilcoxon test.
tected, and bone to soft-tissue ratios. The only sta­
tistically significant difference between the two 
agents in this study was a high tumor-to-bone ratio 
with HEDP.
Following the initial independent random evalu­
ation of image quality, the observers reassessed the 
scan images in sets of three for each of the 17 
patients. Overall there was a subjective impression 
that MDP produced images of higher quality at 4 hr 
after injection when compared with HEDP. This 
was supported by a trend towards higher scores for 
MDP in image quality (Table I) and bone-to-soft- 
tissue ratios (Table 3). However, it was felt that 
there was higher contrast between tum or and nor­
mal bone using HEDP, and this was supported by 
higher tumor-to-bone ratios (Table 4). The subjec­
tive impression of a “ good image” is influenced by 
a high bone to soft-tissue ratio, but in clinical prac­
tice tumor visualization is param ount. For this pur­
pose the agent with the highest tumor-to-normal- 
bone ratio may well be superior.
Comparison of the 2- and 4-hr MDP scans shows 
improvement in all aspects of image quality, lesion 
detection rate, and tumor-to-bone ratios in the later 
study. A similar trend was noted in a previous 
study, which compared 2- and 4-hr scans obtained 
with HEDP (9). Although satisfactory bone scan 
images are obtained with both HEDP and MDP at 
2 hr after injection, 4-hr images are superior.
There was no significant difference for any pa­
ram eter between the results from the nine patients 
receiving one commercial MDP and the eight re­
ceiving the other MDP. This is similar to our pre­
vious experience with HEDP obtained from three 
different commercial sources, where the products 
all provided similar, highly reproducible results 
( 10) .
On the basis of the present study we conclude 
that, although Tc-HED P produces higher tumor-to- 
bone ratios, there is no significant clinical differ­
ence between Tc-HED P and Tc-MDP in terms of 
image quality and lesion detection rate. In the case
of Tc-MDP, scanning at 2 hr will result in some 
missed lesions, so the longer delay after injection 
is recom mended particularly where subtle abnor­
malities are anticipated.
FOOTNOTES
* Osteoscan, Proctor and Gamble, Cincinnati, OH. 
t  Patients Nos. 1-9 with Tc-MDP from Radiochemical Center, 
Amersham Corp., Arlington Heights, IL; patients N os. 10-17 
with Tc-MDP from New England Nuclear Corp., North Biller­
ica, MA.
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Comment
This study involving patients with malignant disease is 
included in a thesis dealing essentially with benign 
disorders because the finding of higher lesion to bone ratios 
with hydroxyethylidene diphosphonate (HEDP) than with 
methylene diphosphonate (MDP) was the first indication to 
me that higher absolute bone uptake of tracer may not 
necessarily be desirable in clinical practice. While no 
significant difference in lesion detection was found between 
MDP and HEDP in the present study, it is theoretically 
possible that lesions in bone will be less apparent against 
a background of higher tracer uptake by the normal skeleton. 
However fashions are such that because MDP produces slightly 
more pleasing normal bone scan images, it is the most widely 
used scanning agent and HEDP is now no longer commercially 
available. A comprehensive review of the differences 
between various diphosphonates as regards skeletal uptake, 
lesion to bone ratios, bone to soft-tissue contrast, and 
the implications of their use in malignant and benign 
disease is presented in paper 15.
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P ape r 14. A comparison of skeletal uptakes of three 
diphosphonates by whole-body retention :
Concise communication (1981)
Journal of Nuclear Medicine 22 ; 880-883
I Fogelman, D W Pearson, R G Bessent,
A J Tofe, M D Francis.
Purpose of Investigation
While differences in the skeletal affinity of the
various diphosphonates had been shown in animal studies
and in vitro experiments, such findings had not been 
confirmed in human subjects. The purpose of the present 
study was to assess relative skeletal uptake of three 
different technetium-99m labelled diphosphonates using 
the 24-hour whole-body retention technique in 20 healthy 
volunteer subjects.
A Comparison of Skeletal Uptakes of Three Diphosphonates by Whole-Body 
Retention; Concise Communication
I. Fogelman, D. W. Pearson, R. G. Bessent, A. J. Tofe, and M. D. Francis
Glasgow Royal Infirmary, Glasgow, Scotland and M iam i Valiey Laboratories, Procter & Gamble Company,
Cincinnati, Ohio
Tw enty norm al volunteers had m easurem ents of 24 -h r w hole-body retention  
(W B R ) of th ree structurally re la ted  T c -9 9 m -la b e le d  phosphonate ske le ta l im aging  
agents: (1 -hyd ro xyeth y lid ene) diphosphonate (H E D P ), m ethylene diphosphonate  
(M D P ), and hydroxym ethylene diphosphonate (H M D P ). The average W BR vaiues, 
reflecting  ske ie ta l uptake, w e re  18 .4 , 3 0 .3 , and 3 6 .6 % , respective ly . These results  
c learly  illustrate that slight a lterations in diphosphonate m oiecuiar structure have  
a significant e ffect upon specific ity  for osseous tissue, and thus m ay affect ske le ta i 
im age quality and the usefulness of the W B R  technique in diagnosing m etabo lic  
bone disease.
J NucI Med 22: 880-883, 1981
The development of skeletal imaging agents has 
been focused around structural modifications of the 
methylene diphosphonate (MDP) molecule. The addi­
tion of the hydroxyl group to the central carbon atom of 
MDP to produce hydroxymethylene diphosphonate 
(HM DP), or an additional methyl group to the hy- 
droxylated central carbon atom to produce 1-hydroxy­
ethylidene diphosphonate (HEDP), have been shown in 
vitro and in animal studies to produce significant dif­
ferences in both the pharmacokinetics and osseous 
specificity of the agents (1-4).
Clinically, the accurate comparative quantitation of 
skeletal uptake at times shortly after administration of 
the skeletal imaging agents presents a number of tech­
nical problems that can be circumvented by using the 
24-hr whole-body retention (WBR) technique (5). In 
this paper, the WBR values for the three structurally 
similar diphosphonates HEDP, MDP, and HMDP (Fig. 
I), were all compared in 20 normal subjects to assess the
Received Mar. 26, 1981; revision accepted June 11, 1981.
For reprints contact: Ignac Fogelman, University Departments of 
Medicine and Nuclear Medicine, Royal Infirmary, Glasgow, G4 OSF, 
Scotland.
relative skeletal affinities of these agents. The clinical 
utility of the differences in absolute skeletal uptake has 
implications for skeletal image quality, the time required 
to obtain images, and the use of the WBR technique in 
diagnosing metabolic bone disease.
METHODS AND MATERIALS
Twenty normal volunteers (age range 22-65 yr, mean 
40.2) had 24-hr WBR measurements following intra­
venous injections of Tc-99m-labeled HEDP, MDP, and 
HM DP. All three were prepared according to manu­
facturer’s instructions with the exception of the activity 
level, which was only 50 pCi  per dose. The whole-body 
count was measured at 5 min and again at 24 hr after 
injection, using a standard shadow-shield whole-body 
monitor (5). Twenty-four-hour WBR values for the 
three agents were calculated, after appropriate back­
ground subtraction, by taking the 5-min count as 100% 
and correcting for radioactive decay. The WBR mea­
surements were performed at least one week apart, with 
17 of the 20 triple studies falling within a 2-mo period. 
The remaining three studies were over a 3- to 4-mo pe­
riod.
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FIG. 1. Unprotonated structures of HEDP, 
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This study uses a randomized block design wherein 
each subject was treated with each of the three agents 
studied. Therefore, the data were analyzed using analysis 
of variance for randomized blocks (d). Comparisons of 
HMDP with each of the other agents were done using 
the ^-distribution procedure described in Sec. 23.4 of 
Ref. 6.
RESULTS
The absolute whole-body retention values for each of 
the 20 normal volunteers are given in Fig. 2. Tests of 
difference for the three treatments in the individuals are 
highly significant (P <0.001). As shown in Fig. 3, the 
mean WBR and standard deviation values for HEDP, 
MDP, and HM DP are 18.41% ±  2.94, 30.30% ±  4.16, 
and 36.55% ±  5.0, respectively. The WBR values ranged 
from 12,89-22.45% for the HEDP agent, 23.22-36.4% 
for the MDP, and 25.07-44.23% for the HMDP, Thus 
the mean WBR of HM DP is about double that of 
HEDP, and is 20% greater than that of MDP. The dif­
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ferences, at 95% confidence interval, between the 
HM DP and HEDP agents, and the HM DP and MDP 
agents, are 18.2% db 1.2 and 6.3% ±1.1, respectively. The 
small standard deviations of the differences reflect the 
fact that results for individual subjects are in closely 
similar order for the three agents (Fig. 2). In other 
words, even within this control group, individual small 
differences are demonstrated similarly by the three 
agents.
The quantitative differences between HEDP and 
MDP are in excellent agreement with WBR values 
previously reported for a small group of subjects (7).
DISCUSSION
In theory, high skeletal uptake of tracer is desirable 
for bone scanning, since this may allow clearer delinea­
tion of the skeleton and minimize the time required to 
perform a study. At present there are no reports of sig­
nificant differences between HEDP, MDP, and HM DP 
when used for the detection of metastatic disease—i.e.,
Mean Whole-Body Retention of Tc99m-HEDP, Tc99m-MDP 
and Tc99m-HMDP In Normals (n =20) at 24 Hours
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FIG. 2. R epeat 24-hr m easu rem en ts of w hole-body retention using  
T c-99m  HEDP, T c-99m  MDP, and T c-99m  HMDP sk ele ta l im aging  
a g e n ts  in 2 0  norm als.
FIG. 3. Mean 24-hr va lu es, with standard deviation, for w hole-body  
retention o f T c-99m  HEDP, T c-99m  MDP, and T c-99m  HMDP.
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increased skeletal uptake of tracer is not necessarily 
advantageous for lesion detection—and indeed we have 
previously suggested that where there is high uptake of 
tracer by normal bone, lesions may even be less clearly 
visualized (7). However, in a recent comparison between 
the lowest-uptake agent, HEDP, and the highest, 
HM DP, this was not found to be the case {8). In the 
studies where images obtained at both 2 and 4 hr after 
injection with either HEDP or MDP have been com­
pared, a significant improvement in image quality was 
seen at the later time (9,10). It therefore appears that 
while bone scans using HEDP and MDP can provide 
satisfactory diagnostic information at 2 hr after injection, 
the quality of such images might be considered poor and 
perhaps even unacceptable by current standards. Image 
quality is principally related to the absolute retention of 
the skeletal imaging agent on bone and the time available 
to allow the soft-tissue tracer component to be excreted 
by the kidneys. The diagnostic quality of images obtained 
with HM DP at scanning times earlier than 4 hr after 
injection has still to be established.
Whereas differences in diphosphonate uptake at 24 
hr cannot necessarily be extrapolated to routine clinical 
scanning times, the validity of the 24-hr value is clinically 
supported by Khedkar et al., who quantitated MDP and 
HMDP bone uptake in the pelvic bones of 12 patients 
and showed higher skeletal retention of HM DP at 0.5, 
3, and 24 hr ( / / ) .  Similar quantitative differences be­
tween MDP and HM DP were obtained by Bevan et al. 
(3) at 1,5 hr in beagle dogs, a model we feel can be ex­
trapolated to humans.
The exact mechanism of diphosphonate uptake in 
bone is as yet incompletely understood {12), but a 
common factor for all three agents is the ability of the 
diphosphonate to coordinate with technetium, with 
subsequent sorption of the tracer onto bone {13). The 
20% differential in WBR value between MDP and 
HM DP is most probably related to differences in the 
bridging (binding) between the agents and hydroxy- 
apatite, primarily the postulated bidentate-bidentate 
binding for nonhydroxy molecules such as MDP and 
bidentate-tridentate binding for molecules with a hy­
droxy group such as HM DP {2,13). Kinetic studies by 
Arnold et al. {14) suggest that such variations in mo­
lecular structure do affect osseous affinity and lead to 
tighter binding of HM DP and subsequent higher re­
tention on bone. Less understood is the dramatic dif­
ference observed between HEDP and HMDP, both ca­
pable of bidentate-tridentate binding. Increased steric 
hindrance associated with the methyl group on the cen­
tral carbon atom, differences in solubility, and differ­
ences in molecular size as well as in the diphosphonate 
polymeric complexes themselves have all been suggested 
{2,4,13).
This study has possible implications relating to the use
of (a) different diphosphonates for bone scanning, and 
(b) WBR in the evaluation of patients with metabolic 
bone disease. Whereas in metastatic disease focal ab­
normalities are seen on the bone scan, in metabolic bone 
disease the skeleton is usually diffusely involved by the 
metabolic process and typically focal abnormalities are 
absent. An awareness of abnormality then depends upon 
a subjective impression of increased tracer uptake 
throughout the whole skeleton. With HEDP several 
metabolic features have been recognized on the scan, and 
these have allowed differentiation of various metabolic 
bone disorders from a control population {15). In the 
case of either MDP or HMDP, the higher absolute up­
take relative to HEDP raises the possibility that it will 
be more difficult to identify a metabolic process against 
this higher background of normal skeletal uptake. Where 
24-hr WBR of diphosphonate is used to identify patients 
with increased skeletal metabolism {5,16-18),  HEDP, 
with its tighter normal range at lower absolute skeletal 
uptake, would seem to be the agent of choice, since it 
provides a wider range in which to detect abnormality 
with less overlap between normal and abnormal.
ACKNOWLEDGMENT
We thank Mrs. Elizabeth Scott for her careful whole-body retention 
measurements.
REFERENCES
1. W a n g  TS, F a w w a z  RA, J o h n s o n  LL, etal: Bone-seeking 
properties of Te-99m  carbonyl diphosplionic acid, dihydrox- 
ym ethylene diphosphonic acid and m onohydroxym ethylene  
phosphonic acid. J Nu cl  M e d  2 1: 7 6 7 -7 7 0 , 1980
2. SEVAN J A, T o f e  AJ, B e n e d i c t  JJ, et al: T c-99m  H M D P  
(hydroxymethylene diphosphonate): A  radiopharmaceutical 
for skeletal and acute myocardial infarct imaging. I. Synthesis 
and distribution in animals. J  N u cl  21: 9 6 1 -9 6 6 , 1980
3. B e v a n  JA, T o f e  AJ, B e n e d i c t  JJ, et al: T c-99m  H M DP  
(hydroxym ethylene diphosphonate): A radiopharmaceutical 
for skeletal and acute myocardial infarct imaging. 11. C om ­
parison o f T c-99m  H M D P with other technetium -labeled  
bone-im aging agents in a canine model. J N ucl M e d  21: 
9 6 7 -9 7 0 , 1980
4. F r a n c i s  M D, F e r g u s o n  DL, T o f e  AJ, et al: Comparative 
evaluation of three diphosphonates: In vitro adsorption (C-14  
labeled) and in vivo osteogenic uptake (Tc-99m  com plcxed). 
J  N u cl  M e d  2\:  1185-1189 , 1980.
5. F o g e lm a n  1, B e s s e n t  RG, T u r n e r  JG, et al: The use of 
whole-body retention o f Tc-99m  diphosphonate in the d iag­
nosis o f  m etabolic bone disease. J  N u cl  M e d  19: 2 7 0 -2 7 5 , 
1978
6. N e t e r  j ,  W asSERM AN W: A p p l ied  Linear S ta t is t ica l  
M odels .  Hom ewood, Richard D. Irwin, Inc., 1974, Chap.
23.
7. F o g e l m a n  1, B e s s e n t  RG: W hat do we want from a 
bone-scanning agent? J  N ucl M e d  21: 296, 1980
S. SiLBERSTEiN EB: A radiopharmaceutical and clinical 
comparison of Tc-99m -Sn-hydroxym ethylene diphosphonate 
and Tc-99m -Sn-hyroxyethylidene diphosphonate. Radio logy  
136: 7 4 7 -7 5 1 , 1980
882 THE JOURNAL OF NUCLEAR MEDICINE
CLINICAL SCIENCES
INVESTIGATIVE NUCLEAR MEDICINE
9. f o g e l m a n  I, G o l l  C, M c K i l l o p  JH, et al: A clinical 
comparison of 2 hour and 4 hour bone scans obtained with 
99m Tc-HEDP. Eur J Nucl M ed  3: 15-17, 1978
1 0 .  F o g e lm a n  1, C i t r in  DL, M c K i l lo p  JH, et al: A clinical 
comparison of Tc*99ni HEDP and Tc-99m MDP in the de­
tection of bone métastasés: Concise communication. J Nucl 
M ed  20: 98-101, 1979
1 1 .  K h e d k a r  N, A r n o l d  JS, M il o T ,  etal: Qualitative and 
quantitative digital comparison of Tc-99m HMDP and MDP. 
J Nucl M ed  20:655, 1979
1 2 .  F o g e lm a n  1: Skeletal uptake of diphosphonate: a review. 
Eur J  Nucl M ed  5: 473-476, 1980
1 3 .  D e u t s c h  E, B a r n e t t  BL: Synthetic and structural aspects 
of technetium chemistry as related to nuclear medicine. Inorg 
Chem in Biology and Medicine. ACS Symp Series No. 140, 
1980, M a r t e l l  AE, Ed
14. A r n o l d  JS, B a r n e s  WF, K h e d k a r  N, et al: Kinetic 
studies of a new and superior Tc-99m diphosphonate bone 
imaging agent. J  N ucl M ed  20: 653-654, 1979
15. F o g e l m a n  1, C i t r in  DL, T u r n e r  JG, et al: Semi-quan­
titative interpretation of the bone scan in metabolic bone 
disease: definition and validation of the metabolic index. Eur 
J  N ucl M ed  4: 287-289, 1979
16. F o g e lm a n  I, B e s s e n t  RG, B e a s t a l l  G, et al: Estimation 
of skeletal involvement in primary hyperparathyroidism. Ann 
In tM ed  92: 65-67, 1980
1 7 .  F o g e l m a n  I, B e s s e n t  RG, C o h e n  H N , et al: Skeletal 
uptake of diphosphonate: method for prediction of post­
menopausal osteoporosis. Lancet 2: 667-670, 1980
18. F o g e l m a n  I: The value of 24 hour skeletal uptake of di­
phosphonate in the exclusion of metabolic bone disease. Nucl 
M ed Commun 1: 351-356, 1980
108.
Comment
As stated in the paper there are understandable reasons 
for seeking relatively higher skeletal uptake of tracer - 
clearer delineation of the skeleton may be obtained with 
the likelihood of more pleasing images, and also the time 
required to carry out a study could be reduced. The 
current trend does indeed appear to be to develop bone 
seeking radiopharmaceuticals with higher skeletal affinity, 
and it has been previously shown in animal studies that the 
most widely used bone scanning agent methylene diphosphonate 
(MDP) has higher absolute skeletal uptake than hydroxyethyli- 
dene diphosphonate (HEDP) (Subramanian et al, 1975).
Recently a new diphosphonate, hydroxymethylene diphosphonate 
(HMDP) has become available which on the basis of animal 
studies appears to have even higher skeletal affinity 
(Bevan et al, 1980). The present study is the first to 
quantitate the relative differences in skeletal uptake 
between these diphosphonates in human subjects. Striking 
differences in skeletal affinity were found. HMDP had the 
highest absolute uptake followed by MDP, and both these 
agents had significantly higher skeletal uptake than HEDP 
(assuming the distribution of tracer in soft-tissue is the 
same or similar in each case). These results are in 
keeping with the published findings from animal studies 
(Bevan et al, 1980) and from in vitro experiments assessing
109 .
the relative affinity of each diphosphonate for hydroxy- 
apatite crystals (Francis et al, 1980).
The three diphosphonates studied are structurally 
similar and it is clear that slight alterations in molecular 
structure can have a significant effect upon specificity 
of a diphosphonate for bone. Why this should be so is not 
clear, and while a possible explanation is provided, based 
on whether or not there is a hydroxyl group present on the 
central carbon atom, it must be realised that the exact 
method of binding between the diphosphonate molecule and 
bone remains incompletely understood.
The implication of higher skeletal uptake of diphosphonate 
for lesion detection in metastatic disease is briefly 
discussed and this topic is more fully dealt with in 
paper 15. As regards metabolic bone disease, it is suggested 
that metabolic features are less likely to be recognised 
on the bone scan image if there is higher background uptalce 
of tracer by bone. However, this view has still to be 
tested by critical study. Where 24-hour whole-body 
retention of diphosphonate measurements are used to identify 
patients with increased skeletal metabolism, HEDP with its 
lower absolute skeletal uptake (and narrower normal range) 
would seem to be the agent of choice, as it provides a 
wider range in which to detect abnormality with less overlap 
between normal and abnormal. However this belief has 
also not been tested by critical study.
1 1 0
Paper 15. Diphosphonate bone scanning agents - 
current concepts
European Journal of Nuclear Medicine (in press)
I Fogelman
Purpose of Investigation
The purpose of this review is to stimulate thought and 
provoke discussion as to which properties are considered 
desirable in a bone scanning agento My own views are 
presented and discussed in the context of both metastatic 
and metabolic bone disease. In addition, I have critically 
summarised the results of all comparative studies between 
diphosphonate bone scanning agents in clinical practice.
DI PHO S P H O N A T E  BONE SC ANNING  AGENTS - CURRENT CONCEPTS
Ignac Fogelman
A B S T R A C T
The bone scan is generally recognised to be an extremely 
powerful investigational tool in the evaluation of patients 
with skeletal disease.. Currently Tc-99m methylene 
diphosphonate is the most widely used bone scanning agent, 
but recently several new diphosphonate compounds have been 
introduced which appear to have relatively higher skeletal 
affinity, leading to greater absolute uptake of tracer by 
bone. While the resulting improved contrast between bone 
and background soft-tissue may provide more pleasing scan 
images, it is not clear that increased bone uptake of tracer 
is equally desirable for identification of disease. Never­
theless, to date, no significant difference in lesion detection 
has been found in any comparative study of diphosphonate 
c ompoun ds „
In this review the clinical studies evaluating 
diphosphonate bone scanning agents are summarised and the 
properties required of an ideal bone scanning agent in both 
benign and malignant disease discussedo
2  .
I N T R O D U C T IO N
The ability to image the skeleton was dramatically 
transformed by the development of Tc-99m labelled 
polyphosphate by Subramanian and McAfee (19 71). This 
important advance meant that a compound with high skeletal 
affinity could at long last be combined with a radionuclide 
with near ideal physical properties,. Nevertheless, there 
was a continuing search for further improvement and several 
phosphate compounds rapidly became available (Subramanian 
et al, 1972a; Fletcher et al, 19 7 3; Citrin et al, 1974).
A T c-9 9 m labelled diphosphonate (hydroxyethylidene 
diphosphonate) bone scanning agent was independently proposed 
and evaluated by several groups of workers (Tofe and Francis, 
1972; Castronovo and Callahan, 1972; Subramanian et al,
19 72b; Y an o et al, 19 73) Since their introduction,
cumulative experience has shown that the diphosphonates are 
the bone scanning agents of choice (Subramanian et al, 1972b; 
Silberstein et al, 1973; Pendergrass et al, 1973; Citrin et al, 
19 75 ; Fogelman et al, 19 77) „ Currently Tc-99m methylene
diphosphonate (Subramanian et al, 1975) is the most widely 
used bone scanning agents
Recently, several new diphosphonate compounds have been 
introduced and there seems to be a trend at present amongst 
radiopharmaceutical companies to develop agents with relatively
higher skeletal affinity, leading to greater absolute uptake 
of tracer by bone„ While this may lead to more pleasing 
images being obtained in normal subjects, due to higher bone 
to background ratios, it is not clear that higher bone uptake 
will be equally valuable in the identification of disease c
The purpose of this review is to discuss the properties 
required of an ideal bone scanning agent and to summarise 
comparative studies that have been carried out with the 
diphosphonate bone scanning compounds.
PROPERTIES REQUIRED OF A BONE SCANNING AGENT
The search for metastatic disease remains the most 
important single indication for performing a bone scan o 
Abnormalities in this situation are identified by the presence 
of focal lesions. Visualisation of a focal lesion depends 
upon the contrast between the lesion and the surrounding 
bone, that is to say the ratio of counts in the lesion to those 
in background bone (L/B). The contrast between bone and soft- 
tissue (B/ST) is important for visualisation of the skeleton 
itself and for a normal subject, a higher B/ST ratio will lead 
to an improved bone scan. However a higher B/ST ratio does 
not signify that lesions will be better visualised on the bone 
scan, nor that disorders leading to diffuse abnormality on the 
bone scan, such as metabolic bone disease, will be more easily 
identified.
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It is even possible that different bone scanning agents 
may be preferred in various clinical situations. Where 
visualisation of normal skeletal anatomy is required (although 
the bone scan is not the technique of choice for this) high 
uptake of tracer throughout the skeleton is desirable. In 
metastatic disease the contrast between tumour and background 
bone is of most importance and it may be argued that if there 
is high background uptake of tracer then lesions may be less 
clearly seen against this background, unless there is even 
higher specific uptake of tracer by bone involved with tumour,
In the metabolic bone disorders a recognition of generalised 
high uptake of tracer depends upon a subjective evaluation of 
the scan and it is also likely that this will be more difficult 
to recognise against high background uptake of tracer by the 
skele ton .
Thus if an extremely satisfactory bone scanning agent is 
available, then on theoretical grounds it would seem that no 
clear advantage is to be derived from further increasing 
skeletal uptake of tracer by the normal skeleton. Certainly 
if two bone scanning agents are to be compared in metastatic 
disease then a simple subjective evaluation of scan appearances 
or even measuring B/ST ratios is not adequate, as it does not 
really matter if one scan looks nicer than the other. What is 
relevant is lesion visualisation and the L/B ratios. Similarly, 
to state that one agent has faster blood clearance than another
5.
does not imply that it is a better agent in clinical practice.
If other properties are similar then the agent with higher 
skeletal affinity will of course have the faster blood clearance 
It should be clear that it is not possible to evaluate 
a bone scanning agent by randomly allocating patients with 
metastatic disease to one or another agent and then measuring 
B/ST ratios or subjectively evaluating the visual quality of 
these scans. Paired studies in individual patients, using 
both agents, should be performed. Lesion counts and L/B 
ratios must be obtained.
THE DIPHOSPHONATE BONE SCANNING AGENTS
(a) Tc-99m Hydroxye thyli dene Diphosphonate (HEDP)
Tc-99m HEDP was the first diphosphonate to be introduced 
into clinical practice and is undoubtedly the diphosphonate 
which has been most extensively evaluated. Several early 
studies demonstrated that HEDP had improved biological 
properties, with faster blood clearance, when compared with 
polyphosphate or pyrophosphate (Dunson et al, 19 73 ; Acke rh alt 
et al, 19 74 ; Krishnamurthy et al, 1974; Hughes et al, 1975) . 
Not all reports, however, were favourable. In an evaluation 
of 140 patient studies Nelson et al ( 19 77) considered HE DP 
to be inferior to both pyrophosphate and trimetaphosphate.
Also Weber et al (1976) in 90 patient studies preferred 
pyrophosphate to HEDP. However in both cases, evaluation 
was essentially based on normal scans, and paired studies 
using both agents in individual patients were not obtained.
6 .
Silberstein et al (1973) carried out paired studies in 
10 patients with carcinoma using both HEDP and fluorine-18 
and found that F-18 detected only 56% of the lesions found 
with HE D P . Pen de rgre s s et al (19 73) reviewed their experience 
with over 500 scan studies using HE D P . They suggested that 
HEDP was more sensitive for detection of skeletal métastasés 
than F-18.
Se rafin i et al ( 1974) compared HEDP and pyrophosphate 
in 18 paired studies ; 7 normal subjects and 11 with lesions
present on scan. In general it was felt that pyrophosphate 
gave more variable results and while the lesion detection rate 
was the same with both agents, L/B ratios were higher with 
HEDP in approximately half the cases. In no case was the 
L/B ratio higher with pyrophosphate. Silberstein et al (1978) 
compared HEDP and pyrophosphate in paired studies in 30 patients 
with carcinoma. While it was considered that there was no 
difference in scan quality between agents, 10 of 30 lesions 
detected with HEDP were not seen with pyrophosphate. Citrin 
et al (19 75) in an excellent study of 29 patients with skeletal 
métastasés compared HE D P , pyrophosphate and polyphosphate.
All patients had studies with 2 or all 3 agents. Citrin 
concluded that HEDP was clearly superior to the other agents 
and showed that significantly higher L/B ratios were obtained 
with HEDP when compared with either pyrophosphate or poly­
phosphate. Fogelman et al (1977) confirmed these findings in 
a smaller study of 11 patients with metastatic disease when 
the quality of scan image, lesion detection and L/B ratios were
all shown to be superior with HEDP compared to pyrophosphate.
bun de 11 et al ( 19 75) studied each of 9 women, who had 
radiologically proven métastasés, with HEDP, pyrophosphate and 
polyphosphate. The scans were visually evaluated and while 
no significant difference in lesion detection was found, it 
was concluded that HEDP provided superior images with higher 
lesion to bone contrast. In addition computer quantitation 
of the bone scan images was obtained in 3 patients (B/ST and 
L/B ratios), and although these results are not presented, 
the authors comment that the findings were in agreement with 
the visual interpretation.
(b ) Tc-9 9 m Methylene Diphosphonate (MDP)
Following the introduction of Tc-99m MDP by Subramanian 
in 1975 (Subramanian et al, 1975), MDP is today the most widely 
used bone scanning agent. However Subramanian's original 
suggestion that MDP was superior to HEDP as a scanning agent 
was based on higher bone uptake in rats, higher whole-body 
retention of tracer in beagle dogs and faster plasma clearance 
in human volunteer subjects. Faster blood clearance of MDP 
c ompare d to HE DP has n ow been con firmed by many groups (Davis 
and Jones, 19 76; Rosenthall et al, 19 7 7 ; Rudd et al, 19 79) , 
The superiority of MDP over HEDP in clinical practice has not 
however been established.
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While Rosenthall et al (1977) in 11 volunteer and 
20 patient studies found higher B/ST ratios with MDP than 
with HEDP, and concluded that MDP was the preferred radio­
pharmaceutical, only 7 patients had skeletal métastasés, 
and in these no difference in lesion detection was found.
Rudd et al (1979) carried out paired studies comparing MDP 
and HEDP in lO patients (6 with carcinoma) and found higher 
B/ST ratios with MDP. They concluded that MDP produced 
superior images although no difference in lesion detection 
was seen. Indeed Rudd commented that in various clinical 
situations MDP and HEDP may have different binding mechanisms 
as in one patient with prostatic carcinoma a lesion was better 
visualised with HEDP, while in a patient with benign collapse, 
this was better visualised with MDP. Fogelman et al (1979) 
compared MDP and HEDP in paired studies in 17 patients with
skeletal métastasés. While no difference in the number of
lesions detected was found, L/B ratios were, however,
significantly higher with HEDP.
(c) T c-9 9 m Hydroxymethylene Diphosphonate (HMDP)
Recently a new diphosphonate, Tc-99m HMDP has become 
available for clinical practice. Early studies demonstrated 
that it had faster blood clearance (Bevan et al, 1980) and 
higher skeletal uptake (Bevan et al, 1980; Francis et al, 
1980; Fogelman et al, 1981) than MDP.
Dorns t ad et al (1980) randomly allocated 102 patients to 
either HMDP or MDP and found higher B/ST ratios with HMDP.
However overall image quality, bone delineation, soft-tissue 
uptake and L/B ratios were the same with both agents.
Silberstein (1980) compared HMDP and HEDP in paired studies 
in 20 patients with carcinoma and found that HMDP provided 
superior images in about half the cases. Quantitative data 
was only available in 7 cases, and L/B ratios in 4. Only 
marginal differences in L/B ratios between HMDP and HEDP 
(although in H M D P 's favour) were found. Rosenthall et al 
(1981) in paired studies compared HMDP and MDP in 10 volunteers 
and 20 patients with carcinoma and found scan quality, B/ST 
ratios and lesion detection to be the same. In addition no 
difference in blood clearance was seen between HMDP and MDP, 
and it was concluded that there was no significant difference 
between these agents,
(d) Tc-99m Dicarboxypropane Diphosphonate (DPP)
T c-9 9 m is the newest of the diphosphonates and as yet has 
not been fully evaluated. Nevertheless as with HMDP it is 
claimed that DPD has significantly higher skeletal uptake than 
MDP (Schwarz and Kloss, 1981) .
Schwarz and Kloss (1981) found DPD to have 15% higher 
bone uptake when compared with MDP in rat studies. In addition 
in 300 patient studies it was considered that DPD showed 
superior skeletal visualisation when compared with MDP. Hale 
et al (1981) in 60 patient studies comparing DPD and MDP 
also found improved skeletal visualisation and higher B/ST 
ratios with DPD.
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C O M M ENTS
There seems little doubt that the Tc-99m labelled 
diphosphonates deserve their virtual monopoly in the bone 
scanning field. Early studies exhaustively evaluated HEDP and 
showed it clearly superior to the other available agents such 
as F-18, T c-9 9 m pyrophosphate and polyphosphate. However 
later diphosphonates have not been so extensively evaluated 
and as can be seen from the above there is no evidence that 
any diphosphonate is superior to HEDP as regards lesion 
detection in malignancy.
In the only study comparing L/B ratios in scans obtained 
with both MDP and HEDP, HEDP showed higher values (Fogelman 
et al, 1979). Arnold et al (1978) using a computerised 
technique for subtracting blood and soft-tissue backgrounds 
from sequential images of bone, found that marked differences 
between the kinetic behaviour of MDP and HEDP exist, with each 
having different binding characteristics. It was suggested 
that while MDP may be the better agent for imaging the skeleton, 
HE DP may image osteoblastic lesions better. However, while 
this evidence perhaps marginally favours HEDP over MDP as 
regards lesion detection, HEDP is no longer commercially 
available and MDP is currently the most popular bone scanning 
agent. This is because of M D P 's higher bone uptake and 
improved skeletal visualisation. Physicians generally seem
1 1
to have a strong preference for bone scans obtained with M D P .
In Figure 1 the relative skeletal uptake of DPD, HMDP,
MDP and HEDP, obtained by the 24-hour whole-body retention 
of diphosphonate technique (Fogelman et al, 1978) is shown.
This confirms that both DPD and HMDP do indeed have higher 
skeletal uptake than MDP, although there is some suggestion 
that DPD may have slightly higher muscle uptake than other 
diphosphonates (Subramanian et al, in press) and it is not 
clear to what extent this is reflected in the WBR results.
It is still to be seen whether either or both of these newer 
agents will displace MDP in popularity.
It is of interest that Subramanian et al (in press) using 
a rabbit model where lesions were drilled in bone found lower 
L/B ratios with both DPD and HMDP when compared with M D P .
This supports the view that the higher background bone uptake 
of tracer, the lower the L/B ratio is likely to be. Neverthe­
less it has not been shown that higher bone uptake of tracer 
(with the agents presently available) leads to lesions being 
missed in clinical practice.
Where quantitative tracer techniques such as 24-hour whole- 
body retention of diphosphonate measurements are used to 
identify patients with increased bone turnover, it has previously 
been suggested that HEDP with its tighter normal range at lower 
absolute skeletal uptake, may be the agent of choice, since it
1 2  .
provides a wider range in which to detect abnormality, with 
less overlap between normal and abnormal (Fogelman et al,
1981) .
It is to be expected that there will be much academic 
interest when any new bone scanning agent becomes available, 
and there is a natural tendency amongst physicians to try 
something new. Also the bone scanning market is extremely 
large and there are commercial interests in showing that 
any one bone scanning agent is the 'agent of choice'. Thus 
any 'favourable' differences between agents are likely to be 
emphasised and widely proclaimed. At present there does not 
appear to be any significant difference amongst the 
diphosphonates as regards lesion detection. However, the 
published studies have generally evaluated gross disease and 
were it possible to study early metastatic involvement of the 
skeleton then differences between agents might emerge. The 
nuclear medicine community should at least reflect on what it 
expects from an ideal bone scanning agent, and whether 
continuing to search for agents with merely higher and higher 
bone uptake is desirable. It is possible that by increasing 
bone uptake of tracer further, a significant reduction in 
lesion detection could occur because of reduced contrast 
between lesions and high background acti vi ty. Nevertheless 
at the present time this does not appear to be a real concern, 
and all the diphosphonates available appear to be excellent 
bone scanning agents.
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Figure 1
Twenty-four hour whole-body retention of diphosphonate 
measurements in 3 volunteer subjects showing the 
relative skeletal uptakes of Tc-99m DPD (taken as 100%) 
HMDP, MDP and HEDP.
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Comment
When Tc-99m hydroxyethylidene diphosphonate (HEDP) 
was first introduced it was extensively evaluated and 
clearly shown to be superior to the other bone scanning 
agents available at that time as regards lesion detection 
and quality of scan image. However, since the introduction 
of methylene diphosphonate (MDP), and its almost instant 
success, HEDP is no longer commercially available. MDP 
was not as extensively evaluated as HEDP, and has not been 
shown to be superior to HEDP as regards lesion detection.
In addition in the only study comparing lesion to bone 
(L/B) ratios (a measure of how well a lesion will be seen 
against background bone) , HEDP was found to have higher 
values (see paper 13). This finding has been confirmed by 
Pauwels (personal communication) and is in keeping with the 
kinetic data from Arnold et al (1978). Further 
Subramanian et al (in press) using a rabbit model with 
lesions drilled in bone showed that the diphosphonates 
with higher skeletal uptake had lower L/B ratios. Thus 
higher uptalce of tracer by bone may not in itself be a 
desirable goal as regards lesion detection, although with 
the agents presently available there does not appear 
to be any significant difference in clinical performance. 
However, it is possible that the studies to date are too 
crude and were it possible to study very early metastatic
1 1 2 .
involvement of the skeleton then subtle differences 
between agents might emerge.
As stated in the paper, when comparing two bone 
scanning agents in metastatic disease, paired studies in 
individual subjects are required and simple subjective 
evaluation of scan images or even measuring bone to 
background soft-tissue activity is not adequate. What 
is relevant is lesion visualisation and the L/B ratios. 
It does not matter if one agent produces particularly 
pleasing images in normal subjects but it does matter 
if that agent is less likely to detect early metastatic 
disease.
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SUMMARY 
CHAPTER 5
COMPARISON OE THE AVAILABLE DIPHOSPHONATE 
BONE SCANNING AGENTS
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This chapter deals with clinical comparisons between the 
available diphosphonate bone scanning agents both in metastatic 
and benign disease.
Paper 13 presents a comparison of Tc-99m methylene 
diphosphonate (MDP) and Tc-99m hydroxyethylidene diphosphonate 
(HEDP) in patients with metastatic disease. While no 
difference in lesion detection was found, it was commented 
upon that higher lesion to bone ratios were obtained with 
HEDP than with MDP, even although MDP showed higher contrast 
between bone and surrounding soft~tissue. It was suggested 
that for identification of metastatic disease, the agent 
with higher lesion to bone ratios may be superior, as there 
is greater contrast between the lesion and surrounding bone.
The results of a study comparing three different 
diphosphonates, hydroxymethylene diphosphonate (HMDP), MDP 
and HEDP in volunteer subjects, using the 24-hour whole- 
body retention of diphosphonate technique are presented in 
paper 14. Striking differences in relative skeletal 
affinity are found with HMDP >MDP >HEDP„ It was suggested 
that higher skeletal uptake of radiopharmaceutical may make 
it more difficult to recognise metabolic features on the 
scan image, but this has not yet been proven by critical 
study. Similarly where 24-hour whole-body retention
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measurements are used to identify patients with increased 
skeletal metabolism it is argued that lower mean skeletal 
uptake of tracer and narrower range in normal subjects 
may be an advantage, but again this remains to be shown by 
critical study.
The question of whether high skeletal uptake of tracer 
is desirable for lesion detection in metastatic disease is 
once again raised in paper 15, and it was suggested that 
theoretically a point may be reached when a fall off in 
detection could occur if tracer uptake were further increased. 
The desirable properties for a bone scanning agent in clinical 
practice are discussed and the relevant investigations for 
any comparison between radiopharmaceuticals in metastatic 
disease are suggested. The published studies comparing 
diphosphonate bone scanning agents in clinical practice are 
then critically reviewed. It was found that while HEDP 
had been extensively evaluated and shown to be clearly 
superior to the other available bone scanning agents at 
that time, subsequent diphosphonates have been less extensively 
evaluated and in clinical practice no difference has been 
shown between agents as regards lesion detection in metastatic 
disease.
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CHAPTER 6
STUDIES WITH THE TECHNIQUE OE 24-HOUR WHOLE-BODY 
RETENTION OE DIPHOSPHONATE IN CLINICAL PRACTICE
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In this chapter, three papers (16-18) are presented 
which illustrate the application of the technique of 
24-hour whole-body retention of Tc-99m diphosphonate 
in clinical practice.
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Paper 16. Estimation of skeletal involvement in primary 
hyperparathyroidism. Use of 24-hour whole- 
body retention of technetium-99m diphosphonate (1980) 
Annals of Internal Medicine 92 : 65-67
I Fogelman, R G Bessent, G Beastall, I T Boyle
Purpose of Investigation
Primary hyperparathyroidism is being diagnosed with 
increasing frequency with the advent of routine serum 
calcium estimations and sensitive parathyroid hormone assays.
The majority of patients with this condition are asymptomatic 
and it is uncommon nowadays for patients to have skeletal 
complaints. Nevertheless bone histology demonstrates 
increased bone turnover in a high percentage of cases. The 
purpose of this study was to assess whether measurements of 
24-hour whole-body retention of diphosphonate (WBR) could be 
used to identify altered skeletal metabolism in patients 
with primary hyperparathyroidism and whether the WBR results 
would correlate with serum alkaline phosphatase and para­
thyroid hormone levels, conventional biochemical markers of 
disease activity. In addition WBR measurements were 
obtained in several patients pre and post parathyroidectomy 
to assess whether alterations in skeletal metabolism could 
be documented in sequential studies.
Reprinted from ANNALS OF INTERNAL MEDICINE, Vol. 92 No, 1, January 1980
Printed in U .S .A .
Estimation of Skeletal Involvement in Primary Hyperparathyroidism
Use of 24-Hour Whole-Body Retention of Technetlum-99m Diphosphonate
IGNAC FOGELMAN, M.B., Ch.B; RODNEY G. BESSENT, M.A., D.Phil.; GRAHAM BEASTALL, Ph.D.; an d  
IAIN T. BOYLE, M.B., Ch.B.; G lasgow , S c o t la n d
T he 2 4 -h  w h ole-b od y  re ten tio n  o f  te c h n e tlu m -9 9 m  
d ip h o sp h o n a te  w a s e le v a te d  in 1 6  p a tie n ts  with prim ary  
hyp erparathyroid ism  (m ea n  w h o le  b od y  re ten tio n , 5 0 .6 % ,  
c o m p a r ed  to  c o n tr o ls , 1 9 .4 % ), with e a c h  resu lt  o u t o f  th e  
co n tro l ra n g e . T h ere  w a s a rank co rre la tio n  b e tw e e n  
w h ole-b od y  re ten tio n  and  p lasm a parathyroid  h o rm o n e  
(r  =  0 .8 6 ,  P <  0 . 0 0 1 )  but th e  co rre la tio n  with seru m  
a lkalin e  p h o sp h a ta se  and ca lc iu m  v a lu e s  w a s l e s s  
s ig n ifica n t (r  =  0 .5 8 ,  P  < 0 .0 5  in e a c h  c a s e ) .  R ep ea t  
s tu d ie s  o f w h o le  bod y  re ten tio n  p erfo rm ed  in fiv e  p a tie n ts  
b e fo r e  and a fter  p a ra th y ro id ecto m y  sh o w e d  a fall to  
norm al or near  norm al v a lu e s . M ea su rem en t o f  2 4 -h  
w h ole-b od y  r e te n tio n  o f  d ip h o sp h o n a te  is  a s im p le , 
s e n s it iv e  t e s t  to  aid  in th e  d ia g n o s is  and  ev a lu a tio n  o f  
p a tie n ts  with prim ary h yp erparathyroid ism . T he t e s t  co u ld  
b e  u se d  a s  a sc r e e n in g  p ro ced u re  in p a tie n ts  with  
recu rren t renal s to n e s ,  for  e x a m p le , or to  a s s e s s  th e  
e x te n t  o f sk e le ta l in v o lv em en t in p a tie n ts  with an  
e s ta b lish e d  d ia g n o s is .
I n  p r i m a r y  h yp erp a ra th y ro id ism  it is u n u su a l for  p a ­
tien ts  to  p resen t w ith  sk e le ta l co m p la in ts , b u t o n  h is to ­
lo g ic  e x a m in a tio n  o f  b iop sy  sp ec im en s fro m  su ch  p a ­
tien ts, th ere  is ev id en ce  o f  sk e le ta l in v o lv em en t in v ir tu a l­
ly  a ll ca ses (1 ). E ven  th o u g h  50%  o f  th ese  p a tien ts  m ay  
sh o w  n o n sp ec ific  g en era lised  o steo p en ia  on  c o n v en tio n a l  
ra d io lo g ic  ex a m in a tio n , m ore sp ecific  ch a n g e s  (for  e x a m ­
p le, su b p er io stea l resorp tion  o f  p h a lan ges , a b sen ce  o f  
lam in a  dura, b row n  tu m ou rs, or  cy sts), are seen  in  o n ly  
10%  o f  ca ses (2).
T h e  cu rren t b o n e -seek in g  ra d io p h a rm a ceu tica l agen ts  
are very  sen s itiv e  for  sk e le ta l a b n orm ality , and  severa l 
g rou p s h a v e  assessed  th e  ro le  o f  b on e sca n n in g  in  p r i­
m ary h yp erp ara th yro id ism  (3 -5 ). H o w ev er , th e  b o n e  scan  
a p p earan ces are n o n sp ec ific  and , a lth o u g h  w e  h a v e  fo u n d  
th em  to  b e  ab n orm al in 50%  o f  ca ses  o f  p rim ary h y p er­
p a ra th y ro id ism  (6 ) , it h as b een  su g g ested  th a t th e  b o n e  
scan  is n o t as sen s itiv e  as rou tin e  ra d io lo g ic  ex a m in a tio n  
in  th is  co n d it io n  (4 ) . T h e  m ajor lim ita tio n  o f  b o n e  sca n ­
n in g  in m eta b o lic  b o n e  d isease , w h ere  th e  w h o le  sk e le to n  
is d iffusely  in v o lv ed  by a m eta b o lic  p rocess , is th a t an  
a w aren ess o f  “a b n o rm a lity ” d ep en d s on  a su b jective  im ­
p ress ion  o f  in creased  tracer u p tak e  by th e  sk e le to n , and  
th e  scan  im a g e  m ay  o ften  appear in d istin g u ish a b le  fro m  a  
n orm al im age. H o w ev er , in p rim ary  h y p erp a ra th y ro id ­
ism  th e  rate o f  b o n e  tu rn over is in creased  an d  th is  sh o u ld  
b e d e tec ta b le  if  to ta l sk eleta l u p tak e o f  th e  ra d io p h a rm a ­
ceu tica l a gen t co u ld  be q u a n tita ted  accu ra te ly , a s u p tak e  
is b e lieved  to  d ep en d  on  o steo b la st ic  a c tiv ity  and  to  a 
lesser  ex ten t on  sk e le ta l vascu lar ity  (7).
► F ro m  the U n ivers ity  D ep a rtm en ts  o f  M edic ine  an d  N u c le a r  M edic ine , R oyal 
In firm ary ; G lasgow , S co tland .
U sin g  a sh a d o w -sh ie ld  w h o le -b o d y  m o n ito r  w e h a v e  
p rev io u s ly  sh o w n  th a t m ea su rem en t o f  2 4 -h  w h o le -b o d y  
(sk e le ta l) reten tion  o f  te ch n e tiu m -9 9 m  (^^'"Tc) d ip h o s ­
p h o n a te  can  d ifferen tiate  p a tien t grou p s w ith  renal o s te o ­
d y stro p h y , o steo m a la c ia , P a g e t’s d isease , an d  p rim ary  
h yp erp a ra th y ro id ism  from  a co n tro l p o p u la tio n  (8 ). O ur  
fin d in gs u sin g  th is tech n iq u e  in 16 p a tien ts  w ith  p rim ary  
h y p erp ara th yro id ism , five o f  w h o m  w ere stu d ied  b efore  
and  after  p a ra th y ro id ec to m y , are d escrib ed .
P a tie n ts  and  M eth od s
Sixteen patients with primary hyperparathyroidism were 
studied (Table 1). H istologic confirmation o f a parathyroid ade­
noma was obtained in 12 patients, and one patient was found’to 
have parathyroid carcinoma. Tw o patients (Patients 1 and 5) 
had hypercalcaemia with elevated parathyroid hormone values 
and are currently being considered for surgery. Patient 2 has 
been intermittently hypercalcaemic over the past 3 years and 
recently has had increasing levels o f  parathyroid hormone. 
However, he has no sym ptom s attributable to hypercalcaemia 
and, as he has severe ischaemic heart disease, surgery has not 
been recommended.
Our control range for whole-body retention o f ”"’T c diphos­
phonate was obtained in 111 healthy volunteers (age range, 20 
to 66 years) who had no history o f skeletal disease, gastrointes­
tinal disorders, or renal impairment.
Serum calcium, inorganic phosphate, and alkaline phospha­
tase were estimated in all patients with standard techniques 
used by the Department o f  Clinical Biochemistry in the Royal 
Infirmary, Glasgow. Plasma parathyroid hormone (PT H ) (im- 
munoreactive PTH) was measured by a double antibody radio­
immunoassay adapted from the m ethod o f Conaway and Anast 
(9) (normal range undetectable to 600 ng/L ). A ny detectable 
immunoreactive PTH in peripheral blood is considered as inap­
propriate in hypercalcaemic patients (10).
R adiologic skeletal surveys were obtained in all patients and 
were assessed for the standard radiologic features associated  
with hyperparathyroidism (11).
Each subject was given an intravenous bolus o f  50 /xCi o f  
99mTc hydroxyethylidene diphosphonate (H E D P ) and the 
whole-body count was measured at 5 min and again at 24 h 
after injection, using a standard shadow-shield whole-body  
monitor. Twenty-four-hour whole-body retention o f the radio­
pharmaceutical agent was calculated after appropriate back­
ground substraction by taking the 5-min count as 100% and 
correcting for radioactive decay. Five patients (Patients 3, 4, 8, 
10, and 15) had whole-body retention studies performed before 
and after parathyroidectomy,
Technetium -99m  H E D P  is either taken up by the skeleton or 
totally excreted via the urinary tract (12), and usually approxi­
mately 70% o f an intravenously administered dose is excreted  
via the urinary tract within 6 h of injection (13). Therefore, the 
value for whole-body retention o f ^^"'Tc H E D P  at 24 h alm ost 
entirely represents skeletal uptake o f radiopharmaceutical 
agent.
A ll correlations between values were performed using the 
Spearman rank correlation test.
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Figure 1: Results for 24-h  whole-body retention of technetium - 
9 9 m  hydroxyethylidone diphosphonate (HEDP) before and after 
parathyroidectomy. Stippled area is control range.
R esu lts
R esu lts  for seru m  ca lc iu m , in o rg a n ic  p h o sp h a te , a lk a­
lin e p h o sp h a ta se , p la sm a  P T H , and  ra d io lo g ic  tests  are 
sh o w n  in T ab le  1. T h e  m ean  w h o le -b o d y  re ten tio n  o f  
’’ '"Tc H E D P  for th e  co n tro l grou p  o f  111 su b jects (age  
range, 2 0  to  66  years) w as 19 .37%  +  3 ,3 7  (1 S D ). W e  
h ave taken  ou r co n tro l range for  w h o le -b o d y  re ten tio n  to  
be 12 .6%  to  2 6 .1 %  (th a t is, m ean  ih  2 S D ). T h e  m ean  
w h o le -b o d y  reten tion  for  th e  p rim ary h y p erp a ra th y ro id ­
ism  g rou p  w as 5 0 .6 % . R esu lts  for w h o le -b o d y  re ten tio n  
for in d iv id u a l p a tien ts w ith  p rim ary  h y p erp a ra th y ro id ­
ism  are sh o w n  in T ab le  1. E a ch  p a tien t resu lt lay  o u ts id e
th e  co n tro l range. T h e  fo llo w in g  co rre la tio n s  w ere  fo u n d  
b etw een  w h o le -b o d y  re ten tio n  o f  ^^ ""Tc H E D P  an d  p la s­
m a  im m u n o rea c tiv e  P T H , seru m  a lk a lin e  p h o sp h a ta se , 
and  seru m  ca lc iu m : r  — 0 .8 6 , P  <  0 .0 0 1 ; r  =  0 .5 8 , 
P  <  0 .05; and  r  =  0 .5 8 , P  <  0 .0 5 , resp ec tiv e ly . F ig u re  1 
sh o w s th e  resu lts for  w h o le -b o d y  reten tion , o b ta in ed  b e ­
fore  an d  after p a ra th y ro id ec to m y  in  five p a tien ts.
D isc u ss io n
O f  th e  16 p a tien ts  w ith  prim ary  h y p erp a ra th y ro id ism , 
ro u tin e  ra d io lo g ic  te s ts  sh o w ed  ev id en ce  o f  sk e le ta l d is ­
ease  in  o n ly  tw o  cases , and  a lk a lin e  p h o sp h a ta se  v a lu es  
w ere w ith in  th e  n o rm a l ran ge in  e ig h t su b jects. H o w ev er , 
th e  2 4 -h  w h o le -b o d y  re ten tio n  o f  ^^ ""Tc d ip h o sp h o n a te  
w as ab n orm al in  a ll subjects.
T h ese  are p re lim in ary  resu lts in  a re la tiv e ly  sm a ll 
g rou p  o f  p a tien ts  and  it w ill be n ecessa ry  to  s tu d y  larger  
n u m b ers, p articu lar ly  th o se  w ith  “ b o rd er lin e” h y p erca l­
ca em ia  to  estab lish  w h eth er  th is test can  re lia b ly  id en tify  
th o se  w ith  p rim ary  h y p erp ara th yro id ism . It is s t ill to  be  
p roved  th at a  n orm al resu lt for  w h o le -b o d y  re ten tio n  e x ­
c lu d es  th is  co n d it io n  as a d ia g n o s is , b u t i f  th is  w ere  so  
th en  m an y  p a tien ts  m ay  b e  spared  p ro lo n g ed  and  c o s t ly  
in v estig a tio n .
E v en  th o u g h  th is test p ro v id es a sen s itiv e  m ea n s o f  
d e tec tin g  c o n d it io n s  w ith  in crea sed  b o n e  tu rn over  (8) 
su ch  a s p rim ary  h yp erp a ra th y ro id ism , an a b n o rm a l re­
su lt d o es  n o t o f  it s e lf  id en tify  a n y  sp ec ific  co n d it io n , and  
fu rth er  in v estig a tio n  w ill b e  req u ired  to  d efin e th e  p a r tic ­
u lar d isea se  state .
T h e  repeat stu d ies  in  five p a tien ts  b efore  and  after  p ar­
a th y ro id ec to m y  h ave  sh o w n  a fa ll to  n orm al or  n ear n o r­
m al v a lu es for  d ip h o sp h o n a te  re ten tio n  in  a ll ca ses , b u t it 
is c lear  th at a co n sid era b le  p eriod  o f  tim e  is requ ired
Table 1. Patients with Primary Hyperparathyroidism
Patient Sex Age Parathyroid
Adenoma
Removed
Serum 
Calcium 
(Normal, 
2.2 to 2,6)
Serum 
Alkaline 
Phospha­
tase 
(Normal, 
80 to 280)
Para­
thyroid
Hormone
(Norrhal,
<600)
Whole-
Body
Retention
(Normal,
< 26)
Radiologic
Findings
yr mmol/L UIL iigIL %
! F 73 No 2.78 223 660 32.8 Normal
2 M 67 No 2.75 252 240 29.3 Normal
3 F 57 Yes 2.86 400 540 35.7 Normal
4 M 53 Yes 3.07 246 1150 46.9 Normal
5 F 58 No 2,68 265 670 29.5 Normal
6 F 74 Yes 2.67 1822 3100 85,9 Evidence of
hyperparathyroidism
7 M 52 Yes 2.97 259 470 35.0 Normal
8 F 59 Yes 2.83 153 1130 40.7 Normal
9 F 43 Yes— parathyroid 3.54 2723 5000 86.9 Evidence of
carcinoma hyperparathyroidism
10 F 64 Yes 2,88 590 800 70.8 Normal
n F 53 Yes 2.96 339 1200 70.8 Normal
12 F 60 Yes 2.42 245 440 27.1 Normal
13 F 66 Yes 2.87 455 700 55.1 Normal
14 F 80 Yes 3.12 390 550 48.4 Normal
15 F 62 Yes 2,75 284 760 43.0 Normal
16 F 77 Yes 3.3 231 1200 ;72.3 Normal
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(p rob ab ly  1 to  2 years) b efore th e  sk e le to n  retu rn s to  
“ n o r m a l” m e ta b o lic  a ctiv ity .
T e c h n e tiu m -9 9 m  d ip h o sp h o n a te  is b e liev ed  to  b e  ad ­
sorb ed  on  to h y d ro x y  ap a tite  cry sta ls  in  b o n e  (1 4 ), but th e  
fa c to rs a ffectin g  th e  rate o f  u p tak e  h ave  n o t b een  c lea r ly  
defined . It seem s lik e ly  th at o steo b la st ic  a c tiv ity  and  v a s­
cu la r ity  are th e  m a in  fa c to rs  in v o lv ed , h o w ev er , an d  m e a ­
su rem en t o f  2 4 -h  w h o le -b o d y  re ten tio n  o f  ^ '^"Tc d ip h o s ­
p h o n a te  m ay  p ro v id e  a d y n a m ic  test o f  sk e le ta l m eta b o ­
lism . W e h ave  fo u n d  a p o sitiv e  co rre la tio n  b e tw een  p la s­
m a P T H , seru m  a lk a lin e  p h o sp h a ta se  va lu es , an d  2 4 -h  
w h o le -b o d y  reten tion  o f  d ip h o sp h o n a te . A lth o u g h  th e  e x ­
act sig n ifica n ce  o f  th is fin d in g  is u n clear , th ese  resu lts  d o  
su p p o rt th e  v iew  th a t th e  sk e le ta l u p ta k e  o f  d ip h o s p h o ­
n a te  is p ro p o rtio n a te ly  related  to  m e ta b o lic  a c tiv ity  as in  
h y p erp a ra th y ro id ism  in creased  p ro d u c tio n  o f  im m u n o ­
reactive  P T H  is  th e  p r im e factor  p r o m o tin g  b o n e  reso rp ­
tion  and  a lk a lin e  p h o sp h a ta se  is regard ed  as a m ark er for  
th e  co m p en sa to ry  in crea se  in  a c tiv ity  o f  th e  b o n e -fo rm in g  
osteo b la sts . T h e  a b so lu te  v a lu es  for 2 4 -h  w h o le -b o d y  re­
ten tio n  o f  ^^"'Tc d ip h o sp h o n a te  m ay  reflect th e  sev er ity  o f  
sk e le ta l d isea se  in  p rim ary  h y p erp a ra th y ro id ism  b ecau se , 
in  gen era l term s, th e  h ig h er  th e  im m u n o rea c tiv e  P T H  
and  a lk a lin e  p h o sp h a ta se  v a lu es  th e  h ig h er  is th e  v a lu e  
for w h o le -b o d y  reten tio n .
M ea su rem en t o f  2 4 -h  w h o le -b o d y  re ten tio n  o f  ^ '^"Tc 
d ip h o sp h o n a te  is a sim p le , sen s itiv e  (bu t n o t sp ec ific ) test  
in th e  d ia g n o s is  and  ev a lu a tio n  o f  p a tien ts  w ith  su sp ec ted  
p rim ary  h y p erp a ra th y ro id ism . It m ay  b e o f  v a lu e  in  in d i­
v id u a l p a tien ts  to  d e tec t sk e le ta l a b n o rm a lity  and  to  a s ­
sess th e  sever ity  o f  b on e  in v o lv em en t, id en tify in g  th o se  
w h o  are at risk  o f  d ev e lo p in g  severe  p o sto p era tiv e  h y p o -  
c a lca e m ia  and  w h o  m ig h t benefit from  p reo p era tiv e  trea t­
m en t w ith  an  a c tiv e  m eta b o lite  o f  v ita m in  D  (1 5 ) . T h e  
te ch n iq u e  a lso  h as p o ten tia l v a lu e  as a screen in g  p r o c e ­
d u re— for ex a m p le , in  p a tien ts  w ith  recu rren t renal 
sto n es  b eca u se  th ere  is up to  a 10%  in c id en ce  o f  prim ary  
h y p erp a ra th y ro id ism  (1 6 ) a sso c ia ted  w ith  th is  co n d it io n  
an d  m ea su rem en t o f  2 4 -h  w h o le -b o d y  re ten tio n  o f  ^ '^"Tc 
d ip h o sp h o n a te  m a y  id en tify  th o se  p a tien ts.
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Comment
In the present study all 16 patients with primary 
hyperparathyroidism had elevated values for 24-hour whole- 
body retention of diphosphonate (WBR). However 
radiological evidence of hyperparathyroidism was seen in 
only two patients, and serum alkaline phosphatase values 
were elevated in eight. An elevated WBR result is however 
non-specific (see paper 9) and this technique does not 
provide a diagnostic test for primary hyperparathyroidism. 
Nevertheless WBR could be used as a screening procedure 
in populations where there is known to be an increased 
incidence of primary hyperparathyroidism, for example, 
in subjects with recurrent renal stones. A normal result 
for WBR makes a diagnosis of primary hyperparathyroidism 
extremely unlikely, although larger studies would be 
required to define the extent of overlap of results, if any, 
with control subjects. WBR also provides a means of 
assessing patients with extensive skeletal involvement 
who may be at risk of developing profound hypocalcaemia 
post-operatively. However in view of the good correlations 
found between WBR and plasma parathyroid hormone and 
alkaline phosphatase levels, perhaps this information 
could be obtained more easily from these results.
1 2 0 .
This study is the first to document change in WBR 
results in sequential studies in individual patients.
In the five patients studied pre and post parathyroidectomy 
WBR values fell to or towards normal with time after 
operation. It was suggested from these results that a 
considerable period of time is required, of the order of 
1 to 2 years, before the skeleton returns to "normal" 
levels of metabolic activity following definitive treatment 
for primary hyperparathyroidism.
1 2 1  .
Paper 17, The value of 24 hour skeletal uptake of
diphosphonate in the exclusion of metabolic 
bone disease (1980)
Nuclear Medicine Communications 1: 351-356
I Fogelman
Purpose of Investigation
This short communication presents four case histories 
which illustrate potential clinical applications of the 
24-hour whole-body retention of diphosphonate technique in 
the exclusion of metabolic bone disease.
CHE VALUE OP 24 HOUR SKELETAL UPTAKE OF DIPHOSPHONATE IN THE 
EXCLUSION OF METABOLIC BONE DISEASE
Cgnac Fogelman
Jniversity Departments of Medicine and Nuclear Medicine 
toyal Infirmary, Glasgow G40SF
Summary
Measurement of 24 hour skeletal retention of technetium-99m 
iiphosphonate is a new test which provides a sensitive means of 
detecting increased skeletal metabolism. Four patients are 
presented where this test was of predictive value in excluding 
:he presence of metabolic bone disease. In all patients bone 
listology was normal and it is suggested that in many such cases a 
lormal value for diphosphonate retention will reduce the extent 
m d  duration of investigation required,
Entroduction
Once the possibility of a metabolic bone disorder (eg osteo- 
nalacia) has been raised in a patient it is often difficult to 
prove or disprove this without resorting to a bone biopsy. In 
addition to diagnosis, bone histomorphometry provides a means of 
studying the pathophysiology of disease and the response of the 
skeleton to therapy. However bone biopsy is an invasive procedure 
/fhich provides information pertinent to only a small area of bone 
vhich may not be representative of the skeleton as a whole and a 
simple 'dynamic' test of total skeletal metabolism is clearly 
desirable.
We have recently shown that measurement of 24 hour whole-body 
retention (WBR) of technetium-99m diphosphonate provides a sensitive 
neans of detecting patients with increased bone turnover (I, 2) and 
:his communication illustrates 4 cases from clinical practice where 
:he knowledge that the WBR result was in the normal range was of 
predictive value in excluding the presence of metabolic bone 
lisease.
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Method
24 Hour Whole-Body Retention of Technetium-99m Diphosphonate
Each subject was given an intravenous bolus of 50 uCi of 
technetium-99m hydroxyethylidene diphosphonate (HEDP) and the 
whole-body count was measured at 5 minutes and again 24 hours 
after injection using a standard shadow shield whole-body 
monitor. Twenty-four hour WBR of radiopharmaceutical was 
calculated after appropriate background subtraction by taking 
the 5 minute count as 100% and correcting for radioactive decay,
Technetium-99ra HEDP is either taken up by the skeleton or 
else totally excreted via the urinary tract (3) and usually 
approximately 70% of an intravenously administered dose is 
excreted via the urinary tract within 6 hours of injection (4), 
Therefore, the Value of WBR of technetium-99m HEDP at 24 hours 
almost entirely represents skeletal uptake of radiopharmaceutical.
Patient 1
SJ, a 20 year old Pakistani male presented with a 2 year 
history of muscular pains and on examination had generalised bone 
and muscle tenderness. Although routine biochemistry (including 
serum calcium and alkaline phosphatase) was normal, he did belong 
to an at risk population (5) and because of the clinical findings, 
it was felt important to exclude osteomalacia. Twenty-four hour 
WBR of diphosphonate was normal at 23.7% (normal<26%) and the bone 
biopsy was also subsequently reported as normal. While this 
patients symptoms could not be fully explained it was considered 
that no organic disease was present.
Patient 2
MC, a 55 year old Religious Sister gave a 6 year history of 
vague aches and pains in her knees and lower back. Radiology showed 
osteoarthritic changes at these sites but initial biochanical 
screening revealed a low serum calcium at 2,1 mmol/1 (normal 2,2-2,6) 
with normal serum albumin and alkaline phosphatase values. The 
25-hydroxyvitarain D level was found to be low at 3.9 ng/1 (normal 4-20)
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and while clinically there was no bone or muscle tenderness it was 
once again considered important to exclude osteomalacia. The WBR 
was normal at 21.3% and no abnormality was detected on bone histology.
Patient 3
HT, a 37 year old overseas PhD student attended a health centre 
complaining of back pain. Radiology revealed a collapsed mid-thoracic 
vertebra, and raised the possibility of generalised osteopenia of the
spine but there was some disagreement as regards this. Idiopathic 
osteoporosis, or increased bone turnover related to other diseases 
(eg tumour or primary hyperparathyroidism) were considered as 
possible diagnoses. Biochemical investigations (including thyroid 
function tests and parathyroid hormone estimation), radionuclide 
bone scan, bone biopsy and WBR (15.5%) were all normal. Subsequent 
listory from the patient revealed that he had been electrocuted 10 
years previously when he touched a 'live' gate and it is therefore 
Likely that his vertebral collapse was an isolated incident due to 
inusually forcible involuntary muscular contraction.
^atient 4
AT, a 19 year old girl was referred with a 3 year history of 
recurrent renal colic and the finding of intermittently elevated serum 
:alcium values. We were unable to confirm hypercalcaemia (although 
:alcium values were persistently in the high normal range at 2.55 mmol/1) 
nd skeletal radiology, parathyroid hormone values and cervical venous 
«rathyroid hormone localisation studies, and all other biochemical 
arameters were normal. WBR (17.9%) and bone biopsy findings were also 
ormal. After prolonged and very detailed investigations, it was felt 
hat this girl did not have primary hyperparathyroidism.
iscussion
Twenty-four hour whole-body retention (WBR) of technetium-99m 
iphosphate provides a sensitive measure of skeletal metabolism but is 
on-specific and where an abnormal result is obtained, further investi- 
ation will be required to elucidate the problem. The most common 
ause of an elevated result for WBR, especially in the elderly, is
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Paget*s disease, A normal result will exclude certain 
conditions eg osteomalacia, renal osteodystophy, polyostotic 
Paget's disease and probably hyperparathyroidism (but this 
has still to be clearly established) (2). This potential role 
for WBR in excluding metabolic bone disease is illustrated by 
the 4 case histories presented. Patient 1 was an Asian with a 
history and clinical features suggestive of osteomalacia, but 
normal biochemistry. Patient 2, on the other hand, had some 
biochemical findings (low serum calcium and 25-hydroxyvitamin D 
values) which were in keeping with a diagnosis of osteomalacia 
but the clinical findings were unconvincing. Patient 3 was an 
unusual case where a young man presented with backache and 
radiology of his spine revealed a collapsed vertebra and possible 
osteopenia. It was initially suggested that he may have primary 
osteoporosis but it was considered important to exclude conditions 
associated with increased, bone turnover. All investigations were 
negative and with the history of previous electrocution it was 
felt that his vertebral collapse was likely to have been an 
isolated incident due to unusually forcible involuntary muscular 
contraction. Patient 4 represents a not uncommon problan in 
clinical practice - where serum calcium measurements are border­
line or intermittently elevated with parathyroid hormone values 
in the normal range. In this situation the knowledge that there 
is, or is not, increased bone turnover present may be of value in 
the assessment of a patient with suspected primary hyperpara­
thyroidism.
In the United Kingdom there remains a significant problem with 
osteomalacia particularly amongst the Asian population (5, 6) and 
the elderly (7, 8). Patients who present with a fractured neck of 
femur may in addition to osteoporosis have associated osteomalacia 
(9). In many such 'at risk' patients osteomalacia is oftai considered 
but a bony biopsy is eventually required to establish or exclude 
this diagnosis. Primary hyperparathyroidism is a relatively 
common condition and is being diagnosed more frequently with
3 5 4
routine serum calcium measurements and the increasing 
availability of sensitive parathyroid hormone assays (10) .
However, as mentioned previously, in those patients with 
borderline serum calcium values there may be difficulty in 
establishing a diagnosis. In all such cases, or where 
metabolic bone disease (associated with increased bone 
turnover) is suspected, 24 hour WBR of diphosphonate can be 
of value as a screening test, and if normal will reduce the 
duration and extent of investigation required.
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Comment
The four patients presented are not unusual, in 
representing the types of problems one may often see in 
any centre with a specialised interest in metabolic bone 
disease.
Once the possibility of a patient having osteomalacia 
has been considered then the only certain way to confirm 
or refute this diagnosis is by bone biopsy with histological 
analysis, thus necessitating an invasive procedure, A 
normal 24-hour whole-body retention of diphosphonate (WBR) 
measurement excludes osteomalacia and in our experience to 
date of 23 patients with this condition there has been no 
overlap whatsoever with control values. As regards 
primary hyperparathyroidism, this diagnosis can on occasion 
prove remarkably difficult to confirm when mild disease 
is present, even if more invasive tests such as neck vein 
catheterisation studies for localisation of parathyroid 
hormone levels are carried out. In practice, such cases 
are often observed over a period pending a final decision 
as to their management. An elevated result for WBR in 
such cases would support a diagnosis of primary hyperpara­
thyroidism and a normal result would be against it. However 
it is likely that a small degree of overlap of results may 
eventually be shown with WBR between disease and normal 
subjects,
123.
As our understanding of the aetiology of osteoporosis 
slowly advances, it is becoming apparent that this is a 
heterogeneous condition. It is recognised that a 
significant minority of patients have high bone turnover 
(Meunier et al, 1979) and if such patients could be 
simply identified by TOR then perhaps specific therapy 
to suppress skeletal metabolism could be used with benefit. 
When osteoporosis presents in a younger age group one is 
particularly anxious to exclude secondary causes of 
osteoporosis and document if accelerated bone loss is 
occurring.
At present further studies are required to confirm the 
above suggestions regarding the sensitivity of WBR in 
osteomalacia, primary hyperparathyroidism and 'high 
turnover' osteoporosis. However, if a normal result for 
WBR does indeed exclude these conditions then clearly many 
patients could be spared extensive, expensive and at times 
invasive investigation.
1 2 4 .
Paper  1 8 .  S k e l e t a l  u p ta k e  o f  d ip h o s p h o n a te .  Method f o r
prediction of post-menopausal osteoporosis (1980) 
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Purpose of Investigation
The most common and important metabolic bone disease is 
osteoporosis. However in the great majority of cases, by 
the time it is diagnosed the disease is irreversible and 
incurable. Thus it would clearly be desirable to identify 
those subjects at risk of developing osteoporosis prior to 
the development of significant bone loss, in order that they 
might benefit from prophylactic therapy. The purpose of 
the present study was to obtain 24-hour whole-body retention 
of diphosphonate (WBR) measurements reflecting skeletal 
metabolism, in a group of oophorectomised women participating 
in a long term study of oestrogen prophylaxis against bone 
loss, and to correlate the results with their rates of bone 
loss as measured by photon absorptiometry. It was hoped 
that assessment of skeletal metabolism with WBR would 
correlate with measured rates of bone loss, thus lending 
support to my belief that WBR may be able to identify 
women with increased bone turnover at a time prior to the 
development of osteoporosis.
125 .
Comment
In the present study, oophorectomised women receiving 
oestrogen therapy had significantly lower values for 24-hour 
whole-body retention of diphosphonate (WBR) and rate of bone 
loss than those receiving placebo, thus providing further 
evidence as to the efficacy of oestrogen in suppressing 
skeletal metabolism and bone loss. In addition it was 
found that those women who had defaulted from oestrogen 
therapy had the highest values for WBR and bone loss, in 
keeping with previous work suggesting accelerated bone loss 
after oestrogen withdrawal (Lindsay et al, 1978; Horsman 
et al, 1979). More recently Christiansen et al (1981) 
did not find accelerated bone loss after cessation of 
oestrogen therapy. However this finding was based on photon 
absorptiometry measurements obtained for only one year after 
discontinuation of therapy. The question of what happens 
to bone after oestrogen withdrawal is clearly important and 
requires further study. While it is generally accepted that 
oestrogens reduce or prevent bone loss in post-menopausal 
women, any previous benefit might be negated if cessation 
of therapy were to lead to accelerated bone loss. This 
would imply that only prolonged oestrogen therapy could 
maintain skeletal mass and this would introduce other
126 .
difficulties such as possible long terra side effects and 
the cost effectiveness of treatment (Weinstein 1980).
A highly significant negative correlation was found 
between WBR and the dose of oestrogen taken. This finding 
suggests that it may be possible to adjust therapy and 
control skeletal metabolism at an optimal level.
Although WBR provides a measure of skeletal metabolism 
and photon absorptiometry a measure of peripheral bone 
mineral content, there was nevertheless good correlation 
between these two quite different investigations. It would 
thus appear that WBR with a single measurement of skeletal 
metabolism can provide parallel information relating to 
rate of bone loss as measured by photon absorptiometry over 
a three year period.
This study has for the first time shown differences in 
WBR measurements between groups of subjects when the results 
themselves were largely within the normal range. In addition 
for the study group as a whole these results correlated well 
with the rate of bone loss measured by photon absorptiometry. 
The WBR technique thus has exciting potential application in 
the identification of post-menopausal women who have slightly 
elevated levels of bone turnover and who may, therefore, go 
on to develop accelerated bone loss. Jeffcoat et al (1980)
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have independently suggested that a quantitative measure of 
diphosphonate uptake in bone may indicate future bone loss. 
Their interest was in periodontal disease and in a 
prospective study of beagle dogs they measured diphosphonate 
uptake by alveolar bone and demonstrated a strong correlation 
between tracer uptalie and subsequent bone loss over a two 
year period.
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SUMMARY 
CHAPTER 6
STUDIES WITH THE TECHNIQUE OF 24-HOUR WHOLE-BODY 
RETENTION OF DIPHOSPHONATE IN CLINICAL PRACTICE
1.29.
This chapter deals with studies utilising the technique 
of 24-hour whole-body retention of diphosphonate (WBR) in 
clinical practice, and highlights potential applications 
for future use.
A study assessing the extent of skeletal involvement 
in primary hyperparathyroidism by WBR is described in 
paper 16. It was found that all 16 patients with primary 
hyperparathyroidism had elevated values for WBR, while only 
eight had elevated values for serum alkaline phosphatase and 
two abnormal skeletal radiology. It would thus appear that 
WBR is the most sensitive of these investigations for the 
detection of increased bone turnover. A significant 
correlation was, however, shown between WBR and both serum 
parathyroid hormone and alkaline phosphatase levels, supporting 
the view that diphosphonate uptake by bone is directly related 
to skeletal metabolic activity. In addition, sequential WBR 
studies were obtained in five patients pre and post para­
thyroidectomy and it was found that WBR values fell to or 
towards normal in all cases following operation.
Four case histories of patients with suspected osteomalacia, 
primary hyperparathyroidism and osteoporosis, are presented 
in paper 17. In this brief communication it is suggested 
that in such cases a normal WBR result would have been 
of value in the exclusion of metabolic bone disease.
130.
On the basis of my experience to date with the WBR technique 
I believe that a normal result for WBR will exclude 
osteomalacia and makes a diagnosis of primary- hyperpara­
thyroidism extremely unlikely. It is also possible that 
an abnormal result may be of value in identifying patients 
with 'high turnover' osteoporosis. However, independent 
evaluation of the WBR technique is required to confirm 
these suggestions. Nevertheless if a normal result for 
WBR does indeed exclude these conditions then clearly 
many patients would be spared intensive and at times 
invasive investigations.
While the WBR technique has been shown in several 
studies to provide a sensitive indicator of increased bone 
turnover, the most important potential application of WBR 
would be as a predictor of accelerated bone loss. To 
obtain further information relating WBR to bone loss, 
oophorectomised women participating in a long term study 
of oestrogen therapy as prophylaxis against bone loss were 
studied and the results presented in paper 18. It was 
shown that women receiving oestrogen had significantly 
lower values for both skeletal metabolism and rate of bone 
loss as measured by photon absorptiometry. A negative 
correlation was found between the dose of oestrogen and 
skeletal metabolism, suggesting that it may be possible to 
adjust therapy to maintain skeletal metabolism at an 
optimal level. A strong positive correlation was found 
between WBR and rate of bone loss for the study group as 
a whole, indicating that WBR may indeed be able to predict
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accelerated bone loss in prospective studies. Jeffcoat 
et al (1980) have independently suggested that quantitative 
uptake of diphosphonate by bone may predict future bone 
loss.
The most exciting potential application of WBR at 
present is in osteoporosis. If it were possible to 
identify post-menopausal women at risk of accelerated 
bone loss using the WBR technique, then these women might 
benefit from prophylactic therapy. However prospective 
studies are required to correlate WBR with bone loss in 
individual patients on a sequential basis.
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Bone scan imaging with the current bone seeking 
radiopharmaceuticals, the technetium-99m labelled 
diphosphonates, has dramatically improved our ability to 
evaluate skeletal pathology. In this thesis, chapter 1 
presents a review of the history of bone scanning, summarises 
present concepts as to the mechanism of uptake of bone seeking 
agents and briefly illustrates the role of bone scanning in 
clinical practice.
In chapter 2 the applications of bone scan imaging and 
quantitative tracer techniques derived from the bone scan 
in the detection of metabolic bone disease are discussed.
Since skeletal uptake of Tc-99m diphosphonate depends upon 
skeletal metabolism one might expect that the bone scan 
would be of considerable value in the assessment of metabolic 
bone disease. However in these disorders the whole skeleton 
is often diffusely involved by the metabolic process and 
simple visual inspection of the scan image may not reveal 
the uniformly increased uptake of tracer. Certain patterns 
of bone scan abnormality have, however, been reported in 
patients with primary hyperparathyroidism and renal osteo­
dystrophy; the present studies extend these observations 
and introduce the concept of "metabolic features" which are 
often recognisable in conditions with generalised increased 
bone turnover. As an aid to systematic recognition of
1 3 4  .
these features on a given bone scan image a semi-quantitative 
scoring system, the metabolic index, was introduced. The 
metabolic index allowed differentiation between various 
groups of patients with metabolic disorders and a control 
population. In addition, in a bone scan study of patients 
with acromegaly, it was found that the metabolic index 
correlated well with disease activity as measured by serum 
growth hormone levels. The metabolic index was, however, 
found to be a relatively insensitive means of identifying 
disease in individual patients.
Patients with increased bone turnover will have an 
absolute increase in skeletal uptake of tracer. As a 
means of quantitating this uptake the use of bone to soft- 
tissue ratios derived from the bone scan image by computer 
was critically evaluated. The technique was shown to be 
observer dependent and again found to be of limited value 
due to the large overlap of patient results with those from 
control subjects.
In chapter 3 the use of bone scan imaging in metabolic 
bone disease has been compared with radiology. Despite 
the difficulties mentioned above the metabolic index was 
employed, and the bone scan found to be the more sensitive 
investigation in primary hyperparathyroidism, renal 
osteodystrophy and osteomalacia. In osteoporosis, 
however, the bone scan was often unable to identify disease
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and radiology remains the investigation of choice. In a 
further study comparing bone scanning and radiology in 
Paget's disease, the bone scan was found to be clearly 
the more sensitive investigation.
As a result of the work described in chapter 2 it 
became apparent that a sensitive means of quantitating 
absolute bone uptake of tracer could be of diagnostic value. 
In chapter 4 a promising new quantitative technique is 
described in which the 24-hour whole-body retention of 
Tc-99m diphosphonate (WBR) is measured using a shadow-shield 
whole-body monitor. At 24 hours after injection, 
diphosphonate has reached a stable equilibrium in bone 
reflecting skeletal metabolic activity, while tracer in the 
soft-tissues of the body has been largely excreted via the 
urinary tract. It was found that this technique provided 
a sensitive means of detecting patients with primary hyper­
parathyroidism, osteomalacia, renal osteodystrophy and 
Paget's disease and that in these conditions all the results 
from individual patients lay outside the control range. In 
further studies the WBR technique was shown to be highly 
reproducible and not subject to any significant technical 
errors. In an analysis of WBR results from 259 normal 
subjects it was found that clear age-related changes were 
present. A comparative study of WBR measurements obtained
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with a whole-body monitor and with a gamma camera showed an 
extremely good correlation between the two techniques.
Several studies comparing the available Tc-99m labelled 
diphosphonates in clinical practice are reported in 
chapter 5, Tc-99m hydroxyethylidene diphosphonate (HEDP) 
has been used for all the bone scan and WBR studies reported 
in this thesis. However, at the present time Tc-99m 
methylene diphosphonate (MDP) is the most widely used bone 
scanning agent and has been shown to have higher skeletal 
affinity than HEDP. It is suggested that this may be a 
disadvantage in metabolic bone disease for it would appear 
to be easier to recognise metabolic features against a 
relatively low background uptake in normal subjects. In a 
study comparing HEDP and MDP in patients with metastatic 
disease, higher lesion to bone ratios were obtained with 
HEDP and this raises the possibility that increased bone 
uptake of tracer could lead to poorer lesion visualisation 
with reduction in diagnostic information. In a further study, 
measurements of WBR with Tc-99m hydroxymethylene diphosphonate, 
MDP and HEDP were obtained in healthy volunteer subjects and 
striking differences in skeletal affinity were found.
In chapter 6 studies relating to the application and 
potential uses of the WBR technique in clinical practice are 
presented. In patients with primary hyperparathyroidism
137.
WBR was found to be elevated in each individual case suggesting 
increased bone turnover. Radiology and routine biochemistry 
performed considerably less well in this respect. The thesis 
also includes a short report of four case histories 
illustrating how WBR may be of value in the exclusion of 
metabolic bone disease. Patients with suspected osteomalacia, 
primary hyperparathyroidism and "high turnover" osteoporosis 
are presented and it is suggested that a normal result for 
WBR could avoid extensive and at times, invasive investigations 
being performed in such cases.
In a study of oophorectomised women participating 
in the longterm evaluation of oestrogen prophylaxis against 
bone loss it was found that women receiving oestrogen had 
significantly lower values for WBR and rates of bone loss 
than those receiving a placebo preparation. These findings 
confirm the protective effect of oestrogen as regards 
suppression of skeletal metabolism and prevention of bone 
loss. In addition for the study group as a whole a highly 
significant correlation was found between WBR and the rate 
of bone loss as measured by photon absorptiometry over a 
three year period. This study raises the possibility 
that with a single measurement WBR may be able to identify 
those women who have a relative increase in skeletal
138.
metabolism and may, therefore, be at risk of accelerated 
bone loss with the subsequent development of osteoporosis.
The skeleton remains a difficult organ to investigate 
and prior to this work there was no satisfactory simple 
technique for assessing skeletal metabolism. While it is 
apparent that we need to know much more about diphosphonate 
uptake in the body, and in particular the mechanism and 
site of its localisation in bone, it is nevertheless 
concluded that WBR measurements provide a sensitive means 
of detecting increased bone turnover. It is likely that 
this tracer technique combined with routine bone scan 
imaging will increasingly be used to assess metabolic bone 
disorders.
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